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Abstract
While mammalian cells provide many of the molecules and machinery required by 
retroviruses to successfully achieve their replication cycle, they have also developed 
specific defences to protect themselves against viral infection. Existence of these 
antiviral "restriction" factors accounts for the limited ability of viruses to spread from 
one species to another. If a new virus becomes successfully established in its new host 
then it can cause serious disease, as is the case in the HIV pandemic. It is thus important 
to identify and understand how these mammalian protective factors work, to understand 
the molecular mechanisms involved and how viruses can evade them.
The aim of my PhD thesis is to better understand the role of these restriction factors in 
innate immunity. My work in the last 3 years has been to examine various aspects of 
retroviral restriction by a cellular protein called TRIM5alpha.
The first part of my PhD thesis shows that the Lvl and Refl class of restriction factors 
are species-specific variants of TRIM5a, a factor that was shown to block HIV-1 
infection in Rhesus macaque cells. Differential splicing of TRIM5 transcripts results in 
the production of several isoforms that lack the TRIM5a C-terminal B30.2 domain. To 
examine the contribution of these short TRIM5 splice variants to antiviral activity I 
cloned the TRIM58 isoform. I have shown that expression of human TRIM58 in cat and 
human cells had a dominant negative effect on the activity of co-expressed human 
TRIM5a.
The second part of my PhD thesis focuses on the role of the peptidyl prolyl isomerase 
enzyme cyclophilin A in TRIM5a's antiviral activity. It shows that cyclophilin A 
renders HIV-1 sensitive to restriction by TRIM5a in cells from Old World monkeys and 
that in human cells the effects of cyclophilin A on HIV-1 infection are independent of 
TRIM5a.
The third part of my thesis investigates the effects of arsenic trioxide, a drug that 
modifies the behaviour of the TRIM protein PML (TRIM 19), on TRIM5a mediated 
restriction. By using molecular biology, biochemistry and microscopy I showed that 
arsenic influences retroviral replication through its effect on TRIM5a and that it causes 
the degradation of this restriction factor.
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Chapter 1
Introduction
1.1 HIV and AIDS
1.1.1 Discovery
Acquired immunodeficiency syndrome (AIDS) was first recognised in the early 1980s 
following an increase in the number of people with symptoms of immunologic 
deficiencies in the United States and Europe. These people were suffering from diseases 
that had until then, been very rare. They included a variety of unusual cancers (non- 
Hodgkin's lymphoma and Kaposi's sarcoma), opportunistic infections {Pneumocystis 
carinii pneumonia, Toxoplasma gondii encephalitis) and a generalized 
lymphadenopathy. A common finding in affected individuals was a considerable 
depletion of the levels of CD4+ T-lymphocytes, a central component of the adaptive 
immune system, in their peripheral blood.
In June 1981 the Centres for Disease Control (CDC) in Atlanta published a report 
describing five young homosexual men from California with Pneumocystis carinii 
pneumonia (PCP), which appeared in the Morbidity and Mortality Weekly Report 
(Gottlieb et al., 1981). Reports of rare cases of Kaposi's sarcoma followed (Fannin et 
al., 1982). All patients were strangely immunosupressed-their immune systems could 
not fight off even common infections.
The disease still did not have a name at this point and different groups referred to it in 
different ways. The CDC generally called it by the name of the disease it was causing, 
for example lymphadenopathy. Because initially, more than 90% of these cases 
occurred in homosexual or bisexual men the term “gay-related immunodeficiency 
disease” (GRID) was used. However, by 1982, many new cases had been reported, not 
only in homosexual men, but also in intravenous drug users, haemophiliacs, blood- 
transfusion recipients and finally heterosexual adults. The occurrence of the disease in 
non-homosexuals meant that names such as GRID were redundant and it was suggested 
that the disease be called AIDS - Acquired Immune Deficiency Syndrome.
In 1983, Luc Montagnier's group at the Institute Pasteur in France reported that they had 
isolated a new virus, which they suggested might be the cause of AIDS (Barre-Sinoussi 
et al., 1983). Because this virus was isolated from the lymph node of a man with 
persistent lymphadenopathy syndrome (LAS) they named it lymphadenopathy-
16
associated virus or LAV. This virus, a retrovirus, was able to replicate in CD4+ cells and 
kill them (Montagnier et a l, 1984). Similarly, a team led by Robert Gallo from the 
National Cancer Institute in the United States also reported the characterisation of a 
human retrovirus, isolated from peripheral blood mononuclear cells from AIDS 
patients. They called this virus human T lymphotropic virus type III (HTLV-III) (Gallo 
et al., 1984; Popovic et a l, 1984; Samgadharan et a l,  1984; Schupbach et a l,  1984). In 
the hunt for the etiologic agent of AIDS was also Levy’s group at the University of San 
Francisco. They reported the recovery of a retrovirus from AIDS patients, as well as 
from asymptomatic patients in the various risk groups, which they called AIDS- 
associated retrovirus (ARV, Levy et a l, 1984).
In 1985 a number of more detailed reports were published concerning LAV, ARV and 
HTLV-III, and it became evident that these viruses were the same and exhibited 
morphologic and genetic characteristics typical of the Lentivirus genus in the 
Retroviridae family of viruses (Marx, 1985; Wain-Hobson et a l, 1985). In May 1986, 
the International Committee on the Taxonomy of Viruses ruled that all those names 
should be dropped and gave the virus a separate name - HIV (Human 
Immunodeficiency Virus) (Coffin et a l,  1986). It was later modified to HIV-1 with the 
discovery of a variant of this virus in West Africa, termed HIV-2 (Clavel et a l, 1986a, 
b). Although HIV-2 is also an AIDS-causing agent, it appears to be less pathogenic than 
HIV-1 and spreads at a slower rate (Whittle et a l,  1994).
1.1.2 Occurrence
According to UNAIDS/WHO AIDS epidemic update for December 2006 AIDS has 
killed more than 25 million people since it was first recognised in 1981 making it one of 
the most serious infectious disease to have affected humankind in recorded history. The 
total number of people living with HIV has reached around 40 million and close to 5 
million people are infected with the virus every year. Sub-Saharan Africa remains the 
most affected, with two thirds of all HIV infected people living there, as are 77% of all 
women with HIV. Growing epidemics are underway in Eastern Europe, Central Asia 
and East Asia (see Figure 1.1).
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460 000
(270 000-760 000)
Eastern Europe 
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Sub-Saharan 
Africa 
24.7 million
(21.8-27.7 million) Oceania
81 000
(50 000-170 000)
✓
Figure 1.1. Global summary of the AIDS epidemic-December 2006. The numbers represent 
numbers of infected people. The ranges around the estimates in this figure define the 
boundaries within which the actual numbers lie, based on the best available information. 
Source: UNAIDS/WHO AIDS epidemic update, December 2006.
1.1.3 Origin and diversity
Since the discovery of the epidemic causing human viruses HIV-1 and HIV-2, 
researchers have searched for their origin.
Their closest relatives were found in primates and are collectively referred to as simian 
immunodeficiency viruses (SIVs). Over twenty primate lentiviruses have been 
identified in Old World monkeys (family Cercopithecidae). SIV infections in their 
natural host are generally asymptomatic and do not cause immunodeficiency despite 
high viral loads over long periods of time (Gardner, 2003). The greatest diversity of 
HIV-1 and HIV-2 viral strains, as well as the highest rates of infection, occurs in sub- 
Saharan Africa providing compelling evidence that the HIV's have arisen through cross­
species transmission from African primates (Peeters and Sharp, 2000).
Soon after the isolation of HIV-2 from patients in western Africa its primate reservoir 
was identified as the sooty mangabey (Cercocebus atys, Hirsch et al., 1989; Gao et al., 
1992). SIV found in these monkeys (SIVsm ) was genetically so similar to HIV-2 that 
some subtypes of HIV-2 are actually closer to SrVsm than they are to each other
18
(Holmes, 2001). HIV-2 is only endemic in western Africa and coincides with the 
natural habitat of SIVsm infected sooty mangabeys. It is therefore likely, that SIVsm has 
been transmitted to humans within this area. Analysis of the phylogenetic trees among 
HIV- 2  and SIVsm strains revealed that cross-species transmission has occurred on 
multiple (at least eight) occasions, giving rise to groups A-H (Chen et al., 1997; Apetrei 
et al., 2005). Strains of SIV closely related to HIV-2 have been isolated not only from 
sooty mangabeys but also from Asian macaque monkeys kept in captivity in North 
America. These species are not naturally infected with SIV in the wild in Asia and it is 
thought that they were infected either through contact with sooty mangabeys in 
captivity (Mansfield et al., 1995) or through invasive experimental manipulations of 
sooty mangabeys and Rhesus macaques (Apetrei et al., 2006). The latter possibility 
might have occurred by serial passages of blood from animal to animal while 
conducting Kuru and Leprosy studies (Apetrei et al., 2006). Interestingly, these SIV 
infections can induce AIDS-like disease in macaques (Daniel et al., 1985; Letvin et al., 
1985).
In contrast to HIV-2, the origin of HIV-1 was less certain. Phylogenetic analysis 
revealed that the only strains of SIV closely related to HIV-1 are found in chimpanzees 
{Pan troglodytes) (Peeters et al., 1989; Huet et al., 1990). But because until recently, 
only three infected animals had been found, it was unclear as to whether chimpanzees 
are really the natural reservoir of these viruses or whether both humans and 
chimpanzees acquired their lentiviruses independently from a third, as yet unidentified, 
African monkey. Later careful characterisations of SIVs from numerous primate species 
as well as from additional SIVcpz strains showed that SIVcpz from the chimpanzee sub­
species Pan troglodytes troglodytes is the most likely ancestor of HIV-1 (Gao et al., 
1999; Keele et al., 2006). Subsequent phylogenetic analysis of the SIVcpz strains from 
Pan troglodytes troglodytes indicated that virus arose from a recombination event 
among SIV from red-capped mangabeys (SIVrCm) and SIV from greater spot-nosed 
monkeys (SIVgsn; Bailes et al., 2003). The phylogenetic relationships of primate 
lentiviruses are shown in Figure 1.2.
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Figure 1.2. Evolutionary history of the primate lentiviruses. Abbreviations for virus primate 
hosts are as follows: col-colobus; cpz-chimpanzees; drl-drill; gsn-greater spot-nosed monkey; 
Ihoest-L'Hoest monkey; mac-macaque; mnd-mandrill; mon-Campbell's mona monkey; rcm-red 
caped monkey; sab-Sabaeus monkey; sm-sooty mangabey monkey; sun-sun tailed monkey; 
syk-Sykes monkey; tan-tantalus monkey; ver-vervet monkey; Reproduced from Rambaut et al., 
2004.
Due to its high replication rate, error-prone reverse transcriptase and high frequency of 
recombination, HIV-1 evolves at an extraordinarily fast rate and has accumulated a 
large amount of diversity since its introduction into humans. Globally circulating strains 
of HIV-1 fall into 3 major phylogenetic groups, termed M (main), O (outlier) and N 
(non M/non O), each resulting from an independent zoonosis into humans. Although 
isolates from all 3 groups cause AIDS it is the group M which is responsible for the 
global AIDS pandemic and comprises by far the majority of known HIV-1 isolates. This 
group had been further subdivided based on the sequence of viral genomes into 
numerous clades, termed subtypes A-K. Members of HIV-1 group O represent highly 
divergent strains found mostly in western equatorial Africa. A recent paper reports the 
discovery of SIVs from wild living gorillas (SIVgor) which are much more closely 
related to HIV-1 group O than any other known SIV. The phylogenetic relationships
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suggest that chimpanzees were the original reservoir of SIVs now found in humans and 
gorillas giving rise to HIV-1 groups M and N. In case of HIV-1 group O it is unclear at 
this point if chimpanzees transmitted O-like viruses to gorillas and humans 
independently or they transmitted it only to gorillas, which then transmitted the virus to 
humans (Heuverswyn et al., 2006). HIV-1 group N, the latest to be discovered, consists 
of a very small number of viruses and is thought to be a recombinant between SIVcpz 
and a virus related to the ancestor of group M (Gao et al., 1999).
The oldest trace of the AIDS pandemic is from a human blood sample taken in 1959 
from an adult male living in what is now the Democratic Republic of Congo in west- 
central Africa (Zhu et al., 1998). In 2000 Korber et al. performed a detailed analysis of 
envelope gene sequences of HIV-1 isolates from more than 150 individuals and 
estimated the common ancestor of HIV-1 (M-group) in 1931.
Chimpanzees, as well as sooty mangabeys and other primate species, are often hunted 
and butchered for food, especially in equatorial Africa, and sold at markets as so called 
’’bush meat". This exposure of humans to animal blood and mucosal secretions together 
with consumption of uncooked contaminated meat provides the simplest explanation for 
the cross-species transmissions of SIVs to humans (Robinson et al., 1999; Sharp et al., 
2001).
1.1.4 Transmission and clinical course of infection
The vast majority of HIV infections are acquired through unprotected sex, both vaginal 
and anal, when infected sexual secretions of one partner come into contact with the 
mucous membranes of another. Various mucosal, chemical and physical aspects of the 
epithelial lining act as a barrier for the initial access of virus to the target cells. These 
limitations account for the low rate of "successful" sexual transmission of HIV, which is 
~1 infection per 1000 exposures through vaginal intercourse (Gray et al., 2001; 
Varghese et al., 2002; Smith et a l,  2005). Direct blood contact is another route of 
transmission and it accounts for infections in intravenous drug users, hemophiliacs and 
recipients of blood transfusions and blood products. The third mode of transmission is 
from mother to child and it can occur before or during birth or through breast milk.
HIV primarily infects cells of the immune system such as CD4+ T-cells, macrophages 
and dendritic cells. As already mentioned, the disease is associated with a progressive 
decrease of the CD4+ T-cells and an increase in virus load which are often used to 
determine a patient's progression of infection. The CD4+ T-cells are destroyed in HIV
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infection either directly (through cytopatic effects of HIV virus) or indirectly (through 
increased rates of apoptosis in infected cells; and through killing of infected CD4+ T- 
cells by CD8  cytotoxic lymphocytes (Schmitz et al., 1999). Moreover, the ability of 
immature progenitors to replace CD4+ T-cells is reduced during HIV-1 infection 
(McCune, 2001; McMichael and Rowland-Jones, 2001).
The first phase of HIV infection, the acute infection, is a stage of rapid viral replication 
that immediately follows the individual's exposure to HIV, with levels of virus in the 
peripheral blood approaching several million viruses per ml (Piatak et al., 1993). This is 
accompanied by a sharp drop in the amount of CD4+ T-cells, which is particularly 
severe in the gut-associated lymphoid tissue (GALT), where close to 90% of CD4+ T- 
cells die within the first weeks of infection (Brenchley et al., 2004). The decline in 
CD4+ T-cells is subsequently associated with the activation of CD8 + T-cells and 
antibody production. Emergence of latter HIV-specific immune responses and 
decreased availability of host CD4+ T-cells results in a down-regulation of viraemia and 
partial recovery of the CD4+ T-cell count. During this period most individuals (80 to 
90%) develop an influenza-like illness and sometimes a rash (Kahn and Walker, 1998). 
Once immune defences lower the number of viral particles in the blood stream, 
although they do not eradicate the virus, the next stage, so called clinically latent HIV 
infection begins. This asymptomatic period can vary between 2 weeks and 20 years. 
Levels of plasma viraemia remain relatively low, which is not due to slower replication 
of the virus, but to the immune response that kills the infected cells within the body. 
The CD4+ T-cell count declines slowly throughout this phase. As the CD4+ T-cell count 
falls below 2 0 0  cells/pl (with the normal value being 1 2 0 0  cells per pi), the risk for 
opportunistic diseases increases. In the final stages of disease, sharp increases in 
viraemia and sharp declines in CD4+ T-cell counts occur (Fauci et al., 1996). The 
clinical course of HIV infection is graphically shown in Figure 1.3. High levels of virus 
replication, cell destruction and turnover occur throughout the whole course of HIV 
infection, although it takes years before the CD4+ cell count falls below a critical level 
for symptomatic immunodeficiency to become manifest. At this stage the immune 
system collapses, cell-mediated immunity is lost and the body becomes progressively 
more susceptible to various infections. Eventually, most HIV-infected individuals 
develop AIDS and die. HIV’s case fatality rate is close to 100% (reviewed in detail in 
Haase et al., 2005).
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Figure 1.3. The clinical course of HIV infection. A generalized graph of the relationship 
between HIV copies (viral load) and CD4 counts over the average course of untreated HIV 
infection; any particular individual’s disease course may vary considerably. CD4+ T-cell count 
(cells per pl)-blue. HIV RNA copies per mL of plasma-red. Fauci et al., 1996.
1.1.5 Vaccines and anti-retroviral therapy
Even after more than 20 years of research, HIV-1 remains a difficult target for a vaccine 
and there is currently no cure for HIV. For many years attention in vaccine research was 
focused towards the viral envelope protein and included a variety of approaches such as 
recombinant proteins, synthetic peptides, recombinant viral or nonviral vectors, 
recombinant bacterial vectors, recombinant particles, whole-killed or life-attenuated 
HIV. HIV vaccines have been evaluated in over 70 phase I (dose-escalation safety and 
toxicity), five phase II (expanded safety and dose optimization) and two phase III 
(efficacy) trials (Nabel, 2001; Excler, 2005). Unfortunately none of these approaches 
has been successful. At present, the most advanced candidate in clinical trials is the 
replication defective adeno-5 vector expressing HIV-1 Gag, which has entered a phase 
IIB trial in 1500 subjects at risk for HIV-1 infection. Data from this trial will be 
available in 3-4 years. The proof for the feasibility of HIV vaccine development was 
provided by the use of live attenuated SIV virus vaccines. They provided complete or 
near-complete protection from homologous challenge by the same wild-type SIV 
strains. The mechanism for protection conferred by these vaccines is not fully 
understood and is currently being extensively studied (Koflf et al., 2006).
Even though it is not possible at the present time to prevent the virus from infecting the 
cells nor clear the body of virus, it is possible, with the use of antiviral drugs, to prevent
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the progression of infection towards AIDS and thus to prolong the life of HIV infected 
individuals. The development of antiviral drugs required the identification of targets 
within the virus whose interference with, would render the virus non-infectious. The 
enzymes reverse transcriptase and protease became the first targets. Currently, 20 anti­
retroviral agents from four classes are available (Table 1.1). Apart from 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) and protease inhibitors (Pis), a novel group of fusion 
inhibitors became commercially available in 2003 (Kalkut, 2005). The single drug in 
this latter class, enfuvirtide is a 36-amino-acid synthetic peptide that binds to the gp41 
envelope subunit of HIV and prevents the conformational change necessary for HIV 
fusion with CD4+ cells. It is the only drug within the anti-retroviral agents delivered by 
injections (Manfredi and Sabbatani 2006, more about fusion in chapter 1.2.3.1). This 
pharmacological class is probably going to expand after the completion of several phase 
II-III trial, with inhibitors of HIV co-receptors. A current focus is the development of 
integrase inhibitors. Several classes of HIV integrase inhibitors have been reported 
(reviewed in Makhija, 2006). The most promising, called raltegravir, is an HIV-1 
integrase strand transfer inhibitor that has been shown to be active against multidrug- 
resistant HIV-1. It is now being evaluated in phase II dose-ranging study (Grinsztejn et 
al., 2007).
At the present time antiviral treatment for HIV consists of, so called, highly active anti­
retroviral therapy (HAART). Because usage of only one specific drug at a time proved 
to be ineffective in the long term due to the fast mutation rate of HIV, current HAART 
is a combinations (or ’’cocktail”) of at least three drugs belonging to at least two classes 
of anti-retrovirals. Typically, these are two nucleoside analogue reverse transcriptase 
inhibitors plus either a protease inhibitor or non-nucleoside reverse transcriptase 
inhibitor. Although HAART stabilises a patient’s symptoms and viraemia, high levels 
of HIV-1, often HAART resistant, return if treatment is stopped (Martinez-Picado et al 
2000; Dybul et al., 2002). Despite this, the use of this therapy has led to a large 
reduction in HIV-associated illness and death in the developed world and improved the 
health and quality of life of many HIV-infected individuals.
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Generic name Manufacturer Brand name
Xne/eoside nucleotide reverse triinseriphi.se inhibitors (MR I'ls)
1987
Zidovudine (AZT) GlaxoSmithKline Retrovir
Didanosine (ddl) Bristol-Myers Squibb Videx
Zalcitabine (ddC) Roche Pharmaceuticals Hivid
Stavudine (d4T) Bristol-Myers Squibb Zerit
Lamivudine (3TC) GlaxoSmithKline Epivir
Abacavir (ABC) GlaxoSmithKline Ziagen
Tenofovir (TDF) Gilead Sciences Viread
Emtricitabine (FTC) Gilead Sciences Emtriva
Xon-ntteleoside reverse triinseriptuse inhibitors ( XXRTIs)  
1996
Nevirapine (NVP) Boehringer Ingelheim Viramune
Delavirdine (DLV) Pfizer Rescriptor
Efavirenz (EFZ) Boehringer Ingelheim Sustiva
Rrotcose inhibitors (R/s)
1995
Saquinavir (SQV) hard 
and soft gel
Roche Pharmaceuticals Invirase
Fortavase
Ritonavir (RTV) Abbott Laboratories Norvir
Indinavir (IDV) Merck Crixivan
Nelfinavir (NFV) Pfizer Viracept
Amprenavir (APV) GlaxoSmithKline Agenerase
Atazanavir (ATV) Bristol-Myers Squibb Reyataz
Fosamprenavir (fAPV) GlaxoSmithKline Lexiva
Lopinavir (LPV) Abbott Laboratories Kaletra
/ us ion inhibitors
2003
Enfuvirtide (T-20) Roche Pharmaceuticals Fuzeon
Table 1.1. Anti-retroviral agents approved by the U.S. Food and Drug Administration (May 
2006). The name of manufacturer, brand name and year of development of first representative 
of each anti-retroviral class is included. Adapted from Makhija, 2006; Manfredi and Sabbatani, 
2006.
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1.2 The Molecular Biology of HIV
1.2.1 Taxonomy
The retrovirus family, the Retroviridae, is a large and diverse family of enveloped RNA 
viruses found in all vertebrates. Retroviruses are associated with a wide variety of 
diseases in mammals including malignancies, immune deficiency and central nervous 
system defects.
Retroviruses are broadly divided into 2 categories: simple and complex, depending on 
the organization of their genomes. The simple viruses encode only the Gag, Pro, Pol, 
and Env gene products; the complex viruses encode these same gene products but also 
an array of additional proteins derived from multiply spliced messages with a range of 
functions. Retroviruses are divided into 7 genera: alpharetroviruses, betaretroviruses, 
and gammaretroviruses are considered “simple” retroviruses, whereas the 
deltaretroviruses, epsilonretroviruses, lentiviruses, and spumaviruses are considered 
“complex.” Some of the best studied retroviruses are Murine leukaemia viruses (MLVs) 
belonging to the gammaretrovirus genus and human immunodeficiency viruses 1 and 2  
(HIV-1, HIV-2) from the Lentivirus genus. Representative members of each genus are 
listed in Table 1.2.
Subf'amilv Genus F \a  m pies
Alpharetrovirus Avian leukosis virus (ALV) 
Rous sarcoma virus (RSV)
Betaretrovirus Mouse mammary tumour virus (MMTV) 
Mason-Pfizer monkey virus (MPMV) 
Jaagsiekte sheep retrovirus (JSRV)
Gammaretrovirus Murine leukaemia viruses (MoMLV) 
Feline leukaemia virus (FeLV) 
Gibbon ape leukaemia virus (GaLV) 
Reticuloendotheliosis virus (RevT)
Orthoretrovirinae Deltaretrovirus Human T-lymphotropic virus (HTLV)-l,-2 
Bovine leukaemia virus (BLV) 
Simian T-lymphotropic virus (STLV)-1,-2,-3
Epsilonretro virus Walleye dermal sarcoma virus 
Walleye epidermal hyperplasia virus 1
Lentivirus Human immunodeficiency virus 1,2 (HIV-1, HIV-2) 
Simian immunodeficiency virus (SIV)
Feline immunodeficiency virus (FIV) 
Caprine arthritis encephalitis virus (CAEV) 
Visna/maedi virus
Spumaretrovirinae Spumavirus Human foamy virus (HFV)
Table 1.2. Taxonomy and representative members of family Retroviridae. Adapted from 
Goff, 2001a.
26
1.2.2 The HIV virion and genome structure
The mature HIV particle is an enveloped spherical structure of about 120 nm in 
diameter with an enclosed conical-shape capsid composed of around 2,000 molecules of 
the viral capsid protein. The viral genome within the capsid is composed of two copies 
of linear, positive, single-stranded RNA with a length of approximately 9-kilobases. 
The virions are therefore functionally diploid (Figure 1.4).
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Figure 1.4. Schematic drawing of the HIV virion. A- Stylised rendering of a cross section of 
the HIV; B- Schematic drawing of HIV virion surface. Taken from http://en.wikipedia.org/wiki/HIV 
and http://www.rkm.com.au/imagelibrary
The HIV-1 RNA molecule contains nine open reading frames which encode fifteen 
proteins (Figure 1.5; reviewed in Frankel and Young, 1998; Coffin et al., 1997; Goff, 
2001a; Anderson and Hope, 2003):
1) Gag (group-specific antigen) polyprotein (p55) is a 55-kilodalton precursor protein 
which is cleaved into structural virus proteins: matrix (MA, p i7), capsid (CA, p24), 
nucleocapsid (NC, p7) and p6.
• MA (Matrix): The viral structural protein derived from the amino-terminal 
domain of the Gag polyprotein. MA is associated with the inner surface of the 
virus envelope surrounding the capsid. Matrix protein has been implicated in the 
nuclear import of HIV-1 preintegration complexes although it is not essential 
(Bukrinsky et al., 1993b; von Schwedler et al., 1994; Fouchier et al., 1997; Reil 
et al., 1998). It undergoes myristylation at amino-acid position 2 (always Gly)
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that targets the Gag polyprotein to membranes during viral assembly (Gottlinger 
et a l , 1989; Bryant and Ratner 1990; Pal et a l , 1990).
• CA (Capsid): This principal structural protein forms the cone-shaped core of 
the virus particle that encloses the viral RNA, enzymes, and accessory proteins 
necessary for infecting the host cell. The HIV-1 CA contains distinct N- and C- 
terminal domains separated by a short flexible linker (Gitti et a l , 1996). The N- 
terminal domain forms the outer surface of the CA core and exposed residues in 
this domain are the ones most likely to interact with cellular host factors. One 
such factor, cyclophilin A, associates with Pro90 on the exposed loop in the N- 
terminal domain (features of this interaction are expanded upon in the following 
sections, Luban et a l, 1993; Thali et a l,  1994; Braaten et a l,  1996b, c; Gamble 
et a l, 1996). The C-terminal domain plays an important role in capsid assembly 
and particle formation and forms dimers in solution and within crystals (Gamble 
e ta l,  1997).
• NC (Nucleocapsid): is a small, basic, zinc-finger protein that is tightly bound to 
the genomic RNA in the core. It binds specifically to the packaging signal and 
delivers the full-length viral RNAs into the assembling virion.
•  p6: Two functions have been proposed for this proline-rich, 6-kDa protein:
incorporation of the HIV-1 accessory protein Vpr into virus and a role in virus 
particle production. It contains the late domain (PTAP) that is necessary for the 
final steps of virion budding (Huang et a l,  1995).
3'LTR
Figure 1.5. Organisation of the HIV-1 genome. The location of the long terminal repeats 
(LTRs) and the genes encoded by HIV-1 are indicated. Fifteen viral proteins encoded by HIV-1 
are shown in rectangles. The sizes of the genes and encoded proteins are not to scale. Freed, 
2004.
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2) Pol Polyprotein; a precursor protein which is processed into 3 viral enzymes: 
protease (PR, plO), reverse transcriptase (RT, p66/51), and integrase (IN, p32).
• PR (Protease): Cleaves the Gag and Gag-Pol polyproteins to produce viral 
proteins in their mature forms. Retroviral proteases function as homodimers.
• RT (Reverse Transcriptase): An enzyme that catalyses the synthesis of the 
viral RNA into double-stranded DNA. Its carboxy-terminal domain contains an 
RNase H activity that cleaves the RNA portion of the RNA-DNA hybrid 
generated during the reverse transcription reaction (Tanese and Goff, 1988). 
HIV-1 RTs are heterodimers.
• IN (Integrase): DNA recombinase responsible for insertion of the linear double­
stranded DNA copy of the retroviral genome into the host chromosome thus 
forming a provirus. HIV-1 integrase forms tetramers (Cherepanov et al., 2003).
3) Env Polyprotein; is a viral glycoprotein produced as a precursor (gpl60) which is 
cleaved into surface glycoprotein (SU, gpl20) and transmembrane glycoprotein (TM, 
gp41).
• SU (Surface) Protein: trimers of this protein are located on the surface of the 
virus and bind to specific cell-surface receptors (CD4 in the case of HIV) and 
co-receptors. Binding of CD4 to SU cause structural changes to the virus that 
facilitate co-receptor binding and subsequent viral entry.
• TM (Transmembrane) Protein: The primary function of this integral envelope 
protein subunit is to anchor SU in the viral membrane and to mediate virus entry 
by triggering virus-host cell membrane fusion. TM is closely associated with SU 
by non-covalent interactions.
Apart from these proteins, common to most retroviruses, HIV-1 encodes six additional 
proteins, often called accessory proteins, three of which (Vif, Vpr, and Nef) are found in 
the viral particle. An overview of these proteins is in table 1.3 and a more detailed 
description of their function is provided in chapter 1.2.3.
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NAMK SIZE FUNCTION
Tat
(Transcriptional
activator)
p l6 /
p l4
Essential for virus replication. Activates viral transcription by binding to 
the TAR RNA element o f newly transcribed pro virus and recruits several 
host factors that enhance RNA polymerase II elongation on the viral 
DNA template.
Rev
(Regulator of  
viral gene 
expression)
p l9
Phosphoprotein that binds to the RRE site (a site located in the env 
coding region) and promotes nuclear export o f unspliced and 
incompletely spliced viral RNAs to the cytoplasm.
V if
(Viral infectivity 
factor)
Allows HIV-1 to evade an innate immune defence in the host cell
p23 mediated by members o f the APOBEC family o f proteins. V if targets APOBEC3G for proteasomal degradation thus preventing it from 
entering the virion during budding from a host cell.
Vpr
(Viral protein R) p l4
Basic protein, found in virions, causes infected cells to arrest in the G2 
phase o f the cell cycle and may target retroviral preintegration complexes 
to the nucleus.
Vpu
(Viral protein 
U)*
p l6
An integral membrane protein that causes degradation o f newly 
synthesised CD4 in the endoplasmic reticulum and enhancement o f  
virion release from the plasma membrane. The latter is possibly due to 
counteracting a dominant host cell restriction o f HIV-1 particle 
production (Varthakavi et al., 2003; Neil et al., 2006). Vpu is unique to 
HIV-1 and SIVCDZ.
Nef
(Negative factor) p27
A myristylated protein that reduces the levels o f  cellular CD4 and MHC I 
molecules, upregulates FasL expression, enhances virion infectivity and 
alters the state o f cellular activation. HIV-1 N ef is lacking the ability to 
downregulate TCR-CD3 and thus to inhibit cell death. This ability is 
common to N efs from other primate lentiviruses, including HIV-2, 
resulting in a decreased pathogenicity o f the virus (Schindler et al., 
2006). HIV pathogenesis is slowed significantly in the absence of Nef. It 
is also hypothesised that N ef prevents virus from being restricted by a 
proteasome-dependent cellular mechanism (Qi and Aiken, 2007).
Table 1.3 Accessory proteins of HIV-1. ‘Comparing to HIV-1, HIV-2 does not encode Vpu but 
contains an additional gene called Vpx (Viral Protein X). Two functions of Vpr in HIV-1 are split 
between Vpr and Vpx in HIV-2, with the HIV-2 Vpr protein inducing cell cycle arrest and the Vpx 
protein required for nuclear import.
HIV RNA contains a number of special RNA elements which are required for viral 
replication. These key sequences are mostly clustered at the termini of the RNA (Figure 
1.6). Starting from the 5' end immediately after the cap is the TAR hairpin. This is the 
Tat-binding site followed by a short sequence, called R (for repeated) region. It is 
present twice in the RNA, at both RNA termini. Downstream of R sequence lies U5 
(unique 5') region, which includes one of the att sites needed for pro viral integration. 
Next follows the primer binding site (pbs) at which a tRNA is hybridized to the viral 
genome and serves as a primer for the initiation of minus-strand DNA synthesis by 
reverse transcription. The region downstream of the pbs contains the major signal for 
the encapsidation of viral RNA into the virion. It is called the Psi (\|/) element or 
packaging sequence. This region also contains a "kissing loop" hairpin which is a 
dimerisation site that facilitates incorporation of 2 genomic RNAs into the virion and a 
major splice donor site which is needed for the formation of subgenomic RNAs. The
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following RNA sequences are coding regions for the viral proteins and include the 
slippery sequence and hairpin that promotes the ribosomal frameshift needed for 
translation of the HIV-1 Gag-Pol polyprotein. An approximately 200 nucleotide RNA 
element called the RRE (Rev Response Element) is encoded within the env region of 
HIV-1. The RRE contains a high affinity binding site for Rev and is necessary for Rev 
function. Downstream of the coding genes lie most of the splice acceptor sites and a 
polypurine tract (ppt), a short site of at least nine A and G residues that is important for 
the initiation of the plus-strand DNA synthesis (lentiviruses also contains a central copy 
of the ppt region (cppt) in the centre of the genome). It is followed by a unique 3' 
sequence (U3) which contains a number of important cis-acting elements for viral gene 
expression and another of the att sites required for DNA integration. Almost at the end 
of the 3' end is the 3' copy of the R region followed by a poly(A) tail.
pbs
U5 U3
cap pp tenv
RREpol
Figure 1.6. The structural elements of the retroviral RNA genome. The single-stranded 
RNA genome is depicted as a curved line. From 5' to 3' along the RNA, the features include a 
5' cap structure; ft, a sequence block repeated at both 5' and 3' ends; U5, a unique 5' 
sequence; pbs, the primer binding site and site of initiation of minus-strand DNA synthesis; Y, 
the major recognition site for the packaging of the viral RNA into the virion particle; the gag, pol, 
and env  genes; RRE, the Rev response element; ppt, the polypurine tract and site of initiation of 
the plus-strand DNA synthesis; U3, a unique 3' sequence; the second copy of the R sequence; 
and finally, a 3' poly(A) sequence. See text for details. Goff, 2001a.
1.2.3 The HIV lifecycle
As intracellular parasites, retroviruses rely heavily on the use of numerous cellular 
machineries for completion of their replication cycle. This section describes the life 
cycle of HIV and considers positive cellular factors necessary for viral replication. 
Examples of dominant negative cellular factors that inhibit retroviral infection are 
described in chapter 1.3.
Retroviruses replicate through a unique life cycle, which differentiates them sharply 
from other viruses (Figure 1.7). The life cycle of a retrovirus starts with the binding of 
particles to the host cell membrane. Fusion of the viral envelope with the cellular
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plasma membrane, via specific receptor-envelope interactions, permits the viral core to 
enter the infected cell. The viral reverse transcriptase is then used to transcribe genomic 
RNA into a double-stranded DNA molecule. After nuclear translocation, viral DNA is 
inserted into the host-cell chromosome by viral integrase and is then called a provirus. 
This integration is required for the synthesis of new viral RNA molecules by the host 
cell RNA polymerase. At this point, the early phase of the viral life cycle ends and the 
late phase begins, where transcription and translation of viral DNA are performed by 
the cellular machinery. New viral RNA strands serve either as viral RNA genomes or as 
mRNA that is translated into viral proteins. After assembly of RNA and viral proteins, 
particles bud from the plasma membrane and are further matured by protease cleavage 
of Gag polyprotein. Retroviruses are examples of enveloped viruses, in which the 
protein shell is enclosed by an outer lipid bilayer membrane (reviewed in Coffin et al., 
1997, Goff, 2001a).
HIV vnon centering 
2 copies ot RNA genome
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viral ccoe 
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into cell
Figure 1.7. A schematic view of the retrovirus life cycle. Indicated are the major steps of 
HIV-1 replication. See text for details. Rambaut et al., 2004.
1.2.3.1 Binding and virus entry
HIV begins its replication cycle by the adsorption of viral particles to the surface of 
their target cell. This early attachment of the virions to the cell surface has been 
attributed to variety of cell-surface molecules, including heparan sulphate (Mondor et
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al., 1998) and nucleolin (Nisole et a l, 1999). HIVs and SIVs are also known to bind 
dendritic cells through interaction of their envelope glycoproteins with DC-SIGN 
(dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin) and DC- 
SIGNR (DC-SIGN related) molecules on the surface of dendritic cells (Pohlmann et a l , 
2001). These attachment factors do not promote viral entry and lead to productive 
infection, but instead, serve to concentrate the virus on the target cell surface prior to its 
interaction with a specific viral receptor or to transport the virus to new compartments 
within the host.
Following binding, retroviral particles, through interactions of viral envelope 
glycoproteins, use specific host receptors to enter the target cell. The main cell surface 
molecule to which the HIV surface protein binds is CD4 (Dalgleish et a l, 1984; 
Klatzmann et a l,  1984; Maddon et a l, 1986). This cell-surface glycoprotein is present 
on cells of the immune system: T lymphocytes, monocytes, macrophages and antigen 
presenting dendritic cells which makes these cells the prime target for infection. 
However, the SU-CD4 interaction is not sufficient for HIV entry. In addition to CD4, 
HIV-1 requires a co-receptor for cell entry. There are 2 types of co-receptors, both of 
them chemokine receptors, the use of which defines two ‘groups’ of HIV. The CCR5 
coreceptor is used by the macrophage-tropic, non-syncytium-inducing viral isolates (R5 
group) and CXCR4 is used by T-tropic, syncytium-inducing isolates (X4 group, 
Alkhatib et a l, 1996; Choe et a l, 1996; Deng et a l,  1996; Doranz et a l,  1996; Dragic 
et a l,  1996; Feng et a l, 1996; Zhang et a l,  1996). R5 strains dominate during the early 
years of HIV infection while X4 strains sometimes occur later in infection.
The interaction of gpl20, CD4 and the co-receptor triggers conformational changes that 
lead to the transition of the gp41 envelope subunit into a fusion-competent 
conformation. Hydrophobic fusion sequences are inserted into the target cell membrane, 
viral and cellular membranes fuse together and viral core is released into the cytoplasm 
(Nisole and Saib, 2004).
1.2.3.2 Uncoating
Once the viral core, containing the viral RNA genome and assorted proteins, is released 
into the cytoplasm, it undergoes at least partial disassembly (a process usually referred 
to as uncoating) before reverse transcription can be successfully completed. This point 
in the retroviral life cycle is poorly understood. Capsid uncoating leads to the formation 
of sub-viral particles called reverse transcription complexes (RTCs) and pre-integration
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complexes (PICs). Typically RTCs are complexes where reverse transcription takes 
place and PICs are integration-competent complexes with completed reverse 
transcription product. Both are large nucleoprotein structures. Biochemical analysis of 
the RTCs/PICs is technically difficult and has failed to provide a clear answer about the 
RTC/PIC’s protein composition. The problem is that the size, components and density 
of RTC are very sensitive to detergents and thus depend on the conditions used for their 
isolation. Another problem is that the majority of the viral particles entering the cell will 
not cause productive infection and thus their purified complexes may not necessarily 
represent the composition of infectious RTCs/PICs.
Most studies have shown that HIV-1 PICs contain the pol gene products (protease, 
reverse-transcriptase, integrase) and Vpr. The presence of the Gag proteins within these 
complexes is less clear. Earlier studies indicated that nucleocapsid and matrix proteins 
were present in purified PICs (Bukrinsky et a l , 1993a, b; Miller et al., 1997) whereas a 
more recent report contradicts this (Fassati and Goff, 2001). However, most studies 
agree that PICs purified from HIV-1 infected cells are not associated with CA protein 
while murine leukaemia virus PICs appear to contain CA. MLV cores persist longer 
than those of HIV since, apart from CA, also MLV NC and MA are detected in the 
vicinity of the nuclear membrane (Risco et a l , 1995). HIV-1 RTCs/PICs seem to recruit 
cellular proteins, for instance cellular Ku70, Ku90, HMG A l, LEDGF and BAF (more 
about these proteins in chapter 1.2.3.6; reviewed in Dvorin and Malim, 2003).
Little is known about how viral core disassembles and which of the viral or cellular 
proteins influence this event. Only one host protein, cyclophilin A, has been 
convincingly shown to functionally interact with the HIV-1 CA. CypA is an abundantly 
expressed cell protein that catalyses the cis/trans isomerisation of peptidyl-prolyl bonds 
and which was shown to be incorporated into HIV-1 virions through its interaction with 
the G89-P90 residues in a protruding CA loop (Luban et a l , 1993; Franke et a l , 1994; 
Thali et a l , 1994; Gamble et a l , 1996). It is estimated that roughly one molecule of 
CypA is packaged per 10 Gags (Cantin et a l , 2005). The failure of HIV-1 CA to bind 
CypA leads to a defect in the early phase of HIV-1 infection, before reverse 
transcription (Franke et a l , 1994; Thali et a l , 1994; Braaten et a l, 1996a, b, c; 
Dorfman and Gottlinger, 1996; Franke and Luban, 1996; Braaten and Luban, 2001; 
Sokolskaja et a l, 2004). The precise functional role of CypA in infection remains to be 
determined. Several groups have hypothesised that CypA functions as an uncoating 
factor and has a role in the disassembly of the CA core (reviewed in Luban, 1996). 
However, later it was suggested that CypA prevents an antiviral factor from accessing
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the viral capsid (Towers et al., 2003; for further details see chapter 1.3.4). The role of 
CypA in HIV-1 replication is the subject of Result Chapter 2.
1.2.3.3 Reverse transcription
In vitro assays have demonstrated that addition of the four dNTPs and a divalent cation 
to HIV virion is all that is required for the reverse transcriptase to start DNA synthesis 
(Zhang et al., 1998; Zhang et al., 2000). Although reverse transcription, can initiate 
within the intact core it seems that for the progression of reverse transcription the 
uncoating of the viral core is essential (Zhang et al., 2000). HIV-1 reverse transcription 
occurs within RTCs during its transport through the cytoplasm of infected cell to the 
nucleus.
As a schematic representation of this process shows in Figure 1.8., HIV reverse 
transcription is initiated by the annealing of a tRNALys primer to a pbs site of the 
genomic RNA. It then proceeds through a complex series of steps and ends with 
formation of a linear, double stranded DNA molecule with a U3, R and U5 repetitions, 
called long terminal repeats (LTRs), at each end of a new DNA molecule. At this point 
the newly formed cDNA is ready for integration.
Very few host factors were shown to be important for the process of reverse 
transcription. Some studies have revealed that an intact actin cytoskeleton is important 
for efficient reverse transcription (Bukrinskaya et al., 1998). Kewalramani and 
colleagues recently reported that expression of a C-terminally truncated form of murine 
CPSF6, a component of spliceosomes and 3’pre-mRNA processing machinery, 
restricted infection by X4- and R5-tropic HIV-1, HIV-2, and SIV but not by MLV. The 
block occurs at the later stages of reverse transcription when the completion of second 
strand synthesis is decreased while the early steps of reverse transcription are 
unaffected. The wild-type form of CPSF6 did not interfere with HIV-1 infection 
(Ambrose et al., in press).
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Figure 1.8. The reverse transcription of the retroviral genome. Yellow and blue colours 
represent RNA; red and green colours represent DNA. Adapted from www.jyi.org/articleimages
1.2.3.4 Trafficking of incoming virus through the cytoplasm
To reach the pores in the nuclear membrane, the RTCs have to travel through the 
cytoplasm to the nucleus. Because of the high viscosity of the cytoplasm, due to the 
presence of organelles, the cytoskeleton and the high protein concentration, significant 
movement of these large particles by simple diffusion is unlikely. To overcome this 
obstacle, HIV-1 utilises the cellular cytoskeleton (reviewed in Dvorin and Malim,
2003).
After the fusion of the viral and cellular membranes, HIV RTCs have been shown to 
initially associate with the actin filaments which may involve a direct interaction 
between matrix and/or nucleocapsid protein and the actin network (Bukrinskaya et al., 
1998; Liu et al., 1999; Wilk et al., 1999; Ibarrondo et al., 2001). Although actin is
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present throughout the entire cytoplasm, its concentration is highest directly underneath 
the plasma membrane. If RTCs are prevented from interacting with actin filaments, 
either by cytochalasin D, an inhibitor of actin polymerization or by blocking the Arp2/3 
complex which promotes actin polymerisation, viral infectivity is significantly reduced 
(Bukrinskaya et al., 1998; Komano et al., 2004). Pseudotyping HIV-1 with a VSV-G 
envelope, which enables it to enter the cells via endosomes, instead of by fusion at the 
cell surface, eliminated the impact of actin microfilaments (Bukrinskaya et al., 1998) 
and Arp2/3 (Komano et a l , 2004) on HIV-1 infection. These studies indicate that 
association with actin is important only for viruses that fuse at the cell surface.
In order for the RTC to reach the nucleus it is translocated via the microtubule network 
where, with the help of cellular dynein-dependent motor complex, it reaches the 
microtubule organizing centre (MTOC) located in the vicinity of the nucleus 
(McDonald et a l , 2002). The switch from actin to the microtubule network might be 
provided through an interaction with the cytoplasmic light chain 8 (LC8) of dynein. 
LC8 was shown to bind Gag proteins (Petit et a l , 2003) and also to interact with 
myosin V, the actin-based motor mainly located at the plasma membrane (reviewed in 
Harrison and King, 2000). Through a yeast-two hybrid screen, Gags from a wide range 
of viruses have been found to interact with Kif4, a member of the kinesin superfamily 
and a component of microtubule motor complexes (Kim et a l , 1998; Tang et a l , 1999). 
HIV-1 IN, which is present in RTCs/PICs, was also shown to interact with yeast 
microtubule-associated proteins (de Soultrait et al., 2002). HIV-1 is not the only virus 
that utilises the microtubule network for intracellular transport—a similar mechanism 
has been demonstrated for other viruses such as herpes simplex virus-1 (Sodeik et a l , 
1997) and adenovirus (Suomalainen et a l , 1999; Kelkar et a l,  2004).
Recently, a published report presented data demonstrating that cyclophilin A associates 
in vitro and in vivo with dynamitin, a component of the dynein/dynactin motor protein 
complex (Galigniana et a l, 2004). These results suggest that CypA may act as a 
connector between the HIV-1 CA core and the microtubule network. However, the 
experiments demonstrating this link have not been reported.
1.2.3.5 Nuclear import
Reverse-transcribed DNA associated with viral proteins in the form of PICs must enter 
the nucleus in order to proceed with the infectious cycle. PICs from most retroviruses 
(like MLV) are unable to enter intact nuclei and must wait for the breakdown of the
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nuclear envelope occurring during mitosis (Roe et al., 1993). In contrast, lentiviruses 
are able to actively cross nuclear membranes allowing them to productively infect non­
dividing cells such as macrophages (Weinberg et a l,  1991; Lewis and Emerman, 1994). 
HIV-1 PICs are too large to diffuse through nuclear pore complexes (NPCs), a large 
supramolecular protein structures that span the nuclear membrane. Instead, HIV-1 PICs 
use an active, energy-dependent mechanism for nuclear import (Bukrinsky et al., 1992). 
Some of the components of HIV-1 PICs contain a nuclear localization signal/s (NLS) 
that engages the cellular transport proteins, which then direct the PIC through the 
nuclear pore. The NLS in the PIC most likely interacts with the nuclear receptor 
importin p, either directly or through the adapter importin a  or another adaptors such as 
snurportin, RIP (Rev interacting protein) or importin 7 (Fried and Kutay, 2003). 
Although importin 7 has been proposed to play a role in the nuclear import of HIV-1 
PICs in primary macrophages (Fassati et al., 2003) a subsequent study failed to confirm 
this finding (Zielske and Stevenson, 2005).
Initially it was thought that the most likely protein mediators of the uptake of HIV-1 
PIC into the nucleus were the HIV-1 MA, IN and Vpr proteins associated with the PIC. 
All of them were shown to contain one or atypical or non-typical nuclear localisation 
signals and to interact with importins (reviewed in Goff, 2001b; Bukrinsky, 2004; 
Nisole and Saib, 2004; Anderson and Hope, 2005; Fassati, 2006). Another factor 
proposed to regulate HIV nuclear import is the unusual structure of the viral cDNA 
intermediate called the “central DNA flap” structure (Zennou et al., 2000). It is a triple 
stranded DNA structure which is produced because of additional initiation of the plus- 
strand DNA synthesis at a central polypurine tract of the HIV genome (within pol 
sequence). It may provide the optimal conformation to the PIC necessary for interaction 
with importins and/or translocation through the nuclear pore (Zennou et al., 2000; Van 
Maele et al., 2003; Ao et al., 2004). However, the importance of each above mentioned 
viral protein in nuclear translocation remains controversial since subsequent studies 
have shown that HIV lacking one or more of these NLS elements still retains a 
significant ability to infect non-dividing cells (Fouchier et al., 1997; Reil et al., 1998; 
Petit et al., 2000; Limon et al., 2002). Moreover, even when all of these viral NLS 
elements were impaired at once (either by mutation, deletion or replacement with MLV 
analogue) a resulting chimeric HIV-1 was still able to infect non-dividing cells 
(Yamashita and Emerman, 2005). Thus, elucidating the mechanism of HIV-1 nuclear 
import is clearly a challenging area of research and it still remains to be fully 
characterised.
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1.2.3.6 Integration
Once within the nucleus, integration of reverse transcribed viral cDNA is carried out by 
the integrase protein (IN). Retroviral integration occurs in 2 catalytic steps, referred to 
as 3'-processing and strand transfer. 3'-processing takes place in the cytoplasm within 
the preintegration complex. During this step, integrase removes a pGT dinucleotide at 
each 3’-end of the viral long terminal repeats (LTRs) which exposes a 3'-OH group of 
an adjacent highly conserved cytosine-adenosine (C-A) dinucleotide. The following 
strand transfer occurs in the nucleus where IN mediates a concerted nucleophilic attack 
by each of the 3’-hydroxyl residues of the viral DNA on the host target DNA. In this 
reaction the viral DNA ends are ligated into the target DNA and the process is 
completed by cleavage of the unpaired dinucleotides from the 5’-ends of the viral DNA. 
The single stranded gaps created in this process are most likely repaired by host-cell 
DNA-repair enzymes (Figure 1.9; reviewed in Van Maele et al., 2006).
CAQT-3' S'-ACTG 
GTCA-5' 3' TGAC
3 ' processing
CA-OH -3' 5'-ACTG. 
pGT GTCA-5' S'-OH-AC'pGT
Cytoplasm
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Nucleus r —^
\ ^ ;  CA-OH-3' 5'-ACTGD N A-strand
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Figure 1.9. Outline of the integration reaction. The 3 -processing reaction occurs in the 
cytoplasm, whereas DNA-strand transfer takes place in the nucleus. The strand-transfer 
reaction is concerted: both viral DNA ends are inserted into the host chromosomal DNA at the 
same time. In the case of HIV-1, the distance between the integration sites of both ends is 
always five base pairs. Repair of the remaining gaps in the chromosomal DNA results in a five- 
base-pair duplication of the host cell genome. Van Maele et al., 2006.
Several host factors have been proposed to be important in the course of HIV-1 
integration. The integrase interactor 1 (Inil or hSNF5), a subunit of the SWI/SNF 
chromatin-remodelling complex, has been shown to stimulate the in vitro DNA-joining
39
activity of IN (Kalpana et al., 1994). The high mobility group chromosomal protein Al 
(HMG A l), a non-histone DNA binding protein important for transcriptional regulation 
and chromatin structure, has also been shown to stimulate the integration reaction in 
vitro. This effect may be regulated through induced changes in DNA structure (Famet 
and Bushman, 1997). The barrier-to-autointegration factor (BAF), a small basic DNA 
binding protein, not matching any other identified protein, prevents intramolecular 
integration of the viral cDNA, possibly through condensing the viral DNA in the PIC 
(Lee and Craigie, 1998; Zheng et al., 2000). Lens epithelium-derived growth factor 
(LEDGF/p75), a protein implicated in the regulation of gene expression and the cellular 
stress response, was also found to interact with lentiviral IN (Cherepanov et al., 2003) 
and to be a component of the PIC (Llano et al., 2004b). Its proposed roles in retroviral 
integration are a) protecting the IN from proteasomal degradation (Llano et al., 2004a) 
and b) assisting with tethering of IN to the chromosomal DNA thereby increasing the 
likelihood that viral cDNA will integrate into a transcriptionally active region (Maertens 
et al., 2003; Ciuffi et al., 2005). A strong knock-down of LEDGF/p75 in cells has been 
reported to not only significantly affect viral replication (Llano et a l , 2006) but also to 
affect HIV integration site distribution (Ciuffi et al., 2005). Another factor involved in 
integration is p300, a cellular acetyltransferase known to acetylate histones and regulate 
chromatin conformation. Direct interaction with integrase was shown both in vitro and 
in vivo (Cereseto et al., 2005). P300 was shown to acetylate three specific lysines in the 
C-terminus of integrase and to modify its activity (Cereseto et al., 2005). The most 
recently discovered factor claimed to participate in HIV-1 integration is emerin, an 
integral inner-nuclear-envelope protein. Recent studies have shown that the interaction 
of viral cDNA with chromatin was dependent on emerin and infection of primary 
macrophages in which emerin was reduced was abortive (Jacque and Stevenson, 2006). 
Although viral cDNA localised to the nucleus its integration into host chromatin was 
inefficient. BAF, which is a binding partner of emerin, was shown to be required for the 
ability of emerin to support HIV-1 replication. However, a later study in which emerin 
expression was potently reduced in human cells or completely knocked-out in mouse 
cells, failed to confirm the importance of this factor in HIV-1 infectivity (Shun et al., 
2007).
Mapping over 500 integration events of HIV-1 and HIV-1-derived retroviral vectors in 
a human T-cell line revealed that integration preferentially occurs in genes highly 
transcribed by RNA polymerase II, without a preference for introns or exons (Schroder
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et a l,  2002). MLV, by contrast, favours integration at or near gene promoter regions 
(Mitchell et a l, 2004; Ciuffi and Bushman, 2006).
I.2.3.7 The late phase of HIV infection
The late phase of the retroviral life cycle begins with the synthesis of viral RNAs and 
proteins, continues with the assembly of virus particles and ends with the budding of 
progeny virions.
Once integrated, the provirus serves as a template for the transcription of viral genes. 
Transcription is carried out by RNA polymerase II which recognises a promoter region 
located in the 5’ LTR. The LTR also possesses binding sites for numerous cellular 
transcription factors, including NF-kB, Spl, AP-1 and NF-AT which are important in 
controlling viral gene expression (reviewed in Pereira et a l,  2000; Freed, 2004; Wu, 
2004; Richter and Palu, 2006). Despite the importance of these factors, transcription 
initiated from the HIV-1 promoter proceeds inefficiently and requires the viral protein 
Tat to enhance the processivity of the RNA polymerase II complex.
Unlike most transcriptional activators, Tat mediates trans-activation by interacting with 
RNA rather than with DNA (Berkhout et a l,  1989). This interaction occurs specifically 
between Tat and a specific 59-residue RNA hairpin at the 5’ end of nascent viral 
transcripts known as the TAR (trans-activating response element; see chapter 1.2.2). Tat 
binds to the TAR as a complex with the human cellular factor cyclin T l, which leads to 
recruitment of cyclin-dependent kinase 9 (Cdk9) to the TAR element (Herrmann and 
Rice, 1993; Wei et a l, 1998). Kinase activities of Cdk9 are activated by this recruitment 
and result in the hyper-phosphorylation of the C-terminal domain of RNA polymerase
II, thereby stimulating transcriptional elongation (Price, 2000).
Successful transcription of the HIV provirus produces a single full-length primary 
transcript, which in some cases is partially or fully spliced to produce mRNA for HIV 
proteins and in some cases is left unspliced. Unspliced RNA transcripts serve as the 
genomic RNA and are encapsidated into progeny virions. Unspliced RNA also acts as a 
template for the synthesis of Gag and Gag-Pol gene products. Because nuclear export of 
unspliced/partially spliced, intron containing, cellular transcripts is restricted in 
mammalian cells, HIV has evolved the viral Rev protein to overcome this obstacle. Rev 
binds to a ds-acting RNA element called the Rev-response element (RRE) present in 
the 3’ region of all unspliced or partially spliced HIV transcripts (Malim et a l, 1989; 
reviewed in Cullen, 2003; Freed, 2004). Nuclear export of RNA-Rev complexes
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involves a direct interaction of Rev with the nucleocytoplasmic transport factor Crml 
(chromosome region maintenance 1), in conjunction with a GTP-bound form of Ran 
GTPase (Fomerod et al., 1997). Once the RNA-Rev-Crml-Ran-GTP complex has 
translocated through nuclear pores to the cytoplasm, the Ran-bound GTP is hydrolyzed 
to GDP and the complex disassembles. Recently a new protein called DDX3 was shown 
to be involved in this process. DDX3 is a member of the DEAD box RNA helicases 
located around nuclear pores that bind Crml (Yedavalli et al., 2004). Rev is imported 
back to the nucleus by its association with the cellular nuclear import receptor importin
(3.
Once within the cytosol, viral mRNA is translated into proteins by the host cell 
translation machinery (reviewed in Coffin et al., 1997; Goff, 2001a). Structural proteins 
encoded by the Gag gene are translated into a 55 kDa polyprotein that contains MA, 
CA, NC and p6 proteins. The full-length unprocessed mRNA, identical in sequence to 
the genomic RNA, serves as a template for the translation. Sometimes, in about 10% of 
Gag translation events, the cellular machinery undergoes a -1 frameshift in the p6 
coding region and allows reading through the gag stop codon to the adjacent pol reading 
frame. This results in the formation of a 160 kDa Gag-Pol fusion protein which, apart 
from the structural proteins, also contains PR, RT and IN. These individual protein 
components are later released by the activity of viral protease. While Gag and Gag-Pol 
polyproteins are synthesised by cytoplasmic ribosomes, env mRNA, encoding the 
envelope polyprotein gpl60, is translated on rough endoplasmic reticulum-associated 
ribosomes. Inside the endoplasmic reticulum gpl60 is glycosylated, associated into 
trimers and cleaved by cellular furin proteases into its SU and TM subunits. This 
complex of envelope proteins is then trafficked through the Golgi to the cell membrane 
for virion assembly and budding.
Encapsidation of full-length viral genomic RNA is specific and occurs in the cytoplasm. 
Specificity is mediated by cw-acting packaging signals, which are mainly located in the 
5' untranslated leader region in the genomic RNA, and by viral proteins acting in tram, 
especially the viral Gag polyprotein. Although the components involved in packaging 
are similar between HIV-1 and HIV-2, the mechanisms appear to be slightly different 
(Kaye and Lever, 1999). The core packaging sequence in HIV-1 is situated immediately 
downstream of the major splice donor (Lever et al., 1989), and thus is present only on 
the viral genomic RNA. The HIV-1 Gag polyprotein specifically recognises and binds 
to RNAs that contains this encapsidation signal (v|/) (Kaye and Lever, 1996) and is able 
to encapsidate RNA without being translated in cis from the viral genome (McBride et
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al., 1997). In contrast, HIV-2 contains its packaging region upstream of the splice donor 
(McCann and Lever, 1997; Griffin et a l , 2001) and thus all viral messages contain the 
encapsidation signal. HIV-2 encapsidates its genomic RNA cotranslationally, so that 
only genomic HIV-2 RNAs which are templates for a full-length Gag polyprotein are 
efficiently incorporated into progeny virions (Kaye and Lever, 1999). This mechanism 
has been termed cis-acting encapsidation and results in a non-reciprocal packaging 
relationship between HIV-1 and HIV-2. Whilst wild-type HIV-2 is able to encapsidate 
mainly its own RNA, HIV-1 efficiently encapsidates both HIV-1 and HIV-2 vector 
constructs in addition to its own RNA (Kaye and Lever, 1998).
Expression of the retroviral Gag polyprotein by itself is sufficient for the formation of 
virion-like particles (Karacostas et al., 1989; Morikawa et al., 1999). The HIV-1 Gag 
polyprotein contains three important domains which play roles in assembly and 
budding. They are the membrane targeting (M), interaction (I), and late (L) domains 
(Wills and Craven, 1991). The M-domain is located within the MA region. It is 
modified by a covalent addition of myristate to its first glycine residue which is 
followed by a stretch of basic residues. Both of these signals are required for 
membrane-targeting function of Gag (Bryant et al., 1989; Gottlinger et a l , 1989; 
Martin-Serrano and Bieniasz, 2003a; Lee and Linial, 1994). The I-domain is responsible 
for Gag multimerisation and is located mainly in the NC region (Sandefur et a l , 2000). 
Retroviral budding is mediated by the L-domain through the conserved P(T/S)AP and 
LYPLxxL motifs located in the p6 region of HIV-1 Gag (Gottlinger et a l , 1991; Huang 
et a l , 1995; Strack et a l, 2003). In the case of MLV a similar L-domain motif is present 
within the pl2 viral protein (Yuan et a l, 1999). The L-domain was shown to require 
modification by mono-ubiquitylation to mediate budding (Ott et a l,  1998; Patnaik et 
a l, 2000). Recently, the ubiquitin-protein ligase hPOSH was found to participate in this 
process (Alroy et a l , 2005).
A better understanding of the HIV budding process was achieved by the identification 
of two cellular factors able to interact with the motifs present in the L-domain of p6. 
TsglOl was shown to interact with the P(T/S)AP motif and AIPl/Alix was shown to 
interact with the LYPLxxL motif (Garrus et a l,  2001; Verplank et a l,  2001; Strack et 
a l,  2003). These findings indicated the connection between the endosomal sorting 
pathway and HIV-1 budding. TsglOl and AIPl/Alix are both members of the Class E 
vacuolar sorting machinery (Vps). TsglOl is a component of the ESCRT-I (endosomal 
sorting complex required for transport-1) complex and AIPl/Alix appears to serve as a 
connector between the ESCRT-I and ESCRT-III sorting pathways by simultaneously
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interacting with TsglOl and CHMP (a member of ESCRT-III complex) proteins (Figure 
1.10; Martin-Serrano et al., 2003b). Altogether, there are three ESCRT multiprotein 
complexes (termed as ESCRT-I, II, III) present in mammalian cells whose function is to 
sort cargo proteins in the multivesicular body (MVB) pathway. Proteins can enter 
multivesicular bodies either via endocytosis from the plasma membrane or via vesicular 
trafficking from the Golgi (reviewed in Cimarelli and Darlix, 2002; Demirow and 
Freed, 2004; Gomez and Hope, 2005). HIV and other viruses can use these components, 
normally involved in the intracellular sorting of membrane proteins, to exit infected 
cells. HIV-1 assembly and budding takes place in the lipid raft regions of the plasma 
membrane (Nguyen and Hildreth, 2000). Some studies, examining HIV-1 assembly and 
budding in macrophages, reported that it can also occur in MVBs and that the virions 
then exit cells using the pre-existing exosome pathway (Nguyen et al., 2003). However, 
a recent study disagreed with these findings and showed that it is assembly at plasma 
membrane that is essential for virus release and the endosomal localisation of HIV-1 
Gag and virions occurs as a result of their internalisation from the plasma membrane 
(Jouvenet et al., 2006).
As shown in Figure 1.10, HIV assembly and budding starts with the targeting of Gag to 
the membrane together with viral RNA and additional viral proteins, which is followed 
by the multimerisation of Gags and recruitment of the ESCRT system through TsglOl, 
AIPl/Alix and other cellular proteins which allows the membrane deformation and later 
fission. Maturation of the virion particle occurs during or after it buds from the host 
cell. During maturation, the HIV protease cleaves the polyproteins into individual 
functional HIV proteins and enzymes. The various structural components then assemble 
to produce a mature HIV virion.
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Figure 1.10. A model for retrovirus release. On the left is a schematic representation of 
endocytosis and MVB sorting of an activated growth factor receptor. On the right is depicted the 
hijacking of MVB sorting machinery for virus release. HIV-1 Gag is believed to mimic Hrs in 
triggering membrane recruitment of ESCRT-I. Virus particles are shown to assemble and bud at 
the plasma membrane or to be released (e.g., from macrophages) through the exosome 
pathway following assembly in the MVB. Additional details provided in the text. Demirow and 
Freed 2004.
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1.3 Restriction Factors
One of the lines of protection against the spread of retroviral infections within different 
species is conferred by the innate immune system of the host. Part of this system is 
exemplified by dominant antiviral factors within cells called "restriction factors". 
Among the array of restriction factors, some act by interfering with early stages of the 
viral life cycle; at the point of viral entry (Fv4), before (TRIM5alpha, TRIMCyp), 
during (APOBEC3G) and after (Fvl, TRIM5alpha) viral DNA synthesis, or by 
interfering with late stages of retroviral infection (ZAP) (Table 1.4). Without doubt the 
list of restriction factors is not yet complete and more will be discovered in the future.
1.3.1 Fv4
The search for host defensive factors active against retroviruses started in the early 
1970s with the study of viruses that cause malignancies in mice. A number of genes that 
affect the susceptibility of mice to infection by Murine leukaemia virus were soon 
described (Lilly and Pincus, 1973). One of these genes, Fv4, located on chromosome 
12, is able to block exogenous infection with ecotropic Friend murine leukaemia virus 
in vivo, in vitro and in transgenic mice expressing the cloned Fv4 gene (Kai et al., 1976; 
Odaka et al., 1981; Ikeda and Sugimura, 1989; Limjoco et al., 1993). Fv4 was shown to 
be expressed at high levels in mouse cells and molecular cloning revealed that it 
encoded a defective ecotropic MLV-related pro virus lacking gag and most of the pol 
sequence but retaining a complete env gene (Kozak et al., 1984; Ikeda et a l , 1985). 
Nucleotide sequencing revealed over 70% homology between Fv4 and ecotropic MLV 
env genes and several substitution mutations were present which when introduced into 
the wild-type MLV env gene blocked viral replication. A viral interference model has 
been proposed as the mechanism of Fv4 restriction (Ikeda et al., 1985; Kai et al., 1986). 
Virus interference refers to the phenomenon in which cells chronically infected with 
one virus are resistant to superinfection with other viruses bearing the same virus 
envelope specificity. Interference is due to the blockade of the virus receptors by the 
envelope glycoprotein of the infecting virus or of an endogenous provirus.
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Species Restriction
factor
Time of Block Restricted viruses I in restricted 
viruses
Mouse Fv4 Entry Ecotropic MLV Amphotropic 
MLV, lentiviruses
Mouse (NIH Swiss) Fvl" Post-reverse 
transcription, before 
integration
B-MLV N-MLV, NB- 
MLV, HIV-1
Mouse (Balb/c) F v lb Post-reverse 
transcription before 
integration
N-MLV B-MLV, NB-MLV
Human TRIM5o/Refl Early post-entry before 
reverse transcription + 
post-reverse 
transcription
N-MLV, EIAV, FIV, 
moderately HIV-1
B-MLV, NB- 
MLV, HIV-2, 
SIVmac, SIVAgm
Human APOBEC3G Viral DNA formation Vif-negative HIV-1, 
SIVAem, EIAV, HBV
Vif-positive HIV, 
MLV
Cow TRIM505265/ 
Bovine Lvl
before reverse 
transcription, some 
cases after reverse 
transcription
N-MLV, HIV-1, 
HIV-2, EIAV, FIV
B-MLV, NB-MLV
Rat ZAP Viral RNA expression MLV, alphaviruses VSV, polio virus
Old World Monkeys
Chimpanzee TRIM5a ? N-MLV, moderately 
HIV-1
S IV m a c , S I V Agm, B -  
M L V ,  N B - M L V
Orangutan TRIM5a ? N-MLV, moderately 
HIV-1
S IV m a c , S I V Agm, B -  
M L V ,  N B - M L V
Rhesus macaque TRIM5a/Lvl Early post-entry before 
reverse transcription+ 
post-reverse 
transcription
HIV-1, FIV, SIVAgm N-MLV, B-MLV, 
S I V mac
Cynomolgus
monkey
TRIM5a ? HIV-1 S IV m a c
African green 
monkey/tantalus
TRIM5a/Lvl Early post-entry before 
reverse transcription
N-MLV, HIV-1, 
HIV-2, SIVmac, FIV, 
EIAV
B - M L V ,  S I V Agm
African green 
monkey /pygerythrus
TRIM5a ? N-MLV, HIV-1 SIVmac, NB-MLV, 
SIVARm, B-MLV
New World Monkeys
Squirrel monkey TRIM5a/Lvl Post-entry after reverse 
transcription
SIVmac, moderately
sivAem
N-MLV, B-MLV, 
HIV-l, NB-MLV
Owl monkey TRIMCyp Early post-entry before 
reverse transcription+ 
post-reverse 
transcription
HIV-1 N-MLV, B-MLV, 
S IV m a c
Tamarin TRIM5a ? SIVmac, moderately 
HIV-1, SIVAgm and 
N-MLV
B-MLV, NB-MLV
Spider monkey TRIM5a ? S IV m a c , S I V Agm, 
HIV-1, moderately 
N-MLV
B-MLV, NB-MLV
Table 1.4. Properties of dominant resistance genes. Lilly, 1967; Hofmann et al., 1999; 
Towers et al., 2000; Besnier et al., 2002; Cowan et al., 2002; Besnier et al., 2003; Hatziioannou 
et al., 2003; Owens et al., 2003; Hatziioannou et al., 2004b; Keckesova et al., 2004; Nisole et 
al., 2004; Perron et al., 2004; Sayah et al., 2004b; Stremlau et al., 2004; Yap et al., 2004; 
Nakayama et al., 2005; Saenz et al., 2005; Song et al., 2005c; Anderson et al., 2006; Si et al., 
2006; Wu etal., 2006; Ylinen etal., 2006. Abbreviations explained on page 12.
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1.3.2 Fv1
Another example of a gene encoding a restriction factor that inhibits the replication of 
Murine leukaemia retroviruses in mice is Fvl (Lilly et a l , 1967). Fvl (Friend virus 
susceptibility 1) gene has three major restricting alleles among inbred strains of mice. 
The F v ln allele, found in NIH Swiss mice, allows replication of N-tropic MLV (N- 
MLV) strains of virus and blocks very closely related B-tropic strains (B-MLV). The 
F v lb allele, present in Balb/c mice, shows precisely the opposite phenotype; allowing 
replication of B-MLV and blocking N-MLV. A third allele, called F v lnr inhibits 
infection by B-MLV and some N-MLV strains. Some strains of MLV, termed NB- 
tropic (NB-MLV), efficiently infect mouse cells irrespective of the presence of any of 
these alleles. The vast majority of divergent mice species encode full length Fvl alleles 
(Qi et al., 1998) but most of them do not restrict the narrow range of mouse viruses 
tested thus far. The Fvl alleles from mice, which are equivalently susceptible to 
infection by N-, B-, and NB-tropic MLV strains, have been referred to as a null Fvl 
alleles (Fvl0) (Kozak, 1985). Fvl was shown to be co-dominant, so that F v ln/b 
heterozygous animals are resistant to both N-, and B-MLV (Hartley et al., 1970; Pincus 
et a l, 1971; Hartley and Rowe, 1975).
Construction of viral DNA recombinants between N- and B-tropic MLVs mapped the 
viral determinant for N and B tropism to the capsid (CA) protein of the virus 
(DesGroseillers and Jolicoeur, 1983). It was shown to be at position 110, with an 
arginine specifying N-tropism and a glutamate B-tropism. Substitutions of glutamate 
with another acidic amino-acid, like aspartate, also produced B-tropic virus and 
substitution of arginine with another basic amino-acid such as lysine kept the N-tropism 
of the virus. This suggested that to change N to B a charge change from positive to 
negative must take place (Kozak and Chakraborti, 1996).
Analyses of viral DNA in infected cells showed that Fvl blocks virus infection in the 
early stages of infection, after reverse transcription, but before the entry of the virus into 
the nucleus. This is indicated by similar levels of linear DNA in restricted versus 
unrestricted infections but a lower accumulation of circular viral DNA, which is thought 
to be indicative of viral nuclear entry, in restricted infection (Jolicoeur and Rassart, 
1980; Yang et a l, 1980). Furthermore, functional PICs can be isolated from Fvl- 
restrictive cells (Pryciak and Varmus, 1992). Fvl restriction is not dependent on 
a specific route of entry because sensitive virus is restricted whether it enters cells via
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amphotropic, ecotropic or vesicular stomatitis virus envelopes, which are known to 
utilise different routes of entry.
The Fvl gene was isolated by a positional cloning strategy (Best et al., 1996). It 
encodes a protein that exhibits 43% and 60% homology at the nucleotide level to the 
gag gene of the ERV-L family of endogenous retroviral elements in mice and humans, 
respectively (Best et a l , 1996; Benit et a l , 1997). So far no other ERV-L-like elements 
have been shown to contribute to viral permissivity, although there are many that are 
even more closely related to MLV than Fvl (Benit et a l , 1997). Examination of DNA, 
by Southern blot, from variety of mammals (mouse, cat, rat, bat, human, pig, cow, 
African green monkey, hamster) revealed that the Fvl gene is unique to mice (Best et 
a l, 1996; Besnier et a l, 2003). Furthermore, Fvl alleles active against MLV are found 
only in mouse strains that contain many endogenous MLVs suggesting that antiviral 
activity probably evolved in response to the presence of these viruses. The N and B 
alleles of Fvl differ at two internal amino-acid positions (358 and 399) and at the C- 
terminus (Best et a l, 1996). Fvl is one of the examples of how defective retroviral 
DNAs carried in the genome can sometimes be useful for the host. The Gag origin of 
Fvl is also supported by the presence of a highly conserved sequence known as the 
major homology region (MHR) (Benit et a l, 1997). This motif (Q-X3-E-X7-R), whose 
precise role is unknown, is present in the capsid protein of all retroviruses and has been 
shown to be important for the viability of retroviruses in both the early and late stages 
of their life cycle (Mammano et a l, 1994; Craven et a l,  1995). In Fvl, as well as in the 
capsid proteins of all other retroviruses, the integrity of this region is required for 
function, and mutation of these conserved amino-acids in Fvl abolishes its ability to 
restrict, suggesting that it is functioning in a CA-like manner (Bishop et a l,  2001). 
Retroviral capsid proteins are known to multimerise and the simplest model for Fvl 
action is that it can bind to the capsid protein of incoming viral preintegration 
complexes and blocks their proper progression into the nucleus for DNA integration. 
(Best et a l, 1996; Goff, 1996). This notion is consistent with the observation that 
a sufficiently large dose of incoming sensitive Gag can titre out the Fvl product and 
allow the remaining virus to escape the restriction. The block to infection is then said to 
be abrogated. Later it was shown that abrogating virus must be introduced into the cell 
as an incoming virion particle because expression of Gag or CA proteins does not 
abrogate restriction of incoming virus (Bassin et a l,  1980; Duran-Troise et al., 1981; 
Dodding et al., 2005). However, no form of physical interaction between Fvl and CA 
protein of the virus has been demonstrated so far and the mechanism of Fvl restriction
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remains unclear. A recent report demonstrated that the MLV CA is sumoylated and 
suggested this modification was necessary for trafficking of the PIC to the nucleus. 
Perhaps Fvl blocks sumoylation of the capsid thereby trapping the PIC in a non- 
infectious cellular compartment (Yueh et al., 2006).
By using microscopy, Fvl was found to be expressed at extremely low levels and to be 
localised in the cytoplasm where it interacts with the tubules of the Trans Golgi network 
(Yap and Stoye, 2003). A recent report suggests that Fvl might act as a homo-dimer 
(Bishop et al., 2006b).
1.3.3 Ref1/Lv1
Although Southern blot and genome sequence analysis indicates that Fvl is unique to 
mouse, many human and primate cell lines were also shown to restrict infection by N- 
MLV and other retroviruses (Table 1.4; Towers et al., 2000, 2002; Besnier et al., 2002; 
Hatziioannou et al., 2003). A number of human cell lines exhibited resistance to 
vesicular stomatitis (VSV-G)-pseudotyped N-MLV, to an equine infectious anaemia 
virus (EIAV), a lentivirus that naturally infects horses, and moderately to HIV-2, but 
not to B-MLV or any other primate lentiviruses tested so far. Most Old World monkey 
cell lines (African and Asian; for example macaque and African green monkey) restrict 
infection by VSV-G-pseudotyped HIV-1, while the majority of the New World monkey 
cell lines (South American for example Squirrel monkey) restrict infection by SIVmac 
(Hofmann et al., 1999). Several monkey species restrict a broader range of retroviruses. 
African green monkey cells restrict macaque simian immunodeficiency virus (SIVmac), 
HIV-1, HIV-2, N-MLV and EIAV. The putative factors responsible for this restriction, 
named restriction factor-1 (Refl) in humans and lentivirus susceptibility factor 1 (Lvl) 
in simians, share several key attributes that are characteristic for Fvl (Besnier et al., 
2002; Cowan et al., 2002; Munk et al., 2002; Towers et al., 2002). The resistant 
phenotype is dominant; fusion of HIV-1-permissive human cells with HIV-1-resistant 
monkey cells results in heterokaryons that are HIV-1 resistant (Cowan et al., 2002; 
Munk et al., 2002). This suggested the presence of an inhibitor in monkeys and not 
merely the lack of a host factor necessary for the virus life cycle. Moreover, restriction 
of sensitive viruses could be abrogated by preexposure of cells to restricted virus or 
virus-like particles (VLP). Exposure of human cells to a high dose of N-MLV virus 
could abrogate restriction to a second dose of N-tropic virus and preexposure of Owl 
monkey or Rhesus macaque cells to high dose of HIV-1 increased the titre of a second
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HIV-1 dose (Besnier et al., 2002; Cowan et al., 2002; Munk et al., 2002; Towers et al.,
2002; Kootstra et al., 2003). By using a chimeric H I V - l / S I V m a c virus it was
demonstrated that the viral determinant is in the capsid protein. Replacement of the 
capsid or parts of capsid in SIVmac with that of H I V - 1  resulted in a virus that behaves 
largely, in terms of its tropism for multiple simian cell lines, as if it was HIV-1 rather 
than S I V m a c  (Dorfman and Gottlinger, 1996; Cowan et al., 2002; Hatziioannou et al., 
2003, 2004a; Owens et al., 2003). In the case of MLV, the same amino-acid 110 within 
CA that differentiates between N- and B-tropism in mice also determines the tropism 
for human and monkey cells (Towers et al., 2000). Abrogation requires Gag cleavage, 
suggesting that the interacting domain on CA is masked on the precursor protein, and 
implying that the interaction can only occur with mature virion cores but not with the 
immature virions which exit the cell (Dodding et al., 2005). This also provides an 
explanation for the observation that MLV producing cells are fully Fvl protected. 
Restriction does not depend on the route of viral entry into the cell. H I V - 1  virions 
which expressed wild-type envelope on their surfaces and fused at the plasma 
membrane were just as restricted as HIV-1 virions pseudotyped with the VSV-G
envelope which entered the cell through the endocytic pathway. The only obvious
difference in the phenotypes conferred by Fvl and Refl/Lvl is that Fvl acts primarily 
after the completion of reverse transcription, while Refl and Lvl usually block the virus 
before reverse transcription as documented by studies of viral DNA formation (Shibata 
et al., 1995; Towers et al., 2000; Cowan et al., 2002).
Other mammalian species, such as cows, pigs and bats, also specifically restrict N- 
MLV, implying that retrovirus restriction factors in mammals are widespread (Besnier 
et al., 2003). The ability of cells from African green monkeys to restrict both, C-type 
retroviruses and lentiviruses allowed the investigation of whether these distinct 
retroviruses whose capsids share little sequence homology are inhibited by the same 
restriction factor. Cross abrogation experiments showed that exposure of Agm cells 
individually to all restricted viruses, but not unrestricted B-MLV, could saturate 
restriction to N-MLV. Similarly, in human cells, treatment with restricted EIAV VLPs 
is able to restore susceptibility to N-MLV. These results strongly implied that 
a common factor is able to recognise multiple divergent retroviruses. (Besnier et al., 
2002; Hatziioannou et al., 2003).
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1.3.4 TRIM5a
Long-standing efforts to find an antiviral factor responsible for restricting HIV-1 
infection in monkey cells bore fruit in early 2004. Stremlau and colleagues used a 
genetic screen to demonstrate that the tripartite motif (TRIM) containing protein 
TRIM5a from Rhesus monkey, but not human, has the ability to potently restrict HIV-1 
replication (Stremlau et a l , 2004; reviewed in Goff, 2004; Nisole et a l,  2005; Towers, 
2005, 2006; Perez and Hope, 2006). Immediately after this discovery the restriction 
field became very competitive and publications from several laboratories quickly 
confirmed and extended the importance of TRIM5a as a restriction factor, showing that 
human and monkey TRIM5a alleles account for the poor species-specific retroviral 
infectivity described as Refl in human and Lvl in simian cells. Human TRIM5a was 
shown to be responsible for N-MLV activity (Hatziioannou et al., 2004b; Keckesova et 
al., 2004; Perron et al., 2004; Yap et al., 2004) and the TRIM5a of African green 
monkey was shown to have restrictive activity against HIV-1, SIVmac, EIAV and N- 
MLV (Hatziioannou et al., 2004b; Keckesova et al., 2004; Yap et al., 2004). Activity of 
human TRIM5a against N-MLV, but not very closely related B-MLV, and 
discriminating between them on the basis of residue 110 of the capsid protein, 
suggested a viral determinant for restriction in the capsid protein of sensitive virus 
(Perron et al., 2004). Interaction of sensitive virus with human TRIM5a was shown to 
lead to a block in viral reverse transcription (Keckesova et al., 2004; Perron et al.,
2004). This was later shown not to be the case in squirrel monkeys. Squirrel monkey 
TRIM5a, active against SIVmac, does not block SIVmac DNA synthesis (Ylinen et al.,
2005). Subsequently, TRIM5a was shown to be responsible for restriction in various 
Old World and New World primates (Table 1.4; Song et al., 2005c). Interests in other 
mammals apart from humans and monkeys led to the recent identification of a broadly 
effective antiviral TRIM protein in cattle, indicating that innate immune activity of 
TRIM proteins extends beyond primates (Si et al., 2006; Ylinen et al., 2006).
Almost in parallel with the discovery of TRIM5a, a TRIM5-derived restriction factor 
was identified in Owl monkey cells (OMK). Owl monkeys are atypical New World 
monkeys because of their ability to inhibit HIV-1 but not SIVmac. However, this block to 
HIV-1 replication is abrogated when the binding between the capsid protein of HIV-1 
and host cyclophilin A is interrupted (Towers et al., 2003). Remarkably, this 
observation has been explained by the identification of Owl monkey TRIM5 as a fusion 
protein between TRIM5 and cyclophilin A (TRIMCyp) (Nisole et a l , 2004; Sayah et
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a l,  2004b). It appears that a complete CypA pseudogene had been inserted between 
exons 7 and 8 of the TRIM5 gene, thus replacing the C-terminal domain. (Figure 1.11).
1.3.4.1 Main features of TRIM family
Tripartite motif (TRIM) proteins are involved in a wide variety of biological processes 
ranging from apoptosis through cell cycle regulation to viral response. There are about 
70 family members in most mammalian genomes and about 20 members in invertebrate 
organisms, such as flies and worms.
The tripartite RBCC motif that defines the TRIM proteins includes a RING domain, 
either one or two B boxes (B1 and B2), and a coiled coil domain (reviewed in detail in 
Meroni and Diez-Roux, 2005).
Human, macaque, African green monkey, squirrel monkey TRIM5a
Owl monkey TRIMCyp
B - B O X B30.2
B - B O X C y p A
C - C
C - C
Figure 1.11. Schematic presentation of TRIM5a and TRIMCyp molecules.
The RING domain is a cysteine-rich zinc binding sequence, typically involved in 
specific protein-protein interactions. Many RING domains have E3-ubiquitin ligase 
activity. The TRIM5 RING domain was shown to act as a ligase for auto-ubiquitination 
in vitro in the context of the TRIM58 splice variant (Xu et al., 2003). The B box is a 
distinct zinc binding motif of around 40 residues putatively involved in protein-protein 
interactions and present only in TRIM proteins, making it a critical determinant of the 
TRIM family. The two B-boxes have not only different primary sequence and zinc 
binding motifs, but also differ in their tertiary structure. The solution of the structure of 
the B-Box 1 from human TRIM 18 demonstrated that it binds two zinc atoms and adopts 
a RING-like fold, raising the possibility that it could either have E3 ligase activity itself 
or it could enhance and modulate the activity of a nearby RING domain; i.e. confer E4 
enzyme activity (Massiah et al., 2006). This was shown not to be the case for a B-Box2 
domain which is the only B-Box domain encoded within the TRIM5 gene. The B-Box2
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domain binds one zinc atom and its tertiary structure is not similar to any other known 
zinc-binding motif (Borden et a l, 1995). The coiled-coil region is involved in homo- 
and hetero-dimerisation of TRIM proteins (Reymond et al., 2001).
Some TRIM proteins, including TRIM5a, contain aC-terminal 170 amino-acid long 
globular B30.2 domain, also found in members of the immunoglobulin superfamily 
(Henry et a l, 1998; Meyer et a l, 2003, Rhodes et a l,  2005). Although the majority of 
the TRIM5 literature refers to this domain as a SPRY domain this is in fact incorrect. 
Whilst SPRY domains are evolutionary ancient, B30.2 domains, found in butyrophilin 
and TRIM proteins, are more recent domains, comprising the combination of SPRY 
with an additional, 50-60 residue long, PRY domain. Thus, the B30.2 domain consists 
of a combination of SPRY and PRY domains (Rhodes et a l , 2005). No clear function 
has been proposed for a B30.2 domain although it is believed to be involved in protein- 
protein interactions, substrate recognition and/or RNA binding (Ponting et a l,  1997). 
TRIM proteins possessing a B30.2 domain have been implicated in at least 3 different 
pathological conditions: Sjogren's syndrome, familial Mediterranean fever (FMF) and 
Opitz G/BBB syndrome.
Sjogren's syndrome is an autoimmune disease where autoantibodies are raised against 
intracellular 52kDa Sjogren's syndrome nuclear antigen A (SSA/Ro, Ro52, TRIM21) 
(Chan et a l, 1991). TRIM21 was shown to bind directly to the Fc region of human IgG 
isotypes through its B30.2 domain suggesting a role of TRIM21 in regulation of 
immunoglobulin G functions (Yang et a l, 2000; Rhodes and Trowsdale, 2007).
FMF is an autosomal recessive rheumatic disease characterised by recurrent attacks of 
fever with peritoneal inflammation. It is caused by mutations in the B30.2 domain of 
pyrin/marenostrin protein (TRIM20, French FMF Consortium 1997; International FMF 
Consortium 1997). FMF primarily affects people of a Mediterranean origin. Because of 
very high frequencies and selective pressures of FMF alleles in this population it has 
been suggested that it might confer increased resistance to an endemic Mediterranean 
pathogen (Stoffman et a l, 2000).
Opitz G/BBB syndrome is an X-linked inheritance disorder characterised by a 
developmental midline defect caused by insertions or partial deletions in the B30.2 
domain of TRIM 18 (MIDI) (Quaderi et a l,  1997). Mutated TRIM 18 is severely 
affected in its ability to bind microtubules and this results in reduced proteolysis of 
microtubule-associated protein phophatase 2A and anomalous microtubule dynamics 
(Trockenbacher et a l,  2001).
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Human TRIM genes are dispersed throughout the genome with the exception of two 
clusters; one is located in the major histocompatibility complex (MHC) region on 
chromosome 6  (TRIM 10, 15, 26, 27, 31, 38, 39, 40) and the other is located on 
chromosome 11 (TRIM 5, 6 , 21, 22, 34) (Reymond et al., 2001; Meyer et al., 2003). 
Each of the various TRIM proteins is localised in particular cellular compartments with 
TRIM5a being present in cytoplasmic bodies when expressed exogenously (Reymond 
et a l , 2001). The role of cytoplasmic bodies is further discussed in chapter 1.3.4.5.
The most famous and well known TRIM protein is the promyelocytic leukaemia (PML, 
TRIM 19) protein, first identified as a fusion partner with the retinoic acid receptor in 
human acute promyelocytic leukaemia (de The et a l,  1991). PML is localised in matrix- 
associated multi-protein complexes within nuclei, known as PML nuclear bodies (Dyck 
et a l , 1994). PML is essential for the formation and subsequent function of these bodies 
which have been implicated in a wide variety of cellular functions, including gene 
expression, chromatin dynamics, apoptosis, senescence, DNA repair, response to 
interferon and viral infection. Interest in the interactions between DNA viruses and 
PML bodies started with the observation of disruption of PML bodies during herpes 
simplex-1 (HSV-1) infection (Maul et a l, 1993). After the entry of the HSV-1 genome 
into the nucleus PML bodies associate with the viral nucleoprotein complexes. This 
occurs through de novo assembly of PML-like bodies at these sites rather than the 
movement of pre-existing PML bodies towards viral genomes (Everett and Murray,
2005). It is thought that this represents an intrinsic cellular response aimed at repressing 
viral gene expression. HSV-1 encodes a protein called ICP0 which is responsible for 
degradation of the PML protein, thus destroying PML bodies and counteracting cellular 
antiviral activity (Maul et a l, 1993). The observation of association with and/or 
degradation of PML bodies was extended to papovaviruses (SV40 and Polyomavirus), 
adenoviruses, parvoviruses, other members of herpesviridae family and some RNA 
viruses (Ahn et a l, 1998; Chee et a l,  2003; Rosa-Calatrava et a l, 2003; reviewed in 
Everett, 2001, 2006; Regad and Chelbi-Alix, 2001).
Apart from TRIM5a and PML, other members of the TRIM family have been 
implicated in antiviral processes. The TRIM1 gene from human, African green monkey 
and owl monkey cells and TRIM22 and TRIM34 from human cells have been reported 
to weakly restrict N-MLV, HIV-1 and SIVmac respectively (Tissot and Mechti, 1995; 
Yap et a l,  2004; Li et a l,  2006a; Zhang et a l,  2006). The role of TRIM proteins in 
innate immunity is supported by the upregulation of some of its members by interferons 
(IFNs, Regad and Chelbi-Alix, 2001). TRIM5a expression is induced by both type I and
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II IFNs and the interferon responsiveness is mainly mediated through an interferon- 
stimulated response element (ISRE) sequence in the proximal promoter region of 
TRIM5a (Asaoka et al., 2005).
1.3.4.2 Involvement of individual TRIM 5a domains in retroviral restriction
Differential splicing of TRIM5 transcripts results in the production of different TRIM5 
isoforms each increasingly shorter from their C-terminus (Figure 1.12; Reymond et al., 
2001). Five of them (a, p, y, 5, e) have been isolated and three of them (a, y, 8 ) have 
been functionally characterised.
a
0
7
s
Ring domain ®  B box 2 Coiled-coil 1— 1 B30.2 domain
domain domain
Figure 1.12. Splice variants o f human TRIM5 gene. Schematic presentation of different 
TRIM5 isoforms. Modified from Reymond etal., 2001.
TRIM5a is the longest, the only one to contain a B30.2 domain and the only one to have 
antiviral activity, indicating the importance of the B30.2 domain for restriction. This 
was confirmed by mutational analysis of TRIM5a, where a number of groups have 
exchanged sections between human and simian TRIM5a genes and tested the resulting 
chimeras for restriction activity (Nakayama et al., 2005; Perez-Caballero et al., 2005a; 
Sawyer et al., 2005; Stremlau et al., 2005; Yap et al., 2005). These studies showed that 
it was mainly the B30.2 domain that was responsible for the species-specific properties 
of TRIM5a. More detailed mapping within the B30.2 domain revealed that a single 
amino-acid change in the human TRIM5a gene to the corresponding residue in Rhesus 
macaque TRIM5a (R332P) was sufficient to lead to HIV-1 restriction by the human 
protein, although not as strongly as the wild-type simian protein (Stremlau et al., 2005; 
Yap et al., 2005). Surprisingly, this mutant was also able to restrict SIVmac, a property 
not shared by either of the wild-type TRlM5a proteins (Stremlau et al., 2005). Later 
investigation revealed that the potentiation of HIV-1 restriction by the R332P mutant of
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human TRIM5a results from the removal of the positively charged arginine rather than 
from introducing the proline residue (Li et al., 2006c). In the case of N-MLV 
restriction, finding the determinants seems to be more complex and data suggest that 
apart from the B30.2 domain, the coiled-coil domain is also important for restriction 
(Yap et al., 2005). As the residues of the B30.2 domain are responsible for virus 
detection, it is in the best interest of the virus to change its structure, thus evading 
recognition by TRIM5a. This competition between virus and TRIM5a leads to a so 
called ’’Red Queen" effect represented by the rapid replacement of amino-acids at the 
interaction interface between pathogen and restriction factor. Indeed, analysis of 
TRIM5a molecules from numerous primate species revealed that the B30.2 domain had 
undergone intensive positive selection, including many insertions and deletions that 
predate the origin of primate lentiviruses, suggesting that distinct episodes of viral 
infection shaped TRIM5a evolution (Liu et al., 2005; Sawyer et al., 2005; Song et al., 
2005b). The B30.2 domain contains four variable regions, designated VI to V4 which 
account for most of the differences between the TRIM5a alleles from different species 
(shown in Figure 3.1; Song et al., 2005b). Variable regions 1 and 3 contribute to the 
potent restriction of N-MLV (Perron et a l , 2006b). These regions are predicted to be 
surface-exposed (Grutter et a l , 2006) and it is speculated that some of the residues 
within these regions might electrostatically interact with N-MLV capsids (Perron et a l , 
2006b). Recent work investigating the B30.2 domain antiviral specificity determinants 
showed that, apart from variable region 1 and 3, variable region 2 is also important for 
restriction of HIV-1 and SIVmac (Ohkura et a l,  2006). Fusing the B30.2 domain from 
one TRIM protein to the RBCC domain of a second TRIM protein can, in most cases, 
transfer the antiviral specificity of the first to the resulting fusion protein (Yap et a l, 
2005; Ohkura et a l, 2006). Collectively, this supports the importance of the B30.2 
domain for the virus-recognition properties of TRIM5a.
It is still unclear whether the RING domain plays a role in restriction or whether it is 
required for a function unrelated to antiviral activity. When the critical cysteine residues 
in the RING domain are removed, or when this domain is completely deleted, the 
resulting TRIM5a mutant is still able to restrict, although with a significantly reduced 
antiviral activity (Stremlau et a l,  2004; Javanbakht et a l,  2005). The RING domain of 
Rhesus TRIM5a was shown to contribute to auto-polyubiquitylation resulting in a 
rapid, proteasome dependent, turnover of TRIM5 molecules (Diaz-Griffero et a l, 
2006a). Studies revealed that the half-life of TRIM5arh is about 60-75 minutes (Diaz- 
Griffero et a l, 2006a; Wu et a l,  2006). Exchanging the RING domain between
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TRIM5arh and the more stable TRIM21 extends the half-life of the resulting chimera 
without having an impact on its anti-HIV-1 restriction properties. Thus, rapid turnover 
is not an absolute requirement for the ability of TRIM5-related proteins to restrict HIV- 
1 infection (Diaz-Griffero et al., 2006a). Interestingly, an impaired allele of TRIM5a 
carrying the RING domain polymorphism (H43Y) has recently been described in the 
human population (Javanbakht et al., 2006a; Sawyer et al., 2006). The H43Y allele is 
found at a frequency of 43% in indigenous Central and South Americans. When feline 
cells over-expressing H43Y TRIM5a, or B-lymphocytes homozygous for this allele, 
were infected with N-MLV, they were about 100-fold more permissive than cells 
expressing wild-type TRIM5a. However, the H43Y allele did still retain weak antiviral 
activity (Javanbakht et a l , 2006a; Sawyer et a l , 2006). This study supports a role for 
the RING domain in maximal TRIM5a activity.
The B-box 2 domain appears to be essential for retroviral restriction. Disruption of this 
domain completely eliminated the anti-retroviral activity of TRIM5a, yet had no effect 
on TRIM5a multimerisation and capsid binding (Javanbakht et a l , 2005; Mische et a l , 
2005; Perez-Caballero et a l , 2005a). These observations suggest that the B-box 2 
domain may mediate an effector function critical for retroviral restriction.
TRIM5a proteins from different species exist as trimers, with the coiled-coil domain 
being necessary for this higher-order formation (Mische et a l , 2005; Perez-Caballero et 
a l , 2005a; Javanbakht et a l , 2006b). It is proposed that trimerisation allows three 
B30.2 domains to interact with threefold pseudo-symmetrical structure on the retroviral 
capsid (Mische et a l , 2005). Changes that disrupt TRIM5a trimerisation 
proportionately affect the ability of TRIM5a to bind retroviral capsid complexes and 
thus to restrict viral infection (Javanbakht et al., 2006b).
Experiments testing HIV-1 restriction capacities of a series of chimeras between 
TRIM5arh and other close human TRIM family members (TRIM6 , 21, 34) revealed that 
in most, but not all, cases heterologous TRIM domains are able to substitute 
functionally for the RBCC domain of TRIM5arh (Li et al., 2006b). This was shown not 
to be the case in restriction of N-MLV, which was much more sensitive to substitution 
with heterologous RBCC domains (Li et al., 2006b). Additionally, studies where the 
B30.2 domain of TRIM1, 18, and 19 was replaced by CypA, an HIV-1 capsid binding 
molecule, showed that it was sufficient to transfer the ability to restrict HIV-1 infection 
to these heterologous TRIMs that are normally incapable of restricting HIV-1. These 
experiments supported the functional independence of RBCC and B30.2 domains and
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indicated that the overall structure of the RBCC is important for restriction (Yap et al., 
2006).
1.3.4.3 A model of the TRIM5a-mediated antiviral mechanism
The exact mechanism by which TRIM5a acts to inhibit retroviral replication is still 
unclear. Studies have shown that human TRIM5a selectively binds capsid protein from 
restriction sensitive N-MLV, but not insensitive B-MLV in a B30.2-dependent way 
(Sebastian and Luban, 2005). This interaction occurs between TRIM5a multimers and 
capsid multimers only when using the intact virion core, composed of stable viral capsid 
with properly folded CA amino termini (Shi and Aiken, 2006). Studies of HIV-1 Gag 
mutants showed that capsid disassembly is a delicate process; both increases and 
decreases in capsid stability are detrimental to HIV-1 replication (Forshey et al., 2002). 
Thus, the simplest explanation would be that TRIM5a binding might sequester the 
incoming virion core and deregulate the controlled uncoating of the sub-viral particles 
required for proper continuation of viral life-cycle. However, identification of TRIM5 
chimeras, which maintained the ability to bind retroviral capsid while losing the ability 
to restrict, indicated that binding between TRIM5a and the retroviral CA complex is 
necessary, but not sufficient, for virus-restricting activity (Li et al., 2006b). Thus, upon 
binding to retroviral capsid, TRIM5a must also exert other effects for the restriction to 
occur.
Although the presence of a RING domain makes it very tempting to speculate that 
TRIM5a might act through the ubiquitination or sumoylation of the sub-viral particles 
followed by their mislocalisation, alteration of conformation or proteasomal degradation 
the involvement of a RING domain and of the proteasome in TRIM5a-mediated 
restriction remains controversial. The expression of a restricting TRIM5a in the target 
cell was shown to correlate with a decrease in the amount of sensitive, particulate viral 
capsid in the cytosol. In certain cases this loss of particulate CA was accompanied by a 
detectable increase in soluble capsid protein. These data, combined in some cases, with 
the use of proteosomal inhibitors, suggested that TRIM5a is promoting a rapid, 
premature proteasome-independent disassembly of HIV-1 and N-MLV capsid (Perron 
et al., 2006a; Stremlau et al., 2006a). Similarly, other studies showed that shortly after 
entry into restrictive cells, HIV-1 CA undergoes an accelerated degradation which is 
independent of the proteasome (Chatterji et a l , 2006). The independence of restriction 
on the ubiquitin/proteasome system was also documented by experiments, in which
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target cells were treated with a proteasome inhibitor or where the ubiquitin-activating 
(El) enzyme was inactivated (Perez-Caballero et a l , 2005b; Stremlau et a l , 2006a). 
What these studies did not take into the account was the possibility of the existence of 
more than one TRIM5a-mediated block to viral infection. The fact that TRIM5a was 
shown to lower reverse transcription of the sensitive virus did not exclude the 
possibility that it might also act at the later, post-RT stages of infection. This was hinted 
at by the report of Ylinen et a l , (2005) showing the ability of the squirrel monkey 
TRIM5a to block SIVmac infection after reverse transcription. Furthermore, analysis of 
viral reverse transcriptase products in the study of Yap et a l , (2006), exploring HIV-1 
restriction mediated by fusion proteins between RBCC domains of TRIM 1, 18 or 19 
and CypA, revealed the ability of these fusion proteins to block HIV-1 replication at 
two distinct stages of its life cycle; either prior to reverse transcription or just before 
integration, depending upon the TRIM family member. These findings were recently 
clarified by Wu et a l , (2006) reporting that the proteasome inhibitors rescued HIV-1 
reverse transcription products from TRIM5arh-mediated restriction, even though viral 
infection and generation of 1- and 2-LTR reverse transcription products remained 
impaired (Wu et a l, 2006). This study convincingly showed that TRIM5a acts at more 
than one step of retroviral life cycle. Thus, the disruption of the proteasomal pathway 
rescues reverse transcription, but not retroviral infectivity because there are additional 
TRIM5a-mediated blocks at the post RT stage of infection (Anderson et a l,  2006; Wu 
et a l, 2006).
Taken together, these data might suggest the following TRIM5a-antiviral mechanism: 
After entry into the cell, the retrovirus is recognised by TRIM5a through viral capsid- 
B30.2 domain interactions. Two distinct antiviral activities of TRIM5a might then 
follow. In one case, TRIM5a restriction mimics the murine restriction factor Fvl, 
allowing viral reverse transcription to proceed but blocking the access of viral PICs into 
the nucleus. This might happen through perturbing the composition, or efficient 
trafficking, of retroviral RTCs towards the nucleus. As discussed in chapter 1.2.3.4, 
retroviruses utilise the cellular cytoskeleton on their transit to the nucleus. Binding of 
TRIM5a might modify or mask the viral sites required for interaction with cellular 
factors associated with the microtubule network. A second activity might involve the 
TRIM5a E3 ligase activity. TRIM5a could induce degradation, or prevent the 
formation, of viral cDNA via proteasome function. Poor performance of either activity 
would still keep the virus restricted. Ultimately, inhibition of retroviral infection by two 
independent mechanisms ensures an efficient block to retroviral infection. It would also
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ensure restriction in a cell type where, due to the different pattern of protein expression, 
one of the activities is inactive or less active. The experiments mentioned above, where 
proteasome inhibition of HeLa cells resulted in no increased viral titre, showed that 
block to RT is not necessary for viral restriction. However, these effects might be cell- 
type specific, and testing other cell lines would reveal further insight into the 
mechanism.
1.3.4.4 Factors involved in TRIM5a-mediated restriction
The only cellular factor thus far identified participating in simian TRIM5a-mediated 
restriction is cyclophilin A (CypA) (Berthoux et a l,  2005b; Keckesova et a l , 2006; 
Stremlau et al., 2006b). CypA was discovered because of attempts to find a gene 
responsible for Fvl activity. It was identified in the yeast two-hybrid screen as a 
binding partner of HIV-1 capsid protein (Luban et al., 1993). CypA belongs to a highly 
conserved, abundantly expressed cyclophilin family, members of which catalyse the 
cis/trans isomerisation of prolyl peptide bonds (reviewed in Min et a l,  2005; Barik, 
2006). CypA binds and isomerises the G89-P90 motif within the capsid protein of HIV- 
1 (Figure 1.13, Gamble et a l, 1996; Gitti et al., 1996; Yoo et a l,  1997; Bosco et a l, 
2002; Bosco and Kem, 2004), and via this interaction is efficiently incorporated into 
HIV-1 particles (Franke et a l, 1994; Thali et a l,  1994; Ott et a l, 1995). Inhibition of 
CA-CypA interactions either with an immunosuppressive drug (cyclosporine A, CSA), 
by mutation of either G89 or P90, or by downregulation of CypA decreased HIV-1 
replication in human cells (Franke et a l,  1994; Thali et a l,  1994; Braaten et a l, 
1996a,b,c; Dorfman and Gottlinger, 1996; Franke and Luban, 1996; Braaten and Luban, 
2001; Sokolskaja et a l, 2004). Examination of CypA-deficient HIV-1 virions failed to 
detect any abnormalities in virion components or ultrastructure (Braaten et a l, 1996b; 
Kong et a l, 1998; Grattinger et a l,  1999; Wiegers et a l,  1999) thus casting doubt on 
the role of incorporated CypA in HIV-1 infectivity. Subsequent studies indicated that 
although CypA can bind to viral CA in the producer cell during viral assembly, it is the 
CypA in the target cells that is important for HIV-1 infectivity (Kootstra et a l, 2003; 
Towers et a l, 2003; Sokolskaja et a l,  2004; Hatziioannou et a l,  2005).
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Figure 1.13. Cyclophilin A bound to N-terminal domain o f HIV-1 capsid protein.
Identification of residues within HIV-1 N-terminal (1-146) CA domain (CAN) important for binding 
and catalysis by CypA. CypA (blue) is shown bound to the flexible surface-exposed loop 
between Pro-85 and Pro-93 of CAN (red). The rest of CAN is shown in yellow (Bosco et al., 
2002).
Initially it was assumed that HIV-1 capsids required CypA to properly uncoat or 
efficiently reverse transcribe (Braaten et al., 1996a,b, 2001; Luban, 1996; Bosco et al., 
2002; Howard et al., 2003; Bosco and Kern, 2004). However three lines of evidence 
suggested the possibility of the involvement of a restriction factor in the effect of 
cyclophilin A: 1) Two mutations in the cyclophilin binding loop of HIV-1, A92E and 
G94D, alter the sensitivity of HIV-1 replication to cyclosporine in a cell-type specific 
way. These mutants were originally derived by serial passage of HIV-1 in CD4+ HeLa 
cells in the presence of a cyclosporine analogue (Braaten et al., 1996a). In these cells, 
the mutants become cyclosporine-dependent; they do not replicate in the absence of 
drug, while in the Jurkat human T-cell line these mutations confer cyclosporine- 
resistance but not drug-dependence. As cyclophilin A is one hundred percent conserved 
between these cell lines, this differential response to CypA might be explained by the 
presence of a A92E-, or G94D-specific antiviral protein within HeLa cells. 2) 
Substitution of the cyclophilin A-binding region in the HIV-1 capsid with that of the 
macrophage tropic primary isolate HIV-1 Ba-L resulted in a virus that was resistant to 
the simian inhibitory factor, and efficiently transduced simian cells. The alteration of 
the CypA region did not affect CypA incorporation into the virions (Kootstra et al., 
2003). 3) Cells from rabbit, Rhesus macaque and squirrel monkey showed different 
permissivities to the very closely related primate lentiviruses HIV-2 and SIVmac. Both of 
these viruses are products of zoonosis from sooty mangabeys and both were shown not 
to bind cyclophilin A. Comparing the amino-acid sequence of their capsid protein
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revealed differences in the small part of the protein homologous to the cyclophilin A- 
binding loop of HIV-1 (Ylinen et a l , 2005). All of this data suggested that the 
cyclophilin A-binding loop within HIV-1 might also function as a viral determinant of 
species-specificity; i.e. it might be the site of the interaction with a potential restriction 
factor. This observation suggested that experiments examining the effect of CSA on 
species permissivity to viral infection in various cell lines might be informative. It was 
found that HIV-1 treated with CSA, but not untreated virus, was able to abrogate 
restriction of N-MLV in human cells. A model was proposed in which CypA protects 
HIV-1 capsid from an antiviral activity in human cells (Towers et al., 2003). The effect 
of CypA on HIV-1 replication was shown to be species-specific. Although treatment of 
cells with CSA has been shown to decrease the titre of HIV-1 in human cells, it 
increased the titre of HIV-1 in simian cells implying that while CypA protects HIV-1 
from antiviral factor/s in human cells it facilitates restriction in monkey cells (Towers et 
al., 2003). The observation made in one of the monkey species, specifically owl 
monkeys, has recently been explained by the identification of the Owl monkey 
restriction factor as a fusion protein between restriction factor TRIM5a and cyclophilin 
A (TRIMCyp, Sayah et al., 2004b; Nisole et al., 2004; see chapter 1.3.4.6). It raised the 
possibility that free CypA is also somehow relevant to TRIM5a restriction of HIV-1 in 
other primate species where TRIM5a is not fused to CypA. This was confirmed by 
findings that Rhesus macaque, and African green monkey, cells required CypA for 
maximal TRIM5a-mediated restriction (Berthoux et al., 2005b; Keckesova et a l , 2006; 
Stremlau et a l, 2006b). Depletion of TRIM5a from these cells abolished the effects of 
CypA on HIV-1 infectivity. In these species, CypA activity has no effect on the ability 
of TRIM5a to restrict N-MLV or SIV, suggesting that CypA acts on HIV-1 CA rather 
than on TRIM5a (Berthoux et a l, 2005b; Keckesova et a l,  2006; Stremlau et a l, 
2006b). However, in the case of human cells, the stimulatory effect of CypA on HIV-1 
replication was shown to be independent of TRIM5a (Keckesova et a l, 2006; 
Sokolskaja et a l, 2006a; Stremlau et a l, 2006b).
Apart from cyclosporine, another drug, arsenic trioxide, was shown to have an effect on 
TRIM5a-mediated restriction (Keckesova et a l,  2004; Sebastian et a l, 2006). Arsenic 
trioxide (AS2 O3 ) is known as an effective therapeutic agent for treatment of acute 
promyelocytic leukemia (Shen et a l,  1997). This type of cancer is caused by a 
chromosomal translocation resulting in the fusion of the promyelocytic leukemia (PML) 
and retinoic acid receptor (RARa) proteins (de The et a l, 1991). PML is a tripartite 
motif protein (also called TRIM 19), related to TRIM5, with roles in apoptosis,
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transcription and innate immunity (more about PML in chapter 1.3.4.1; Quignon et a l , 
1998; Wang et a l , 1998a,b; Choi et a l,  2006; reviewed in Mann and Miller, 2004; 
Takahashi et a l, 2004). Arsenic trioxide causes the deactivation and/or degradation of 
PML and PML-RARa, thus eliminating the carcinogenic effect of this fusion protein 
(Lallemand-Breitenbach, 2001). It was also shown to influence retroviral infection; to 
stimulate HIV-1 replication (Turelli et a l,  2001; Berthoux et al., 2003) and to 
specifically rescue infectivity of restricted N-MLV and EIAV virus without affecting 
the unrestricted B- or NB-MLV virus in human cells (Berthoux et a l,  2003; Keckesova 
et a l , 2004). The interesting observation of the ability of AS2 O3 to enhance retroviral 
infection in human cells was recently explained by its effect on TRIM5a. When 
TRIM5a expression is downregulated in human cells, AS2 O3 is no longer able to 
influence retroviral restriction in these cells (Sebastian et a l , 2006). Overexpression of 
TRIM5a in otherwise nonrestrictive feline cells, where viral titres are not responsive to 
arsenic treatment, renders viruses on these cells sensitive to this drug (Keckesova et a l , 
2004; Sebastian et a l , 2006).
TRIM5a orthologs from different species (Berthoux et al., 2005a; Nakayama et a l, 
2006), mutated TRIM5a (Mische et a l,  2005; Perez-Caballero et a l,  2005a) and 
TRIM5 isoforms gamma (Stremlau et a l , 2004) and delta (Passerini et a l , 2006) have 
been shown to have a dominant negative activity on TRIM5a-mediated restriction when 
co-expressed with wild type TRIM5a. In general it can be said that almost any 
functionally defective TRIM5 protein retaining a coiled-coil domain and capable of 
binding wild-type TRIM5a might exhibit a dominant-negative effect on this protein. 
Whether the dominant-negative activity of the short splice variants of TRIM5 is 
important for modulating TRIM5a activity in vivo is unclear at present.
1.3.4.5 Involvement of cytoplasmic bodies in TRIM5a activity
Exogenously-expressed TRIM5a has been shown to be localised in punctuate 
cytoplasmic structures referred to as "cytoplasmic bodies" (Reymond et a l, 2001). 
Whether endogenous TRIM5a forms these cytoplasmic bodies is unclear, but it is clear 
that localisation of TRIM5a in these bodies is not required for antiviral activity (Perez- 
Caballero et a l, 2005a; Song et a l,  2005a). Stable cell lines expressing TRIM5a 
sometimes do not form discernible cytoplasmic bodies, yet these cells restrict infection 
effectively. Moreover, cells treated with geldanamycin, an inhibitor of the heat shock 
protein Hsp90, which was shown to reduce or eliminate the association of TRIM5a with
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cytoplasmic bodies, had no effects on the ability of TRIM5a to restrict retroviral 
infection (Perez-Caballero et al., 2005a; Song et al., 2005a). Cytoplasmic bodies are 
likely to be formed in response to high expression levels. Induction of protein 
expression using sodium butyrate promotes TRIM5a body formation but does not 
impact on restriction (Perez-Caballero et al., 2005a).
Misfolded or over-expressed proteins are, in the presence of proteasome inhibitors, 
usually accumulated in cytosolic aggregates which might be later transported via 
microtubules to the microtubule-organizing centre and concentrated within perinuclear 
structure known as aggresomes (Johnston et al., 1998, 2002). Aggresomes are often 
enveloped in vimentin structures and have been shown to contain heat shock proteins, 
ubiquitin and proteasomal components (Garcia-Mata et al., 2002). Examination of 
subcellular localisation of inducible nitric oxide synthetase demonstrated, that 
aggresomes function not only as a site where misfolded or aggregated proteins are 
directed, but also where functional physiologically-folded proteins are placed in order to 
regulate their intracellular function (Kolodziejska et al., 2005).
A study by Diaz-Griffero et al., (2006a) showed that human and Rhesus TRIM5a 
proteins undergo rapid turnover with half-lives of approximately one hour. Their 
steady-state levels in cell are therefore maintained by continuous synthesis and rapid 
degradation and it was suggested that cytoplasmic bodies might result when levels of 
synthesis are greater than the cell's ability to refold or degrade the TRIM5 proteins. 
Thus cytoplasmic bodies might simply represent aggresomal precursors, linked to the 
aggresome by microtubular transport (Diaz-Griffero et al., 2006a).
1.3.4.6 Characteristics of TRIMCyp
The mechanism of action of TRIMCyp is suggested by its structure. The B30.2 domain, 
which governs restriction specificity by serving as a capsid recognition domain in the 
TRIM5a molecule, is almost precisely replaced by CypA in the TRIMCyp chimera. 
This results in the exchange of one virus-binding domain for another. Stable, polymeric 
viral capsids with properly folded amino-terminal CA subunits are essential for 
recognition by TRIMCyp (Forshey et al., 2005). Kinetic studies revealed that inhibition 
of incoming HIV-1 capsids by TRIMCyp occurs within 15 minutes of their delivery to 
the target cell. This suggests that the sub-viral structure that is targeted either exists only 
transiently after virus entry, or moves quickly to a location where restriction cannot 
occur (Perez-Caballero et al., 2005b). As is the case for TRIM5a, TRIMCyp has a rapid
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turnover of about one hour, and this is dependent on the proteasome and the presence of 
a RING domain (Diaz-Griffero et al., 2006a). Its activity does not require cytoplasmic 
bodies (Perez-Caballero et al., 2005b). Capsid binding occurs most efficiently when 
TRIMCyp is trimeric, and has intact coiled-coil and cyclophilin A domains. Its antiviral 
function also depends upon the B-box 2 domain (Diaz-Griffero et al., 2006b).
The CypA insertion appears to be unique to owl monkeys. It arose after the divergence 
of the New and Old World primates when a LINE-1 retrotransposon catalysed the 
insertion of a CypA cDNA into the TRIM5 locus. It serves as the first vertebrate 
example of a chimeric gene mediated by this mechanism of gene shuffling (Nisole et 
a l, 2004; Sayah et al., 2004b; Ribeiro et al., 2005).
1.3.4.7 TRIM5a polymorphism and gene therapy
Human TRIM5a exerts only modest restriction of HIV-1, and is unable to block 
productive infection in human cells (Hatziioannou et al., 2003; Stremlau et al., 2004). 
However, it was hypothesised that polymorphism within the TRIM5 gene might explain 
the observed variability of human susceptibility to HIV-1 infection and disease 
progression, and might result in increased restriction of HIV-1 infection in some 
individuals. This notion led to the investigation of polymorphism in the TRIM5 gene 
from primary lymphocytes of many HIV-1 infected, or exposed, seronegative subjects 
(Speelmon et al., 2006). These and similar studies observed no significant effect of 
individual TRIM5a nonsynonymous mutations on the HIV-1 susceptibility of human 
CD4+ T-cells (Goldschmidt et al., 2006; Javanbakht et al., 2006a; Speelmon et al.,
2006).
Studies of intra-species variation within TRIM5a coding sequences of two distinct Old 
World monkey species, Rhesus macaques and sooty mangabeys, revealed very 
extensive polymorphism within these species resulting in the presence of multiple 
TRIM5a alleles (Newman et al., 2006). Interestingly, certain alleles were more closely 
related to orthologs of other species than to one another. This led to the conclusion that 
the TRIM5 locus of Old World primates was shaped by long-term balancing selection, 
which is rare and can be seen, for example, in the case of the evolution of the MHC 
locus and ABO blood group system (Newman et al., 2006). Since diversity is necessary, 
in terms of antiviral protection, the existence of multiple TRIM5a alleles might have 
given these species the advantage of recognising more viral epitopes, thus enabling 
them to fight off infections by a broader array of viruses.
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The ability of Rhesus macaque TRIM5a to strongly restrict HIV-1 replication in vitro 
highlighted its potential as a protective molecule for gene therapy applications. This led 
to initiation of experiments that showed that TRIM5arh-transduced human CD34+ 
hematopoietic progenitor cells produce transgenic macrophages which are highly 
resistant to HIV-1 infection and do not present any apparent phenotypical or functional 
defects (Anderson and Akkina, 2005). Such cells could theoretically be used to 
repopulate the immune system of an HIV-1 infected individual.
1.3.5 APOBEC3G
Another of the antiviral mechanisms was discovered from studies of the HIV-1 viral 
infectivity factor (Vif) protein. The v if gene was shown to be dispensable for HIV-1 
replication in certain cell lines (termed "permissive"), but was very important for 
replication in other cells (termed "nonpermissive"). Fusion of these cell lines showed 
that the phenotype is dominant (Madani and Kabat, 1998; Simon et al., 1998). The gene 
responsible for this antiviral activity was identified by subtractive cloning as 
apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G (APOBEC3G) 
(Sheehy et al., 2002). This protein belongs to the APOBEC family of cytidine 
deaminases, which target cytosines in RNA and/or DNA and convert them to uracils. A 
well characterised member of this group is AID (activation-induced deaminase), which 
regulates somatic hypermutation and isotype class switching in B-cells, and APOBEC 1 
that regulates the expression of different isoforms of Apolipoprotein B in the small 
intestine. APOBEC3G is incorporated into HIV-1 particles (Kao et a l , 2003; Zennou et 
al., 2004) in the producer cell through the interaction with the nucleocapsid portion of 
Gag polyprotein (Alee and Popik, 2004; Cen et al., 2004; Luo et al., 2004; Schafer et 
a l , 2004) and acts during HIV-1 reverse transcription in the target cell. It was found to 
act on a single-stranded DNA intermediate and it mutates as many as 4% of the C 
residues of the minus-strand viral DNA of vif-minus HIV-1 (Harris et a l , 2003; 
Mangeat et a l , 2003; Zhang et a l , 2003; Yu et a l , 2004). The C to U mutations in the 
minus strand produce G to A mutations in the complementary cDNA strand. Viral 
genomes bearing these mutations are either degraded by cellular DNA-repair enzymes 
or are unable to direct the synthesis of functional viral proteins due to the introduction 
of premature stop codons and heavy mutations. Other APOBEC family members were 
also found to inhibit HIV-1 infection, such as APOBEC3F, 3B and 3DE (Bishop et a l , 
2004; Liddament et a l , 2004; Zheng et a l , 2004; Dang et a l , 2006; reviewed in Goff,
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2004; Zheng et al., 2005; Malim, 2006; Perez and Hope, 2006). However, it is 
becoming increasingly clear from recent data that a strong antiviral effect of APOBEC 
proteins can also be achieved in the absence of detectable hypermutation. Mutated 
APOBEC proteins that are unable to function as cytidine deaminases still retain 
substantial levels of antiviral activity, correlating with disruptions in viral cDNA 
accumulation (Newman et al., 2005; Bishop et al., 2006a). From the data available, it is 
not yet possible to determine whether this effect is due to the degradation of reverse 
transcripts, or whether these products are simply not made (reviewed in (Holmes et al.,
2007).
The HIV protein Vif impairs the ability of APOBEC3G to enter virions (Mariani et al.,
2003). Vif was shown to bind directly to APOBEC3G and induce its proteosomal 
degradation through linking APOBEC3G with a ubiquitin-ligase complex that contain 
several cellular proteins such as elongin B, elongin C, cullin-5 (CUL5) and ring-box-1 
(RBX1, Conticello et al., 2003; Marin et al., 2003; Sheehy et al., 2003; Stopak et al., 
2003; Yu et al., 2003). HIV-1 Vif is able to eliminate APOBEC3G in humans and 
chimpanzees but not those of Old World monkeys like African green monkeys (Bishop 
et al., 2004). A single amino-acid of human APOBEC3G (aspartic acid at position 128) 
was shown to be responsible for its sensitivity to inactivation by HIV-1 Vif (Bogerd et 
al., 2004; Mangeat et al., 2004; Schrofelbauer et al., 2004).
Several members of the APOBEC family were shown to be active not only against 
retroviruses but also against hepatitis B virus (Turelli et al., 2004) and endogenous 
retroelements (Esnault et al., 2005) using both editing and non-editing mechanisms 
(reviewed in Holmes et al., 2007).
1.3.6 ZAP
The zinc finger antiviral protein (ZAP) was identified by a screen of a rat cDNA library 
as a gene conferring resistance to the infection of cells by MLV (Gao et al., 2002). ZAP 
is an RNA-binding protein that contains a cluster of four CCCH-type zinc fingers. An 
analysis to determine the step at which ZAP blocked virus infection revealed that while 
it has no effect on MLV entry, DNA synthesis or integration, there is a dramatic and 
specific loss of appearance of viral RNAs in the cytoplasm (Gao et al., 2002). 
Mutational studies suggested that the zinc fingers are involved in direct binding of ZAP 
to MLV mRNA (Guo et al., 2004). ZAP was found to interact with exosome; a 
cytoplasmic complex of about ten proteins responsible for mRNA turnover. It directly
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binds exosome's hRrp46p component and targets the viral RNA for exosome-mediated 
destruction (Guo et al., 2007). In addition to its inhibition of MLV, ZAP was shown to 
potently inhibit the replication of several members of Alphaviruses (Bick et a l , 2003).
1.4 Project introduction
The aim of my PhD research was to identify host factors impacting on viral 
permissivity, and to understand the molecular mechanisms involved. Identification of 
TRIM5a as a factor responsible for HIV-1 restriction in Rhesus macaque cells allowed 
us to test if TRIM5a is also responsible for Refl activity in human cells and Lvl 
activity in monkey cells, and thus if Lvl and Refl are species-specific variants of 
a single restriction factor, or if these activities are encoded by separate restriction 
systems. Furthermore, we have examined whether the properties of TRIM5a cloned 
from different species account for the characteristic restriction patterns seen in 
corresponding cell lines. We also wanted to examine the contribution of shorter 
isoforms, specifically TRIM58, to retrovirus restriction. We sought to identify other 
host factors involved in the TRIM5a restriction pathway. One host factor known to 
directly bind retroviral capsid is cyclophilin A. Since mutations at the base of the CypA 
loop (H87Q), or in the CypA binding site modulate the susceptibility to different 
TRIM5a variants, we decided to analyse the role of CypA in TRIM5a-mediated 
restriction. Given the fact that arsenic trioxide was shown to stimulate retroviral 
infectivity, we also wanted to examine if this stimulatory effect involves suppression of 
TRIM5-mediated restriction activity and to uncover details of the involvement of 
arsenic in TRIM5a-mediated restriction.
The results presented in this work clearly show that TRIM5a is an important 
component of innate antiviral defense mechanisms. Proper understanding of its function 
and the way it interacts with other cellular factors could reveal ways to enhance, induce, 
improve or broaden the activities of this aspect of antiviral innate immunity to our 
advantage.
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Chapter 2 
Materials and Methods
2.1. Cell Culture
2.1.1 Cell lines
Cell line Description
293T Human embryonic kidney cell line expressing the Simian Virus 40 
(SV40) Large T antigen.
CRFK Crandall-Reese feline kidney cell-line established from Felis catus 
species
CRFKhuT5a CRFK cells stably expressing human TRIM5a
CRFKHAhuT5a CRFK cells stably expressing human TRIM5a fused to an HA-tag
CRFKAgmT5a CRFK cells stably expressing African green monkey TRIM5a
CRFKHAAgmT5a CRFK cells stably expressing African green monkey TRIM5a fused to 
an HA-tag
CRFKhuKlOR CRFK cells stably expressing human TRIM5a mutant K10R
CRFKhuKK263,264RR CRFK cells stably expressing human TRIM5a mutant KK263,264RR
CRFKTRIMCyp CRFK cells stably expressing Owl monkey TRIMCyp
CV1 African green monkey kidney cell-line (Cercopithecus aethiops 
tantalus)
CVldT5 CV1 cells stably knocked-down for Agm TRIM5a expression
CVldcypA CV1 cells stably knocked-down for cyclophilin A expression
FRhK Fetal Rhesus macaque monkey kidney cell-line
FRhKdT5 FRhK cells stably knocked-down for Rhesus macaque TRIM5a 
expression
FRhKdcypA FRhK cells stably knocked-down for cyclophilin A expression
HeLa Human epithelial cells established from a cervical carcinoma 
transformed by human papillomavirus 18
TE671 Human rhabdomyosarcoma cell-line
TEdT5 TE671 cells stably knocked-down for human TRIM5a expression
TET56 TE671 cells stably over-expressing the human TRIM55 isoform
Table 2.1. Cell lines.
All cells are adherent. CFRK cells are permissive for all of the viruses tested including 
N-MLV, B-MLV, SIVmac, HIV-2 and HIV-1. HeLa, TE671 and 293T cells were 
obtained from the American Type Culture Collection (ATCC). CRFK were donated by 
Yasuhiro Ikeda, University College London. FRhK cells were obtained from the Centro 
Substrati Cellulari, Brescia, Italy. CV1 cells were a kind gift of P. Jat, Ludwig Institute 
for Cancer Research, London.
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2.1.2 Thawing cells
Cells were removed from liquid nitrogen or -80°C freezer and thawed rapidly at 37°C. 
Thawed cells were then added to 20 ml of Dulbecco’s Modified Eagle Medium (DMEM, 
Invitrogen, U.K.) with 10% fetal calf serum (FCS, Biosera, U.K.). Next day media was 
changed for 10 ml of fresh DMEM media with 10% FCS.
2.1.3 Passaging cells
All cell lines, except 293T, were maintained in DMEM (Invitrogen, U.K.) with 10% FCS 
(Biosera, U.K.) in 5% CO2 at 37°C. 293T cells were maintained in DMEM (Invitrogen, 
U.K.) with 15% FCS (Biowest, France) in 10% CO2 at 37°C. No antibiotics were added. 
Cells were split 1:5 to 1:20, depending on cell density and rate of growth, two or three 
times per week.
2.1.4 Freezing cells
Cells from confluent 10 cm plate were trypsinised, centrifuged at 1200 rpm for 5 minutes 
and resuspended in 3 ml of cold FCS (Biosera, U.K.) containing 10% dimethyl 
sulphoxide (DMSO, Sigma, U.K.). Cells were aliquoted into cryovials (Nunc, USA) and 
gradually cooled to -80°C in an isopropanol-containing cryo-container (Nalgene, USA) 
before being transferred to liquid nitrogen.
2.1.5 Transfection and viral vectors
Vesicular stomatitis virus glycoprotein (VSV-G) -  pseudotyped MLV (N, B), EIAV, 
HIV-2, SIVmac, and HIV-1 GFP-encoding vectors were prepared by transient triple 
transfection of 293T cells with FuGENE- 6  (Roche) according to a protocol by 
G.J.Towers. The transfection mixture contained lpg  pMDG (encoding the pantropic 
VSV-G envelope), lpg of the packaging vector (Gag-Pol expression construct from 
the virus of interest) and 1.5 pg of the marker-encoding transfer vector in 200 pi Opti- 
MEM (Invitrogen, U.K.) with 18 pi FuGENE-6 . The mixture was incubated at room 
temperature for 15 minutes before being added dropwise to the confluent 293-T cells 
in 10 cm petri dish with 8  ml of DMEM medium (Invitrogen, U.K.) and 15% fetal calf 
serum (Biowest, France).
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ITransfected 293-T cells were incubated 
Mntpoptcvsv-COTV overnight at 37°C and with 10% CO2 .
GFP c&ailn^  w tto r
Media was changed after 24 hrs, and
3 plasmid transient
transfection into 293T ceils supernatant was harvested at 48, 72 and
i Harvest virus
Infect target cells
Figure 2.1. Schematic drawing of viral 
vector production. Modified from 
http://www.clontech.com/images.
96 hours post-transfection, passed 
through a 0.45 pm filters (Vivascience, 
U.K.), aliquoted and stored at -  80°C 
(Figure 2.1). Marker-encoding transfer 
vectors encoded green fluorescent 
protein (GFP) or puromycin resistance 
gene (puro). The following plasmids 
were used for the packaging: CM Vi 
Gag-Pol for NB-tropic MoMLV and its 
derived vectors, N Gag-Pol (pCIG3-N) 
for N-MLV, B Gag-Pol (pCIG3-B) for 
B-MLV, pONY3.2 for EIAV, HIV-2 
pack (pSVRdNBDM) for HIV-2 (a kind 
gift of A.M. Lever, see Griffin et al., 
2001), MVP5180 for MVP, MVP5180- 
G89V for MVPG89V, 92BR for 92BR HIV-1, 92BRG89V for 92BR-G89V HIV-1, 
Bal for HIV-1 Bal, SIV3 + for SIVmac, p8.91 for HIV-1 and p8.91G89V for G89V 
HIV-1. The following plasmids were used as a marker-encoding vector: pCNCG for 
MLV GFP expression, CSGW for HIV-1 GFP expression, pONY8.0 for EIAV GFP 
expression, HIV-2 GFP plasmid for HIV-2 GFP expression. HIV-2 GFP plasmid was 
derived from pSVRdNBPuro (kindly provided by A.M. Lever, see Griffin et al, 
2001) by exchanging the SV40-Puro cassette with a CMV-GFP cassette from CNCG. 
SIV-GFP was used for making SIVmac GFP, CT58CR for human TRIM55 (TRIM55 
cDNA was kindly provided by P.G. Pelicci), siT5/CSPW for expression of siRNA 
against TRIM5 (a kind gift of S.J.Wilson, see Ylinen et al., 2005), R-P/CSPW for 
expression of siRNA against LacZ (a kind gift of S.J.Wilson), RETROcypA/MLV for 
expression of siRNA against cyclophilin A, CT5hCR for human TRIM5a, CT5macCR 
for Rhesus macaque TRIM5a (kindly provided by L.M.J.Ylinen), CT5ha-iiCR for 
human TRIM5a fused to HA-tag, CT5AgmCR for African green monkey (Agm) 
TRIM5a, CT5HA-AgmCR for Agm TRIM5a fused to HA-tag, CT5t-cCR for owl 
monkey TRIMCyp (gene for TRIMCyp kindly given by J.P.Stoye, see Nisole et al.,
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2004), CT5zk8CR for human TRIM5a mutated in KK263,264RR, CT5qt312CR for 
human TRIM5a mutated in K10R (For plasmid reference see Naldini et al., 1996; 
Bainbridge et al., 2001; Besnier et a l 2002; Hatziioannou et a l 2003).
Name of plasmid Type of plasmid Encoded protein Vector produced*
CSGW marker-encoding vector GFP, Ampr GFP or Puro encoding 
HIV-1CSPW marker-encoding Puror, Ampr
p8.91 packaging construct Gag, Pol, Tat, Rev, Ampr
SIV3+ packaging Gag, Pol, Tat, Rev, Vif, 
Vpx, Vpr, Ampr GFP encoding SIVmac
SIV-GFP marker-encoding GFP, Ampr
HIV-2 pack 
(pSVRdNBDM)
packaging Gag, Pol, Tat, Rev, Nef, 
Vif, Vpx, Vpr, Ampr GFP encoding HIV-2
HIV-2 GFP marker-encoding GFP, Tat, Rev, Nef, Vif, 
Vpx, Vpr, Ampr
PONY3.2 packaging Gag, Pol, Tat, Rev, Ampr GFP encoding EIAV
PONY8.0 marker-encoding GFP, Ampr
CM Vi packaging Gag, Pol, Ampr
GFP or Red Express 
encoding MLV
pCIG3 packaging Gag, Pol, Ampr, Blastir
CNCR marker-encoding Red Express Fluorescent 
Protein, Neor, Ampr
CNCG marker-encoding GFP, Neor, Ampr
Table 2.2. Plasmids used for vector production. * In addition to marker-encoding and 
packaging plasmid also envelope-encoding plasmid (in our study it is pMDG) is needed for 
vector production.
2.1.6 Drugs
Cyclosporine A (CsA, Sandoz, Frimley, U.K.) was prepared in dimethyl sulfoxide to a 
1 mM stock concentration and later diluted in tissue culture medium to the indicated 
concentrations prior to each experiment. The drug was stored in a dark place at room 
temperature.
0.1 M AS2 O3 (Sigma) was prepared in 1 N NaOH, diluted to ImM in PBS, pH 
adjusted to 7.0 with HC1 and filtered through a 0.2 pm filter (Vivascience). The drug 
was then kept at 4°C for up to 3 months without loss of activity.
Polybrene was dissolved in double distilled water to a 5 mg/ml stock concentration 
and filtered through 0.2 pm filter (Vivascience). It was later diluted in tissue culture 
medium to a final concentration of 5 pg/ml.
Puromycin was dissolved in double distilled water to a 2.5 mg/ml stock concentration 
and filtered through 0.2 pm filter (Vivascience). It was later diluted in tissue culture 
medium to a final concentration of 1 pg/ml for human cells and 4-8 pg/ml for simian 
cells.
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2.1.7 Infection assays
Target cells were seeded in either 24-well (0.25 x 105 cells/well) or 6 -well (105 
cells/well) plates. For virus titration experiments, cells were inoculated with 3-fold 
serially diluted virus stocks that express a GFP reporter gene (either N-MLV GFP, B- 
MLV GFP, HIV-1 GFP, HIV-2 GFP, SIVmac GFP or EIAV GFP) in the presence of 5 
pg/ml polybrene. Infected target cells were enumerated 48 h later by FACS analysis 
(Facs Calibur, Becton Dickinson) and Cell Quest software. GFP was recorded on the 
fluorescence FL1 channel and a total of 10,000 to 50,000 cells per sample were 
analysed. Murine Leukaemia Virus (MLV) titres were equalized on permissive CRFK 
cells and, where relevant, titres are described as CRFK infectious units per millilitre. 
Lentiviral reverse transcriptase activity was measured using an ELISA assay (Cavidi 
Tech, Uppsala), according to the manufacturer's protocol. Where indicated, cells were 
treated with AS2 O3 or CSA at the time of infection.
2.1.8 Deriving clonal cell populations
TE671 or CRFK cells stably expressing MLV vectors were generated by infecting 
CRFK, or TE671 cells at high MOI with a Moloney NB-MLV based vector encoding red 
fluorescent protein (RFP) and either human TRIM5a, human TRIM5a mutants, Agm 
TRIM5a or human TRIM58. 48 hours later, cells were trypsinised and cell density was 
determined using a neubauer-improved haemocytometer. Cultures were diluted to 2 
cells/ml and cultured in 24-well plates containing 500 pl/well. Cells were left for two 
weeks to expand and single clones were screened by fluorescent microscopy and 
analysed by flow cytometry for a single RFP fluorescent population as an indication of 
clonality. They were then tested for their ability to restrict virus by titration of viral 
stocks (section 2.1.7).
TE671 or CRFK cells stably expressing short hairpin RNA (shRNA), for TRIM5 or 
cyclophilin A downregulation, were generated by infecting TE671, CV1 or FRhK cells at 
high MOI with a retroviral HIV-1-based CSPW vector (siT5/CSPW) containing 
puromycin resistance gene and encoding shRNA against TRIM5 or with a retroviral 
MLV-based pSUPERretro vector (RETROcypA/MLV) containing a puromycin 
resistance gene and encoding shRNA against cyclophilin A. 48 hours post-infection 
puromycin dihydrochloride from S. alboniger (Sigma) was added to cultures at a final 
concentration of 1 pg/ml on human cells (TE671) or 4-8 pg/ml on simian cells (FRhK
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and CV1). Cell were left in the presence of puromycin for one or two weeks (media was 
changed and supplied with fresh puromycin once in three days) until the sufficiently 
expanded, puromycin-resistant multi clonal population was derived. In the case of 
deriving single cell clones, 96 hours after the addition of puromycin dihydrochloride 
single clonal cell populations were derived by dilution as described above in the 
continued presence of puromycin. Single or multi clonal populations were then tested 
either for functional restriction of different ML Vs or for the sufficient decrease of 
cyclophilin A protein levels by western blot. The puromycin-selected cells were then 
cultured in medium supplemented with puromycin.
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2.2 Molecular Biology
2.2.1 Oligonucleotides
Oliao Name Oliao Seauence DescriDtion
GT269 5'CAGACGAATTCCACCATGGCTTCTGGAATCCT
GGTTAATG-3’
TRIM5a fwd EcoRl
GT270 5'ATCGTTCGAATCAAGAGCTTGGTGAGCACAGA
G-3'
TRIM5a rev Csp45I
GT303 5'ATCGTTCG AATT AGGCGT AGTCGGGC ACGTCG 
TAGGGGTAAGAGCTTGGTGAGCACAGAGTCA-3'
TRIM5a-HA rev Csp45I
GT296 5'CAGACGAATTCCACCATGGCTTCTGGA
ATCCTG-3'
TRIM5 fwd Ecorl short
GT386 5'TCGATTTCGAATTAAAGTTGTCCACAGTCAGC
AAT-3'
Owl monkey TRIMCyp 
rev, Csp45I
ZK8sense 5'ACGGAGAACGTGACCTTGAGAAGACCAGAAA
CTTTTCCAAAAAAT-3'
change KK263,264RR in 
huT5a sense
ZK8anti-
sense
5'ATTTTTTGGAAAAGTTTCTGGTCTTCTCAAGGT
CACGTTCTCCGT-3'
change KK263, 264RR in 
huT5a antisense
GT312sense 5'ATCCTGGTTAATGTAAGGGAGGAGGTGACCTG
C-3'
change K10R in huT5a 
sense
GT3 ^anti- 
sense
5'GC AGGTC ACCTCCTCCCTT AC ATT AACC AGG AT 
-3'
change K10R in huT5a 
antisense
GT337 5'GATCCCCGGGTTCCTGCTTTCACAGATTCAAGA
GATCTGTGAAAGCAGGAACCCTTTTTGGAAA-3'
anti CypA hairpin for 
pSuper, sense
GT338 5'AGCTTTTCCAAAAAGGGTTCCTGCTTTCACAGA 
TCTCTTGAATCTGTGAAAGCAGGAACCCGGG -3'
anti CypA hairpin for 
pSuper, antisense
GT308 5'TCGATTTCGAACTACTTGGGAGGCTGAGGCAG
GAG-3'
TRIM55 rev Csp45I
Table 2.3. Oligonucleotides. Restriction sites are in bold. Kozak sequences are underlined.
2.2.2 Molecular cloning
• CT5hCR: The human TRIM5a gene was amplified by PCR from the human IMAGE 
clone no. 6160154 (MRC Gene Service, Cambridge, U.K.) using forward primer 
GT269 and reverse primer GT270. It was cloned into the MLV vector CFCR 
between Bell and Csp45I sites such that it was expressed under the control of the 
Moloney MLV LTR in infected cells (see Figure 2.2). The CFCR vector was first cut 
with Bell, blunted by T4-DNA polymerase according to manufacturer's protocol 
(Promega, U.K.) and subsequently cut with Csp45I, thus cutting out the gene for Fvl. 
The PCR fragment encoding human TRIM5a was cut with Csp45I, the Csp45I site 
was introduced into the PCR product by the reverse primer, and ligated into the 
CXCR backbone. The CXCR vector also encodes red fluorescent protein (RFP, 
Clontech) under the control of a CMV promoter.
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• CT5AgmCR: Agm TRIM5a was PCR amplified from a cDNA library derived from 
Agm Cercopithecus aethiops tantalus sp. CV1 cells by using primers GT296 and 
GT270 and cloned into CXCR as above.
• The CXCRdEcoRl plasmid was derived from the CFCR plasmid in order to make 
cloning into this vector easier. The CFCR plasmid encodes two restriction sites for 
EcoRl (see Figure 2.2). In CXCRdEcoRl we deleted the EcoRl site at position 5736 
of the CFCR vector. To do this we cut out the part of the vector containing the EcoRl 
site at 1557 with SnaBl and religated the vector (see Figure 2.2). Vector was then cut 
with EcoRl, blunted with T4-DNA polymerase (Promega, U.K.) and religated. The 
vector was then reconstituted by cloning back the SnaBl fragment. We then cut out 
the Fvl gene encoded by this vector using the 5' EcoRl site and the 3' Csp45I site. 
These two sites were used for subsequent insertion of genes of interest.
SnaBl (290)
CHV
MLV BU5 EcoRI (1557) 
B ell (1568)
Csp451 (2904)
r40 o r i
SnaB I (3725)
7f± 1
EcoRI (5736)
Figure 2.2. Circular map of CFCR plasmid. CFCR is an MLV vector derived from the CNCG 
vector made by Oxford Biomedica, U.K. CMV drives expression of the RNA in the packaging 
cells. The MLV LTR is reconstituted during reverse transcription and drives expression of Fv1-N 
in target cells. The CXCRdEcoRl plasmid used in this thesis was derived from CFCR by deleting 
the EcoRI site at position 5736 and by replacing the Fv1 gene with our genes of interest.
• CT5gCR: Human TRIM55 gene was amplified by PCR from a plasmid kindly 
provided by P.G. Pelicci using primers GT269 and GT308 and cloned into 
CXCRdEcoRl using EcoRI and Csp45I sites within primers.
•  CT5nA-hCR and CT5nA-AgmCR vectors expressing human TRIM5a and Agm TRIM5a 
fused to haemagglutinin tags at their C-terminus were generated by PCR from
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CT5hCR and CT5AgmCR, respectively, using primers GT269 and GT303 in the case 
of CT5RA-hCR and GT296 and GT303 in the case of CT5HA-AgmCR and cloned into 
CXCRdEcoRl using the EcoRI and Csp45I sites as above.
•  CT5t_cCR: The Owl monkey TRIMCyp cDNA was kindly provided by J.P.Stoye, 
see Nisole et ah, 2004. The cDNA for TRIMCyp was PCR amplified using primers 
GT296 and GT386, cut with EcoRI and Csp45I and re-cloned into the CXCRdEcoRl 
vector cut with the same restriction enzymes.
• CT5gt312CR and CT5zksCR: Human TRIM5a mutants K10R and KK263,264RR 
were made by site-directed mutagenesis of wild type human TRIM5a encoded within 
the pBluSKP (pBS) vector. pBS was cut with N otl, blunted with T4-DNA 
polymerase (Promega) according to the manufacturer's protocol and then cut with 
EcoRI. The PCR fragment of wild type human TRIM5a was cut with EcoRI (the 
EcoRI site was introduced into the PCR product with the forward primer) and ligated 
into the pBS backbone. The TRIM5a K10R mutant was made using primers GT312 
sense and antisense and mutant KK263,264RR was made using primers ZK8  sense 
and antisense by site-directed mutagenesis (section 2.2.6). The resulting mutant 
TRIM5a genes were cut out of pBS with EcoRI and Csp45I restriction enzymes and 
cloned into CXCRdEcoRl opened with the same enzymes.
• RETROcypA/MLV: Oligonucleotides GT337 and GT338 encoding shRNA targeting 
a sequence within CypA (GGGTTCCTGCTTTCACAGA) were ligated into the 
pSUPERretro MLV expression vector using Bglll and HinDIII restriction sites (as 
described by Sayah et al., 2004b).
All constructs were verified by DNA sequencing (Lark Technologies, U.K.). The 
sequence of human, Agm and Rhesus macaque TRIM5a was determined by sequencing 
three independent clones. DNA analysis was performed with DNA Dynamo (Blue 
Tractor Software, U.K.).
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2.2.3 Disruption of TRIM5a expression
• Transient disruption of gene expression: Synthetic short interfering RNA (siRNA) 
oligonucleotide duplexes (Qiagen, U.K.) were targeted to sequences within human 
TRIM5 (AAGCTCAGGGAGGTCAAGTTG) as described by Stremlau et a l , 2004. 
HeLa cells were transfected with 60 pmol (20 pmol/pl) of the specific RNA duplex 
using Oligofectamine (Invitrogen) according to the manufacturer’s instructions. 48 
hours after siRNA transfection the cells were infected with GFP-encoding MLV (N, 
B), HIV-1, HIV-2, SIVmac or EIAV-based vectors. Green fluorescing, infected cells 
were enumerated by FACS 48 hours after infection. Control siRNA transfections 
were performed with a negative control siRNA against the p2 subunit of AP2 (a kind 
gift of Alberto Fraile-Ramos; Fraile-Ramos et al., 2003).
• Stable disruption of gene expression: Cells were infected at high multiplicities with
HIV-1 based CSPW vector (siT5/CSPW) encoding shRNA targeted against human or
Agm TRIM5alpha (AAGCTCAGGGAGGTCAAGTTG, a kind gift of S.J.Wilson) or 
with MLV based pSUPERretro vector (RETROcypA/MLV) encoding shRNA 
against cyclophilin A (GGGTTCCTGCTTTCACAGA). This vector was packaged 
into VSV-G pseudotyped HIV-1 or MLV virus by transfection of 293T cells as 
described above and a stable knock-down of TRIM5 or cyclophilin A was generated 
in TE671, CV1 and FRhK cells as described above. Efficient and specific knock­
down was tested either by western blot analysis (in the case of cyclophilin A) or 
genetically, by infection with different MLVs (in the case of TRIM5).
2.2.4 Introduction of plasmid DNA into E. coli
• Electroporation: 1-100 ng of plasmid in a volume not exceeding 2 pi was mixed with
80 pi of cold electrocompetent XL-1 Blue Escherichia coli (kindly provided by
L.M.J.Ylinen) and incubated on ice for 1 minute. The mixture was then transferred to 
an electroporation cuvette (Biorad, U.S.A.) and electroporated in a Gene Pulser™ 
(Biorad, U.S.A.) set at 25 pF, 2,5 kV and 200 Q. After the pulse, 1 ml of SOC media 
(Invitrogen, U.K.) was added to the mixture. The whole reaction was then transferred 
to a falcon tube and shaken at 37 °C for 1 hour. Finally, the cells were plated on LB- 
agar plates containing 50 pg/ml ampicillin or kanamycin.
79
• Heat-shock: 1-200 ng of plasmid in a volume not exceeding 10 pi was mixed with 
100 pi of heat-shock competent TOP 10, HB101 or DH5a Escherichia coli strains 
(Invitrogen, U.K. or kindly provided by L.M.J.Ylinen) and incubated on ice for 15 
minutes. Cells were then heat shocked for 30 seconds at 42 °C and cooled on ice for 2 
minutes. The mixture was then either directly streaked on to LB-agar plates 
containing 50 pg/ml ampicillin or 200 pi of SOC media (Invitrogen, U.K.) was 
added, the mixture was shaken at 37 °C for 45 minutes and then transferred to LB- 
agar plates containing 50 pg/ml kanamycin or ampicillin.
2.2.5 Plasmid DNA mini-preps
Bacterial clones were streaked on LB-agar plates containing relevant antibiotics and left 
overnight at 37 °C. The next day, they were scraped off using sterile loops (Greiner Bio- 
one, Germany) and mini-preps of plasmid DNA were produced using the Miniprep Kit 
(Qiagen, U.K.) according to the manufacturer’s instructions.
2.2.6 PCR-amplification and ligation
DYAD or TETRAD PCR-machines (MJ Research, U.S.A) were used for basic PCR 
techniques and PCR mutagenesis using Pfx Platinum DNA-polymerase (Invitrogen, 
U.K.), generating blunt-end PCR products, according to the manufacturer’s instructions. 
The PCR reaction mixture had a total volume of 50 pi and consisted of:
5 pi of DNA-polymerase buffer (lOx)
1 pi of plasmid DNA (app. 1 OOng)
5 pi of forward primer (10 pM)
5 pi of reverse primer (10 pM)
2 pi of supplied Mg2 SC>4
2 pi of dNTP (lOmM)
0.5 pi of Pfx Platinum polymerase
29.5 pi of sterile water
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• The basic PCR: 50ng of plasmid DNA or lOOng of genomic DNA was used to PCR- 
amplify the target region, of approximately 1500 nucleotides, by using the following 
PCR cycle:
1. 3 minutes at 94 °C
2 . 30 seconds at 94 °C
3. 1 min at 60 °C
4. 2 min at 6 8  °C
5. Steps 2-4 an additional 30 times
6 . 10 minutes at 70 °C
The PCR product was resolved by agarose gel electrophoresis, purified from the gel 
using a QIAquick gel extraction kit (Qiagen, U.K.), cut with relevant restriction enzymes 
and ligated into a plasmid backbone using T4-DNA ligase (Promega) as recommended 
by the manufacturer’s protocol. Alternatively, PCR product was directly cloned into a 
TOPO expression plasmid using the Zero Blunt TOPO Kit (Invitrogen, U.K.) according 
to the manufacturer’s protocol.
• PCR mutagenesis: 100-200 ng of plasmid DNA was used for site-directed mutagenesis, 
using the following PCR cycle:
1. 3 minutes at 94 °C
2 . 30 seconds at 94 °C
3. 30 seconds at 60 °C
4. 12 min at 6 8  °C
5. Steps 2-4 an additional 20 times
6 . 20 minutes at 70 °C
The extension time of 12 minutes is applicable for plasmids smaller than 6000 
nucleotides. In some cases the plasmid was about 10 Kb so the extension time was 
extended to 20 minutes. Dpnl enzyme (1 pi) was then added to the reaction, which was 
incubated for 2 hours at 37 °C. 2 pi of the reaction was then transformed into Escherichia 
coli bacteria using heat-shock.
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2.2.7 Quantitative PCR
TaqMan PCR to measure viral DNA synthesis was performed using primers and probe 
sequences specific for GFP: forward primer CAACAGCCACAACGTCTATATC 
AT, reverse primer ATGTTGTGGCGGATCTTGAAG, Probe 5'-FAM-CCGACAAGC 
AG AAG AACGGC ATC AA-3 'T AMRA.
The viral vectors were first treated with DNasel to remove contaminating GFP-encoding 
DNA. DNase buffer and DNasel (Promega) were added to eppendorf tubes containing 
viral vectors (70 units of DNasel/ml) and incubated at 37 °C for 2 hours. 105 cells were 
then infected in six-well plates in triplicate. Six hours after infection, total DNA was 
extracted (DNeasy kit, Qiagen, U.K.) from two samples. The third sample was incubated 
for a further 48 hours and then subjected to FACS analysis to enumerate infected cells. 
The DNA concentrations of all samples were measured using a NanoDrop ND-1000 
spectro-photometer (NanoDrop Technologies, U.S.A.). 2pl of sample was then subjected 
to TaqMan quantitative PCR as described (Towers et al., 1999) using TaqMan 2X 
quantitative PCR buffer (Applied Biosystems) with primers and probe at 300 nM and 
150 nM, respectively. All TaqMan PCR reactions contained 0.1 mg/ml salmon sperm 
DNA (Sigma, Poole U.K.) as a carrier.
The PCR was executed using an ABI Prism 7000 (Applied Biosystems) using the 
following hot start cycling parameters.
1. 10 min 95 °C
2. 15 seconds 95 °C
3. 1 min 60 °C
4. Steps 2-3 an additional 50 times
The data was analysed using ABI prism 7000 SDS software CTS 1.0 (Applied 
Biosystems). A standard curve was generated by preparing a 10-fold serial dilution of 
plasmid DNA encoding GFP (CNCG) from 5.10s to 50 molecules per reaction. Using the 
standard curve in Figure 2.3 the absolute copy numbers of GFP encoding DNA 
molecules present in the PCR reaction could be determined. These values were then 
corrected using the known concentration of the DNA sample, to give a value for the 
DNA copy number per 100 ng of total DNA. All PCR reactions were carried out in 
duplicate and the data was only accepted if no GFP target was detected in the blank 
controls or in DNA extracted from uninfected cells.
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Figure 2.3. Standard curve. The standard curve for the data presented in figure 3.5. R2 : 
0.998408. Generated by ABI prism 7000 CTS 1.0 software.
2.2.8 Flow cytometry
48-hours post-infection, cells were trypsinised (trypsin-EDTA, Invitrogen, U.K.) for 2 
minutes at 37 °C, resuspended in 300-500 pi of phosphate-buffered saline (PBS), 
transferred to FACS tubes (Falcon) and kept on ice, prior to analysis.
Green cells were then enumerated by fluorescence-activated cell sorting (FACS) analysis 
using a Facs Calibur or LSR (Becton Dickinson, U.K.) using Cellquest software (Becton 
Dickinson, U.K.). Intact cells were identified based on light scatter profiles, and only 
these were included in the analysis. GFP fluorescence was recorded in the FL1 channel 
and red fluorescence in the FL2 channel. For double-fluorescence recordings, 
compensation was performed using the relevant controls. A total of 104  to 5xl04 cells 
were analysed per sample.
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2.2.9 Confocal microscopy
105 cells were seeded into 35mm Glass Bottom Culture Dishes of diameter (MatTek 
Corporation, USA). In the case of the arsenic experiments, cells were treated the next day 
with 8  pM AS2 O3 for the indicated periods. Cells were then washed in PBS and fixed in 
freshly prepared 3% paraformaldehyde (PFA, Sigma) in PBS for 30 minutes at room 
temperature. Cells were washed three times for 5 minutes in PBS and quenched in 50mM 
ammonium chloride in PBS for 15 minutes at room temperature. Cells were again 
washed three times in PBS for 5 minutes and incubated in 2%FCS-PBS-0.1%TritonX 
(TX) for 15 minutes at room temperature to block non-specific binding. 50 pi of primary 
mouse anti-HA antibody (Covance, U.S.A.) diluted 1:1000 in 2%FCS-PBS-0.1%TX was 
added for 30 to 45 minutes at room temperature. Cells were rinsed twice in PBS- 
0.1 %TX, washed three times in PBS-0.1 %TX for 5 minutes and incubated further in 
2%FCS-PBS-0.1%TX for 15 minutes at room temperature to block non-specific binding. 
50 pi of secondary anti-mouse AlexaFluor 488 antibody (Molecular Probes) diluted 
1:500 in 2%FCS-PBS-0.1%TX was added for 30 to 45 minutes at room temperature. 
Cells were rinsed twice in PBS-0.1 %TX and washed four times in PBS-0.1 %TX for 5 
minutes. 1 ml of PBS was left inside the dish and cells were ready for confocal 
microscopy.
Microscopy analysis was executed with a Leica TCS NT Confocal Microscope (Leica 
Microsystems) using the Leica TCS software. The secondary antibody conjugated to 
photostable, green-fluorescent AlexaFluor 488 was visualised after excitation with 488 
nm light for each sample. No image enhancement was used. The images in figure 3.23 
are magnified 63 times.
2.2.10 Western Blot
106 cells were plated in 10 cm culture dishes (Helena Biosciences, U.K.). The following 
day, cells were incubated with the indicated concentrations of AS2 O3 for the indicated 
time period. The experiment was designed so that all the incubations end at the same 
time. Cells were then trypsinised, resuspended in PBS and counted with a 
haemocytometer (Hawksley BS., U.K.). Equal numbers were pelleted by centrifugation 
at 1200 rpm for 5 minutes. The pellet was resuspended in 300 pi of RIPA lysis buffer 
(0.15 M NaCl, 50 mM Tris-pH 8.0, 1% NP-40, 0.1% SDS, 0.5% deoxycholate) with 
protease inhibitors, according to the manufacturer's instructions (Protease inhibitor Mini
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cocktail, Roche), and lysed for 30 minutes on ice. The lysate was centrifuged in a table- 
top microcentrifuge at 13,000 rpm for 3 minutes. The supernatants were transferred into 
clean, labelled eppendorf tubes and small aliquots were subjected to Bradford protein 
assay (Bio-Rad, according to the manufacturer's protocol). This allowed equalisation of 
samples by protein content. Samples were frozen at -20°C for subsequent SDS-PAGE 
electrophoresis and immunoblotting.
Gels were prepared using ProtoGel reagents according to the manufacturer's protocol 
(National Diagnostics, U.S.). Small aliquots of samples were mixed with 2xLaemli 
Sample buffer (125 mM Tris-HCl (pH 6.8), 1.4% SDS, 20% glycerol, 0.001% 
bromophenol blue, where 200 pi of (3-mercaptoethanol/ml was added on the day of the 
experiment), boiled for 5 minutes, centrifuged at 13,000 rpm for 3 minutes and 100 ng of 
protein was loaded onto the gel. Kaleidoscope protein standard (Bio-Rad) was loaded as 
a control. Gels were electrophoresed at 50 Volts per gel (variable Amps). 
Electrophoresed proteins were transferred to a PVDF membrane using a Hoefer
'j
Semiphor transfer apparatus at 0.8 mA/cm transferable area, for 45-60 minutes. This 
was sufficient for complete transfer of 55-60 kDa proteins. Blocking of non-specific 
binding sites on the PVDF membrane was performed in a solution of 5% non-fat milk 
powder in 0.1% Tween20 in Tris-buffered saline (TBS). Membranes were incubated for 
1 hour with primary anti-HA, anti-cyclophilin, anti-p-actin, or anti-HD AC-1 antibodies 
(see table 2.3), washed three times for 10 minutes in TBS and incubated for 45 minutes 
with species-specific secondary, horseradish peroxidase-linked (HRP) antibodies 
(Sigma). Membranes were washed again in TBS (three times for 10 minutes). Proteins 
were then detected by enhanced chemiluminescence (ECL, Amersham) and the 
immunoblots were exposed to Amersham hyperfilm.
In some cases immunoblotted, exposed membranes were later stripped by incubating 
membranes for 20 minutes in Stripping Buffer (0.2 M glycine in distilled water, pH 2.0) 
at room temperature, washed three times for 10 minutes in TBS and re-blocked in a 
solution of 5% non-fat milk powder in 0.1% TBS. Immunoblotting with new antibodies 
followed as described above. As many as 3 stripping procedures could be performed 
without affecting the quality of the subsequent blot.
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Name Protein Size (kDa) Source DescriDtion
Anti-HA-Peroxidase detects HA-tagged 
TRIM5a in this study 
o f app. 55-60 kDa in 
size
Roche monoclonal rat antibody against 
HA peptide (YPYDVPDYA), used 
in this study to detect HA-tagged 
TRIM5a, dilution 1:500
Anti-cyclophilin A 18 Biomol rabbit polyclonal antibody against 
cyclophilin A, dilution 1:10 000
Anti-actin 42 Sigma mouse monoclonal antibody 
against a- or p-actin, dilution 
1:5000
Anti-HD AC-1 65 Upstate
Biotechnology
rabbit polyclonal antibody against 
histone deacetylase-1, dilution 
1:1000
Table 2.4. Antibodies.
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Chapter 3
Results 
3.1. Results 1
3.1.1 Introduction
The cross-saturation studies and the similarities between the Refl and Lvl restriction 
phenotype suggested that Refl might be a human-specific variant of Lvl that lacks the 
ability to restrict HIV-1, HIV-2 and SIVmac. Variability in the restriction profiles of cell 
lines from different primate species might be explained by the divergence of a single 
ancestral Lvl gene. Alternatively, it is also possible that restriction factors could have 
arisen on multiple occasions and that the different restriction properties of primate cell 
lines reflect the action of several independent genes. Indeed, endogenous retroviral 
envelope-mediated Fv4-like restrictions have arisen on multiple occasions (reviewed in 
Stoye, 2002; Bieniasz, 2003; Towers, 2003).
The identification of TRIM5a as a molecule responsible for HIV-1 restriction in Rhesus 
macaque cells (Stremlau et a l, 2004) allowed us to resolve this issue. There are two 
experimental approaches to test if a certain molecule contributes to the restrictive 
phenotype of a cell line. We can either express the potential restriction factor in cells that 
naturally do not restrict, and see if they acquire the restrictive phenotype, or we can 
downregulate the expression of the molecule in wild type restrictive cells and test 
whether these cells lose the ability to restrict. In our study, we employed both of these 
methods. Primates exhibit significant variability in retrovirus restriction specificity. This 
specificity might depend on the presence of different TRIM5a alleles within these 
species. We therefore cloned the TRIM5a cDNA from African green monkey cells by 
PCR and tested whether it accounts for the characteristic restriction pattern of the cells 
from which it was derived. By comparing the amino-acid sequences of human-, Rhesus 
macaque- and Agm TRIM5a molecules we aimed to define the part of the TRIM5a 
protein that might be responsible for the species-specificity. Interest in the character of 
the TRIM5a-mediated block led us to examine this using the quantitative PCR technique. 
Multiple splicing of the TRIM5 primary transcript gives rise to several protein isoforms, 
each increasingly shorter from the C-terminus. It was previously shown that the y splice 
variant of Rhesus monkey TRIM5 can act as a dominant negative to Rhesus macaque 
TRIM5a antiviral function (Stremlau et a l, 2004). To examine the contribution of other
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TRIM5 splice variants to antiviral activity, we cloned the human TRIM58 isoform. 
TRIM58 is shorter than the y variant, completely lacks the B30.2 domain sequence and 
due to splicing contains different amino-acids at the C-terminus than the y isoform. We 
therefore examined its ability to restrict and/or its potential to modulate TRIM5a activity 
when coexpressed.
3.1.2 Variations of TRIM5a from different primate species
Cells from different primate species show specific differences in their restriction 
properties for HIV-1, SIVmac and MLV. To test whether these differences in restriction 
patterns can be explained by genetic differences between the TRIM5a genes of the 
species, we PCR amplified the TRIM5a cDNAs from human (hu), Rhesus macaque 
monkey (mac) and African green monkey (Agm) and cloned them into the MLV 
retroviral vector CXCRdEcoRl. The human TRIM5a gene was amplified by PCR from a 
human IMAGE clone number 6160154, whilst the macaque and Agm TRIM5as were 
PCR amplified from Rhesus macaque cDNA or from a cDNA library derived from 
African green monkey CV1 cells (for details see chapter 2.2.2). The sequence of the 
Agm-, human- and Rhesus macaque TRIM5a was determined by sequencing three 
independent clones.
An alignment of the sequences is shown in Figure 3.1. Human and Rhesus monkey 
sequences shared 87% sequence identity. Agm TRIM5a differed from both human and 
Rhesus monkey alleles at multiple positions and contained a 20 amino-acids insertion in 
the B30.2 domain compared to the human sequence and 18 amino-acids compared to the 
Rhesus macaque sequence. This insertion is a result of tandem sequence duplication. 
Important structural elements in the TRIM domains, such as the cysteines and histidines 
of the RING and B-box 2 domains, are conserved among the primate TRIM5a proteins 
studied. The most dramatic interspecies variation in TRIM5a is seen in the B30.2 
domain.
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(----------------------  RING domain ---------------------------------- 1
macT5a MASGILLNVKEEVTCPICLELLTEPLSLHCGHSFCQACITANHKKSMLYKEGERSCPVCR
AgmT5a MASGILLNVKEEVTCPICLELLTEPLSLPCGHSFCQACITANHKESMLYKEEERSCPVCR
huT5a MASGILVNVKEEVTCPICLELLTQPLSLDCGHSFCQACLTANHKKSMLDK-GESSCPVCR
* * * * * * . * * * * * * * * * * * * * * * * ; * * * *  * * * * * * * * * . * * * * * . * * *  *  *  * * * * * *
I  B-box 2 domain
macT5cx ISYQPENIQPNRHVANIVEKLREVKLSPEEGQKVDHCARHGEKLLLFCQEDSKVICWLCE
AgmT5a ISYQPENIQPNRHVANIVEKLREVKLSPEEGQKVDHCARHGEKLLLFCQEDSKVICWLCE
huT5a ISYQPENIRPNRHVANIVEKLREVKLSPE-GQKVDHCARHGEKLLLFCQEDGKVICWLCE
• 'k'k'k'k’k'k'k'k'k'k'k'k'k'k'k'k'k'k'k'k ^
--------------- 1 |---------------------------------------  Coiled-coil domain ------------------
macT5a r s q e h r g h h t f l m e e v a q e y h v k l q t a l e m l r q k q q e a e k l e a d i r e e k a s w k i q i d y d k
AgmT5a RSQEHRGHHTFLMEEVAQEYHVKLQTALEMLRQKQQEAEKLEADIREEKASWKIQIDYDK
huT5a RSQEHRGHHTFLTEEVAREYQVKLQAALEMLRQKQQEAEELEADIREEKASWKTQIQYDK
  1
macT5a TNVSADFEQLREILDWEESNELQNLEKEEEDILKSLTKSETEMVQQTQYMRELISELEHR
AgmT5a TNVSADFEQLREILDWEESNELQNLEKEEEDILKSLTKSETEMVQQTQYMRELISDLEHR
huT5a TNVLADFEQLRDILDWEESNELQNLEKEEEDILKSLTNSETEMVQQTQSLRELISDLEHR
★ ★★ ★★★★★★★ • 'k'k'k'k-k'kieie'k'k'k'k'k'k'k'k'k'k'k'k'k'k'k’k'k • 'k'k'k'k'k'k'k'k'k'k • ★★★★★ • ★★★★
I
macT5a LQGSMMDLLQGVDGIIKRIENMTLKKPKTFHKNQRRVFRAPDLKGMLDMFRELTDARRYW
AgmT5a LQGSMMELLQGVDG11KRIENMTLKKPKTFHKNQRRVFRAPDLKGMLDMFRELTDVRRYW
huT5a LQGSVMELLQGVDGVIKRTENVTLKKPETFPKNQRRVFRAPDLKGMLEVFRELTDVRRYW
--------------------------------  B30.2(SPRY) domain-------------------------------------------
macT5a V DVT LATNNIS HAVIAE DKRQV S S RN PQIM Y QAPGT L F---------------------TFPS
AgmT5a VDVTLAPNNISHAVIAEDKRQVSYQNPQIMYQAPGSSFGSLTNFNYCTGVLGSQSITSRK
huT5a VDVTVAPNNISCAVISEDKRQV S S PKPQIIYGARGTRY----------------------- QT
macT5a LTNFNYCTGVLGSQSITSGKHYWEVDVSKKSAWILGVCAGFQSDAMYNIEQNENYQPKYG
AgmT5a LTNFNYCTGVLGSQSITSGKHYWEVDVSKKSAWILGVCAGFQPDATYNIEQNENYQPKYG
huT5a FVN FN YCTGILGSQS IT SGKHYWEVDVSKKTAWILGV YQPKYG
• •k'k'k'k'k'k'k»'kie'k'kie'k'ki('k'kie'k"k'k'k'k'k'k'k'k»'k'k'k'k'k'k'k'k'k'kic ★★
rnacT5a YWVIGLQEGVKYSVFQDGSSHTPFAPFIVPLSVIICPDRVGVFVDYEACTVSFFNITNHG
AgmT5a YWVIGLQEGDKYSVFQDGSSHTPFAPFIVPLSVIICPDRVGVFVDYEACTVSFFNITNHG
huT5a YWVIGLEEGVKCSAFQDSSFHTPSVPFIVPLSVIICPDRVGVFLDYEACTVSFFNITNHG
* * * * * * . * *  *  * > * * * > *  * * *  _ * * * * * * * * * * * * * * * * * * . * * * * * * * * * * * * * * * *
macT5a FLIYKFSQCSFSKPVFPYLNPRKCTVPMTLCSPSS 4 97
AgmT5a FLIYKFSQCSFSKPVFPYLNPRKCTVPMTLCSPSS 515
huT5a FLIYKFSHCSFSQPVFPYLNPRKCGVPMTLCSPSS 4 93
* * * * * * * . * * * * . * * * * * * * * * * *  * * * * * * * * * *
Figure 3.1. Sequence variations of TRIM5a from different species. Comparison of protein 
sequence of TRIM5a from human, Rhesus macaque (Macacca mulatta) and Agm (Cercopithicus 
sp.) deduced from the cDNA sequence. There are sixty amino-acid residues per full line. 
means that the residues in that column are identical in all sequences in the alignment. means 
that conserved substitutions have been observed. means that semi-conserved substitutions 
are observed. Residues representing V1 variable region are in blue, V2 variable region are in 
green and V3 variable region are in pink. Variable regions are labelled according to Song et al., 
2005b.
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3.1.3 Expression of the human and African green monkey TRIM5a genes in 
permissive feline CRFK cells
The finding that the TRIM5a protein from Rhesus macaques is able to block HIV-1 
infection encouraged us to examine whether human TRIM5a contributes to the block to 
N-MLV and EIAV replication in human cells.
We cloned the human TRIM5a-encoding cDNA into a retroviral vector that also encodes 
red fluorescent protein (RFP). We chose a red fluorescent protein over puro resistance or 
other antibiotics markers because of the poor sensitivity of some cell lines to antibiotics. 
Human TRIM5a, RFP-encoding MLV virus vector was prepared and used to stably 
transduce feline CRFK cells. These cells were chosen because they are unable to restrict 
any of the retroviruses tested so far, and N-MLV and B-MLV are equally infectious on 
this cell line. Stable clones expressing RFP and therefore TRIM5a were then infected 
with N-MLV or B-MLV vectors encoding GFP. Forty-eight hours later, infected cells 
were analysed by FACS and the percentages of GFP-positive target cells were used to 
generate infectious titres. The results showed that CRFK cells expressing human 
TRIM5a are approximately 150-fold less permissive for N-MLV GFP than untransduced 
cells (Figure 3.2 A, B). The titre of B-MLV GFP remained almost unchanged in both 
control and transduced feline cells (Figure 3.2 C, D).
We performed a similar analysis to test the restriction properties of Agm TRIM5a and to 
examine its contribution to the Lvl phenotype in Agm cells. African green monkey cells 
are known to restrict N-MLV, HIV-1, HIV-2 and SIVmac. Upon the introduction of Agm 
TRIM5a into CRFK cells we observed 15-25-fold lower infectivity of HIV-2 GFP, N- 
MLV GFP and SIVmac GFP, and 6-fold lower titre of HIV-1 GFP while B-MLV GFP 
infectivity was unaffected (Figure 3.3).
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Figure 3.2. Expression of human TRIM5a in cat cells enables them to restrict N-MLV but 
not B-MLV. Cat CRFK cells were transduced with a retroviral vector encoding human TRIM5a 
and single-cell clones were isolated. Untransduced CRFK cells (A, C) and TRIM5a-positive 
clones (B, D) were infected with equivalent doses of N-MLV (A, B) or B-MLV (C, D) encoding 
GFP. The multiplicity of infection for unmodified CRFK cells was 0.1. Forty-eight hours later, the 
cells were analysed for green fluorescence by FACS. Side scatter is shown on the y  axis, and 
GFP or MLV infectivity is shown on the x axis. Percentages given indicate the proportion of GFP- 
positive cells (MLV infected). Data shown are representative of experiments performed on 12 
independent TRIM5a -positive CRFK clones.
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Figure 3.3. Expression of Agm TRIM5a in cat cells enables them to restrict various 
retroviruses. Cat CRFK cells were transduced with a retroviral vector encoding TRIM5a from 
Agm CV1 cells, and single-cell clones were isolated. Untransduced CRFK (A-E) cells and Agm 
TRIM5a -positive clones (F-J) were infected with N-MLV (A, F), B-MLV (B, G), HIV-1 (C, H), HIV- 
2 (D, I) or SIVmac (E, J) encoding GFP. The multiplicity of infection was between 0.01 and 0.1. 
Forty-eight hours later, the cells were analysed for green fluorescence by FACS. Side scatter is 
shown on the y  axis, and green fluorescence is shown on the x axis. Percentages given indicate 
the proportion of GFP-positive cells (virus infected). Data shown are representative of 
experiments performed on 7 independent Agm TRIM5a -positive CRFK clones.
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3.1.4 Disruption of TRIM5a expression in human and Agm cells
To further confirm the identity of human TRIM5a as R efl, we transiently downregulated 
its expression in human HeLa cells by introducing short interfering RNAs (siRNA) 
directed against human TRIM5a. These siRNAs were previously shown to significantly 
decrease Rhesus macaque TRIM5a protein levels (Stremlau et a l,  2004). This treatment 
had no effect on the HeLa titre of B-MLV GFP but increased that of N-MLV GFP by 
around 50-fold, almost up to the level of B-MLV GFP. Untransduced cells were used as 
a control (Figure 3.4 A).
Similarly, to confirm that Agm TRIM5a is the factor responsible for Lvl activity, and 
responsible for restricting N-MLV GFP, HIV-1 GFP , SIVmac GFP and ELAV GFP, in 
African green monkey CV1 cells, we transiently downregulated expression of Agm 
TRIM5a in these cells. Disruption of Agm TRIM5a expression in Agm CV1 cells 
rescued permissivity to restricted virus by 1- to 2- orders of magnitude without 
significantly affecting the titre of unrestricted B-MLV GFP (Figure 3.4 B).
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Figure 3.4. Disruption of TRIM5a expression by siRNA in human or Agm cells increases 
permissivity fo r restricted virus but not unrestricted virus. Human HeLa cells (A) or Agm
CV1 cells (B) were transfected with siRNA to TRIM5a (red bars) or left untransfected as a control 
(black bars). Infectious titres of restricted and nonrestricted viruses were determined by infection 
followed by assay of GFP by FACS 48 h later. Infections were performed such that between 1% 
and 3% of wild type target cells were infected. Results are representative of three independent 
experiments.
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3.1.5 Examining the impact of TRIM5a on MLV reverse transcription
The block to N-MLV infection in human cells was shown to be early post-entry, before 
reverse transcription (Towers et a l, 2000). Measuring the levels of reverse transcription 
DNA products of restricted N-MLV, and unrestricted B-MLV, in human cells by PCR 
showed that reverse transcription of N-MLV is less efficient than reverse transcription of 
B-MLV. Thus, relieving the block to N-MLV infection by disruption of TRIM5a 
expression should also rescue the ability of N-MLV to reverse transcribe.
We therefore compared the levels of viral DNA synthesis of restricted and nonrestricted 
virus in human HeLa cells in the presence or absence of human TRIM5a. Viral DNA 
was measured 6 hours post-infection by TaqMan quantitative PCR using primer and 
probe sequences specific for GFP. To exclude the possibility of contamination by GFP- 
encoding DNA from the virus preparation, all viral vectors were treated with DNasel 
before infection. In the wild type cells, N-MLV synthesised between 10-100-fold less 
viral DNA than B-MLV. In the cells where the expression of human TRIM5a was 
downregulated by siRNA, N-MLV was able to synthesise approximately 10 times more 
viral DNA than in control unmodified cells, whereas the level of B-MLV reverse 
transcripts remained unchanged (Figure 3.5).
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Figure 3.5. Disruption of TRIM5a expression by siRNA in human cells increases N-MLV 
but not B-MLV viral DNA synthesis. Human HeLa cells were transfected with siRNA to TRIM5a 
(red bars) or left untransfected as control (black bars) and infected with equivalent doses of N- 
MLV and B-MLV encoding GFP. Six hours after infection total DNA was purified and subjected to 
TaqMan quantitative PCR as described in Materials and Methods. Viral DNA copy number per 
100 ng of total DNA is plotted. Results are representative of two independent experiments.
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3.1.6 Investigating the role of the TRIM5delta splice variant in restriction
The human TRIM58 gene was amplified by PCR from a plasmid kindly provided by P.G. 
Pelicci and cloned into a retroviral vector expressing red fluorescent protein. Cloning of 
human TRIM58 allowed us to test its restriction capability and its contribution to 
TRIM5a-mediated restriction. We stably transduced human TE671 cells with a 
Moloney retroviral vector encoding RFP and human TRIM58, and challenged these cells 
with N-MLV or B-MLV vectors encoding GFP. Overexpression of TRIM58 did not 
enhance the block by TE671 cells to N-MLV. On the contrary, it increased the 
permissivity to N-MLV infection by almost 60-fold, demonstrating that TRIM58 exerts 
dominant negative activity on TRIM5a function (Figure 3.6 A, B). Unrestricted B-MLV 
infectivity was unaffected (Figure 3.6 C, D).
We were also interested to see if human TRIM58 has dominant negative activity on 
TRIM5a from species other than human. We therefore transiently expressed human 
TRIM58 in cat cells stably over-expressing human TRIM5a or Agm TRIM5a. 
Introduction of human TRIM58 into wild type feline CRFK cells did not impact on 
permissivity to MLV infection (Figure 3.7 A, B) thus confirming the importance of the 
B30.2 domain in restriction. However, transient expression of huTRIM58 in cat cells had 
a dominant negative effect on the activity of co-expressed huTRIM5a, and relieved the 
block to restricted N-MLV GFP (Figure 3.7 E, F). This rescue of N-MLV infectivity was 
not seen when TRIM58 was expressed in cat cells expressing Agm TRIM5a, 
demonstrating a species-specific dominant negative effect (Figure 3.7 I, J). The titre of 
B-MLV GFP remained unaffected in all cases (Figure 3.7 C, D, G, H, K, L).
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Figure 3.6. Human TE671 cells stably over-expressing the human TRIM55 isoform have 
increased permissivity to N-MLV but not B-MLV infection. TE671 cells were transduced by a 
retroviral vector encoding human TRIM56 and single-cell clones were isolated. Wild type TE671 
cells (A and C) and red fluorescent protein expressing TRIM 56-positive clones (B and D) were 
infected with N-MLV (A, B) or B-MLV (C, D) encoding GFP. Forty-eight hours later, the cells were 
analysed for green fluorescence by FACS. Percentages given indicate the proportion of GFP- 
positive cells (virus infected). Infections were performed such that around 0.5% of wild type target 
cells were infected. Data shown are representative of experiments performed on 3 independent 
TRIM56 -positive TE671 clones.
CRFK
12<73
CRFK/huT rim5a
huT5 8 
+N-MLV
3.5 %
N-MLV
2.32 %
0.53 %
B-MLV
2 %
0
10°
1.61 %
huT5 8 
+B-MLV
3.48 %
1.56%
103 - F . / W 'l l G .  /■ 10 I) H. , •
J j P ^ - - i l P p L a i ^ .
0 0 - 0 — ,i i r
10* 10u 10*
i/3
0 . 1 0 % 0.14%
CRFK/AgmT rim5
>3 -I
eG FP in FL1
Figure 3.7. The dominant negative effect of human TRIM55 is species specific. We infected 
unmodified cat CRFK (A-D) or cat cells stably over-expressing either human TRIM5a (E-H) or 
Agm TRIM5a (l-L) with N-MLV GFP {A, B, E, F, /, J) or B-MLV GFP (C, D, G, H, K, L) in the 
presence (B, D, F, H, J, L) or absence (A, C, E, G, I, K) of human TRIM56 isoform. 48 hours later 
cells were analysed by FACS. Infections were performed such that around 2% of untransduced 
target cells were infected. Results shown are representative of 3 independent experiments.
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3.1.7 Discussion
Intracellular antiviral responses are one of the defense mechanisms employed by host 
organisms against retroviral pathogens. Although evidence of specific innate cellular 
factors that inhibit retroviral replication was first provided by studies of MLV replication 
in mice (Lilly et al., 1967; Lilly and Pincus, 1973) it later became evident that primate 
species including humans also possess these innate anti-retroviral activities (Besnier et 
a l , 2002; Cowan et a l , 2002; Munk et a l , 2002; Towers et a l , 2002).
Human cells were shown to block the infection of N-tropic MLV and of the distantly 
related equine retrovirus EIAV. Monkey cells displayed a broader range of restrictive 
activities, and blocked viruses like HIV-1, HIV-2, N-MLV, EIAV and certain types of 
SIV (Towers et a l , 2000, 2002; Besnier et a l , 2002; Hatziioannou et a l , 2003). The 
factor responsible for this block was termed Refl in human cells and Lvl in monkey 
cells (Cowan et a l, 2002; Towers et a l, 2002). It was not known if Refl and Lvl were 
two independent restrictive mechanisms responsible for retroviral blocks in humans and 
monkeys or if they are related. An increasing amount of circumstantial evidence 
suggested that Refl and Lvl are related. Both restriction factors are saturated with high 
doses of restricted virus, they both act before reverse transcription, are able to restrict 
divergent mammalian retroviruses and both distinguish between very closely related N- 
tropic and B-tropic MLV (Towers et a l, 2000; Besnier et a l,  2002; Cowan et a l,  2002; 
Munk et a l, 2002; Towers et a l, 2002; Hatziioannou et a l, 2003). The discovery of 
TRIM5a restriction factor in Rhesus macaque monkey cells (Stremlau et a l , 2004) made 
it possible to examine whether TRIM5a encodes Refl and Lvl activity.
By over-expression of human and African green monkey TRIM5a in otherwise 
nonrestricting feline cells (Figure 3.2 and 3.3), and their depletion from wild type cells 
(Figure 3.4), we showed that TRIM5a is responsible for both Refl activity in humans 
and Lvl activity in simians. In Figure 3.2 we showed that expression of human TRIM5a 
in nonrestricting cat cells renders them able to restrict N-MLV but not the very closely 
related B-MLV. The degree of restriction was over 2 orders of magnitude higher than 
when not expressed and comparable with restriction of N-MLV in human cell lines. We 
also observed a slight (3-fold) block to B-MLV infection in cat cells expressing human 
TRIM5a. This is likely to be due to over-expression of human TRIM5a. It was shown 
previously that the over-expression of the murine restriction factor Fvlb expanded its 
specificity, leading to a weak restriction of B-MLV (Bock et al., 2000). The ability of 
human TRIM5a to restrict retroviral infection is further confirmed in Figure 3.4, where
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disruption of human TRIM5a expression restored the infectivity of restricted N-MLV in 
nonpermissive human HeLa cells to titres equivalent to unrestricted B-MLV. The titre of 
B-MLV is only slightly affected.
We performed analogous experiments to test if TRIM5a is also responsible for the 
restrictive properties of monkey species other than Rhesus monkey. We tested the 
restrictive properties of African green tantalus monkey TRIM5a from CV1 cells. African 
green monkeys were shown to restrict a broad range of retroviruses (Table 1.4). Our data 
showed that expression of Agm TRIM5a in nonrestricting cat cells confers on them the 
ability to restrict N-MLV, HIV-1, HIV-2 and SIVmac, but not B-MLV (Figure 3.3). 
Furthermore, stable down-regulation of Agm TRIM5 in Agm CV1 cells restores 
infectivity to a range of restricted viruses, including N-MLV, HIV-1, SIVmac and EIAV 
(Figure 3.4 B). The titre of N-MLV is restored to that of B-MLV (Figure 3.4 B). The titre 
of restricted viruses increased in concordance with the strength of the blocks, as defined 
by titration of these viruses on nonrestricted feline cells.
Thus, we demonstrated that human- and Agm TRIM5a can potently, and specifically, 
block infection of many unrelated retroviruses, and that Refl and Lvl are species- 
specific variants of a single restriction factor. TRIM5a is both necessary and sufficient 
for the establishment of the specific restriction of retroviral infection in human, Agm and 
feline cell lines expressing these proteins. The results also indicate that any cofactors 
required for the block to retrovirus replication must be functionally conserved between 
humans, cats and monkeys.
It has also become clear that primate TRIM5a orthologues inhibit retrovirus replication 
in a species-specific and virus-specific manner. Human cells were shown to restrict N- 
MLV and EIAV but not B-MLV, HIV-1, or SIVmac, while Rhesus macaque cells are able 
to restrict HIV-1, HIV-2 and SIVAgm but not MLV viruses. African green monkey cell 
lines exhibit the broadest range of restricted retroviruses, namely N-MLV, HIV-1, HIV- 
2, SIVmac and EIAV, although this apparent broader specificity is likely to be a 
consequence of the range of viruses tested. As we have shown, expression of TRIM5a 
from a certain species in cat cells bestows on them the same restrictive properties as the 
cell line from which the TRIM5a was derived. Therefore, it appears that the observed 
specificity for particular retroviruses arises from differences in the TRIM5a proteins 
themselves.
In Figure 3.1 we compared the amino-acid sequences of TRIM5a alleles from human 
TE671, Rhesus macaque monkey FRhK and African green monkey CV1 cells, and 
showed that considerable variation among TRIM5a proteins of these primate species
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exist. Human TRIM5a and Rhesus macaque TRIM5a exhibit approximately a 13% 
variation in amino-acid sequence. Agm TRIM5a differed from both human and Rhesus 
monkey variants at multiple positions and, as a result of tandem sequence duplication, 
contained an insertion in the B30.2 domain (relative to the human and Rhesus sequence). 
Key elements of TRIM domains, such as the cysteines and histidines of the RING and B- 
box 2 domains, are preserved among the primate TRIM5a proteins studied. The other 
sequences of the RING, B-box 2 and coiled coil domains share many similarities. The 
most dramatic variation among primate TRIM5a proteins occurs in the B30.2 domain, 
suggesting that this domain is under the most selective pressure and might be responsible 
for the differential retroviral restriction capabilities of different TRIM5a's. It may 
therefore be possible that the 20 amino-acid insertion in the B30.2 domain of Agm 
TRIM5a, compared to the human one, might be responsible for the broader range of 
targeted viruses by Agm TRIM5a. Indeed, this was examined in the recent publication of 
Nakayama et al., where it was shown that mutant Agm TRIM5a lacking the 20 amino- 
acid duplication completely lost the ability to restrict SIVmac infection while still 
retaining the ability to restrict HIV-1 (Nakayama et a l , 2005). These results, together 
with finding of other groups performing mutagenesis studies on simian and human 
TRIM5a, clearly indicated that the B30.2 domain contains a determinant of species- 
specific restriction (Nakayama et al., 2005; Perez-Caballero et al., 2005a; Sawyer et al., 
2005; Stremlau et al., 2005; Yap et al., 2005).
In Figure 3.5 we examined the levels of N-MLV reverse transcription in the presence or 
absence of human TRIM5a. Our results showed that reverse transcription of N-MLV in 
human cells is rescued in the absence of human TRIM5a and thus it is TRIM5a that is 
responsible for the block of N-MLV before reverse transcription. Levels of viral DNA of 
unrestricted B-MLV were unchanged in both cases, in the presence or absence of 
endogenous TRIM5a. However, it is important to point out that the magnitude of the 
block to DNA does not necessarily account for the block to infection. Virus can be 
restricted in more than one step of its life cycle. Wu et al., (2006) showed that this is the 
case for TRIM5a-mediated restriction. This study revealed that even when you let 
TRIM5a-sensitive virus efficiently reverse transcribe, it is still restricted by TRIM5a at a 
later post-RT step.
Investigating the involvement of other TRIM5 variants in retroviral restriction showed 
that the 8 splice variant of TRIM5 lacking the C-terminal domain lost its restriction 
activity. This further confirms the importance of the C-terminal domain for restriction 
(compare Figure 3.7 A and B). TRIM55 exerts a dominant-negative effect on wild type
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TRIM5a when these two proteins are co-expressed, and this effect is seen only in the 
species-specific context (Figure 3.6 and 3.7). It is likely that TRIM5a proteins might 
homo-multimerise through their coiled-coil domain in order to make a functional 
antiviral complex. As the 5 isoform possesses the same coiled-coil domain, its dominant 
negative effect might simply be explained by the disruption of TRIM5a homomultimers 
when expressed at sufficient levels, which might cause improper creation of functional 
antiviral TRIM5a complexes. In concordance with this is the recent report that the 
TRIM5a protein oligomerises into trimers, and that trimerisation is needed for the B30.2 
domains to interact with threefold pseudo-symmetrical structures present on retroviral 
capsids (Mische et al., 2005). Thus, truncated TRIM5a proteins lacking B30.2 domains, 
but maintaining the coiled-coil domain, form heteromultimers with full-length TRIM5a, 
and are dominant inhibitors of its function (Javanbakht et al., 2005; Perez-Caballero et 
al., 2005a). It is not only truncated TRIM5a proteins that can act in a dominant negative 
way. Expression of full-length Rhesus monkey TRIM5a, or Owl monkey TRIMCyp, in 
human cells interfered with the anti-N-MLV activity of endogenous human TRIM5a 
(Berthoux et al., 2005), and TRIM5a from cynomolgus monkey had a dominant- 
negative effect on the anti-SIVmac activity of Agm TRIM5a (Nakayama et al., 2006). 
The dominant negative effect of human TRIM58 was only seen on human TRIM5a and 
not Agm TRIM5a (Figure 3.7). Similarly, overexpression of human TRIM58 in Agm 
CV1 cells did not exert a dominant negative effect on endogenous Agm TRIM5a (L.J. 
Ylinen, unpublished results). This could be explained by human TRIM58 not being able 
to form multimers with Agm TRIM5a, or that the multimers created between human 
TRIM58 and Agm TRIM5a are tolerated and do not inhibit the restrictive properties of 
the a  molecules. The presence and conservation of truncated TRIM5 products within the 
genomes suggests that it might serve some, perhaps regulatory, function in TRIM5a- 
mediated activity.
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3.2 Results 2
3.2.1 Introduction
The aim of the study described in this chapter is to understand the relationship between 
cyclophilin A and host factors impacting on permissivity to HIV-1 in mammalian cells. 
Cyclophilin A is recruited into nascent HIV-1 virions, as well as incoming HIV-1 
capsids, through the binding to HIV-1 capsid protein, where it isomerises an exposed 
proline residue (Franke et a l , 1994; Thali et al., 1994; Ott et a l , 1995; Gamble et a l , 
1996; Gitti et al., 1996; Yoo et a l , 1997; Bosco et al., 2002; Bosco and Kern, 2004). 
CypA influences an early, post-entry step of HIV-1 replication in the target cell. 
Inhibition of CypA's activity with CSA changes the infectivity of HIV-1 in both a cell 
line and species-specific way. This is exemplified by the fact that the HIV-1 titre is 
decreased in human cells but increased in simian cells following CSA treatment. Thus, 
CypA has been proposed to prevent binding of restriction factor to viral capsid in human 
cells, resulting in enhancement of HIV-1 infectivity, and also to potentiate restriction of 
HIV-1 in monkey cells (Towers et a l , 2003). Several lines of evidence agree that the 
activity of CypA and TRIM5a may be linked: i) the viral determinants for restriction by 
TRIM5a map to the CypA-binding loop in the capsid protein (Ylinen et a l , 2005), ii) the 
TRIM5a block to HIV-1 generally occurs prior to reverse transcription, and this is the 
point in the retrovirus life cycle where CypA acts, and iii) the isolation of a restriction 
factor from Owl monkey cells showed it to be a fusion between TRIM5 and cyclophilin 
A. We therefore sought a connection between CypA and TRIM5a in cells where HIV- 
infectivity is influenced by CypA, but where TRIM5a is not fused to CypA.
We set out to examine the effect of CypA on HIV-1 infectivity using cells from two Old 
World monkey species, Rhesus macaque and African green monkey, by either treating 
the cells with CSA or stably downregulating cyclophilin A levels using shRNA. By 
stable downregulation of TRIM 5 a , we wanted to examine the dependence of the 
cyclophilin A effect on the presence of a TRIM5a. Further, we wanted to test if 
expression of simian TRIM5 in permissive feline cells renders them able to restrict HIV- 
1 in a cyclosporine A-sensitive way. TRIMCyp recruits its tripartite motif to HIV-1 
capsid via cyclophilin A and, therefore, its ability to restrict completely depends on the 
ability of the virus to bind CypA. HIV-1 mutated in its CypA-binding loop is thus 
protected from the TRIMCyp restriction activity. By using CypA-binding loop mutants,
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we wanted to examine whether cyclophilin A has the same recruitment role in the case of 
Old World monkey TRIM5a. Furthermore, we extended this investigation to human cells 
to learn more about the involvement of cyclophilin A and TRIM5a in permissivity of 
human cells to HIV-1 infection.
3.2.2 Cyclophilin A has anti-HIV-1 activity in Old World monkey cell lines
We examined the effect of cyclophilin A on HIV-1 replication in two different simian 
cell lines, Rhesus macaque FRhK cells and African green monkey CV1 cells. We 
inhibited CypA enzymatic function with 5 pM CSA, or by stably downregulating CypA 
expression with CypA-specific shRNA. These cells were then infected with titrations of 
various strains of VSV-G-pseudotyped HIV-1 GFP vectors. We used NL4.3, an X-4- 
tropic laboratory-adapted HIV-1 strain (Adachi et al., 1986). NL4.3(Ba-L) is NL4.3 
encoding the CypA-binding loop from HIV-1 Ba-L (CA mutations H87Q, A88P, and 
19IV) and has been reported to be CypA independent and higher titre in simian cells 
(Kootstra et a l , 2003; Ikeda et al., 2004). 92BR is a naturally occurring subclass C 
primary isolate identified in Brazil (Gao et al., 1996). MVP5180 is an O group virus 
reported to be CypA independent in human cells (Braaten et al., 1996c; Wiegers and 
Krausslich, 2002).
As shown in Figure 3.8, the effect of cyclophilin A on retroviral infection is species and 
HIV-1 sequence specific. Reduction of CypA expression had the same effect as treatment 
with 5 pM CSA in each case, confirming CypA as the relevant target for CSA (Figure 3.8 
A to H). Infection of both, NL4.3 and 92BR strains is enhanced by around 10-fold in the 
absence of cyclophilin A activity on cell lines from Agm and Rhesus macaques (Figure
3.8 A, C, E, G). Infectivity of the NL4.3 (Ba-L) strain is not affected by cyclophilin A in 
any cell line (Figure 3.8 B, F). The influence of cyclophilin A on the infectivity of MVP 
differs between FRhK and CV1 cell lines. Whilst MVP titre is enhanced by around 7- 
fold on Agm CV1 cells when CypA activity was abrogated (Figure 3.8 D), it was not 
significantly increased in FRhK cells (Figure 3.8 H). These data indicate that elimination 
of CypA activity, either by reduction of CypA expression or by inhibition of CypA 
enzymatic activity, increases the infectivity of wild-type HIV-1 on Old World monkey 
Agm and macaque cell lines. Furthermore, mutations within HIV-1 capsid protein can 
render HIV-1 insensitive to CypA activity.
The efficiency of downregulation of CypA levels in FRhK and C V 1 cells was confirmed 
by biochemical and genetic approaches. Treatment with CSA did not significantly
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increase NL4.3 infectivity when CypA expression was reduced, indicating that the 
reduction of CypA expression by shRNA is significant (Figure 3.8 I, J). Similarly, 
western blot analysis revealed that CypA levels were substantially reduced, with actin 
expression levels shown as a control (Figure 3.8 K).
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Figure 3.8. Abrogation of cyclophilin  A activity rescues HIV-1 infectivity in Old World 
monkey cell lines. HIV-1 GFP-encoding vectors were made using Gag from NL4.3, 92BR, 
MVP5180, and NL4.3(Ba-L). Threefold serial dilutions were titrated onto Agm CV1 (A to D) and 
Rhesus FRhK4 (E to H) cells. The cells were unmodified and untreated as a control (•), stably 
expressed shRNA to CypA (CypAKD) (A) ,  or were treated with 5 pM CSA (•). NL4.3 GFP was 
also titrated onto Agm CV1 cells (/) or Rhesus FrhK4 cells (J) stably expressing shRNA to CypA 
in the presence ( A)  or absence ( A)  of 5 pM CSA. Virus input doses were measured in 
nanograms of reverse transcriptase as measured by ELISA. Results are representative of two 
independent experiments performed with two independent preparations of virus. (K) Western blot 
of extracts of CV1 and FRhK4 cells expressing reduced levels of CypA. Extracts probed for 
cyclophilin A from wild-type cells (wt) and cells expressing shRNA to CypA (KD) are shown, a- 
actin blots are shown as a control for equal loading.
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3.2.3 TRIM5a is required for anti-HIV-1 activity of CypA in simian cells
We next examined the role of TRIM5a involvement in the effect of cyclophilin A on 
HIV-1 infection in simian cells. We stably downregulated TRIM5a expression in 
macaque FRhK and Agm CV1 cells using TRIM5-specific shRNA cloned into a 
lentiviral vector. These cells (FRhK-T5KD and CV1-T5KD) were then subjected to 
infection by NL4.3, Ba-L, 92BR and MVP HIV-1 vectors encoding GFP in the presence 
or absence of 5pM CSA.
Although previous results showed that CSA increased the titre of the virus around 10- 
fold on wild type cells, this effect was not seen when the levels of TRIM5a were reduced 
(Figure 3.9). HIV-1 infectivity on unmodified cells was included as a control. Infectivity 
of all four viral vectors was enhanced on Agm and Rhesus macaque cells by reduction of 
TRIM5a expression. NL4.3, Ba-L and 92BR were enhanced by around 10-fold on both 
CV1-T5KD and FRhK-T5KD (Figure 3.9 A-C, E-G), while infectivity of MVP was 
enhanced by 10-fold on Agm T5KD cells (Figure 3.9 D), but not significantly on Rhesus 
T5KD cells (Figure 3.9 H). Importantly, inhibition of CypA with CSA had no significant 
effect in the absence of TRIM5a expression (Figure 3.9 A-G), with the possible 
exception of MVP on Rhesus macaque cells (Figure 3.9 H). These data indicate that, in 
most cases, the negative effect of CypA on HIV-1 infectivity is dependent on TRIM5a 
expression, and suggest the cooperation between CypA and TRIM5a in HIV-1 
restriction. Insensitivity of virus to CypA activity, as is the case with NL4.3 (Ba-L), does 
not necessarily indicate insensitivity to TRIM5a (Figure 3.9 B, F). Thus, wild-type HIV- 
1 is maximally sensitive to TRIM5a in the presence of active CypA, while an HIV-1 
mutant is sensitive to TRIM5a regardless of CypA activity [NL4.3(Ba-L)]. We tested, 
functionally, the efficiency of TRIM5a reduction in the cell lines knocked-down for 
TRIM5a (Figure 3.10). In Agm T5KD cells, infectivity of HIV-1 is increased around 10- 
fold (Figure 3.9), and the titre of Agm TRIM5a-sensitive N-MLV becomes equal to that 
of B-MLV, which is TRIM5a-insensitive (Figure 3.10 B). In Rhesus macaque cells, a 
significant reduction in TRIM5a expression is indicated by a 10-fold increase in HIV-1 
infectivity (Figure 3.9). N-MLV infectivity is also slightly increased to the level of B- 
MLV (Figure 3.10 D), in concordance with previous data showing weak restriction of N- 
MLV, but not B-MLV, by Rhesus macaque TRIM5a (Hatziioannou et al., 2004b). Wild- 
type, untreated, Agm and Rhesus macaque cells infected with N-MLV and B-MLV are 
shown as a control (Figure 3.10 A, C).
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Figure 3.9. Reduction of TRIM5a protein levels renders HIV-1 infectivity insensitive to 
cyclosporine A in cells from Old World monkeys. HIV-1 GFP-encoding vectors were made 
using Gag from NL4.3, 92BR, MVP5180, or NL4.3(Ba-L). Threefold serial dilutions were titrated 
onto Agm CV1 cells (A to D) and Rhesus FRhK4 cells (E to H). The cells were unmodified and 
untreated as a control (•), stably expressed shRNA to TRIM5 (T5KD, A),  or stably expressed 
shRNA to TRIM5 and treated with 5 pM CSA (■). Input doses are measured in nanograms of 
reverse transcriptase as measured by ELISA. Results are representative of two independent 
experiments performed with two independent preparations of virus.
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Figure 3.10. Reduction of TRIM5a protein levels renders N-MLV and B-MLV infectivity 
equal in simian cells. To control for the reduction of TRIM5a expression, we show that N-MLV 
(•) and B-MLV (•) GFP-encoding vectors have similar titres on Agm CV1 (B) or FRhK4 Rhesus 
(D) cells expressing reduced levels of TRIM5a (T5KD). N-MLV and B-MLV infectivities on 
untreated cells are shown as control Agm (A) and Rhesus (C). MLV input doses are shown as 
CRFK infectious units per millilitre. Results are representative of two independent experiments 
performed with two independent preparations of virus.
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3.2.4 Expression of simian TRIM5a enables permissive feline CRFK cells to 
restrict HIV-1 in a cyclosporine-sensitive way
We tested whether expression of simian TRIM5a in non-simian cells enables them to 
restrict HIV-1 in a cyclosporine A-sensitive way. We stably expressed Rhesus macaque 
and African green monkey TRIM5a in feline CRFK cells. As mentioned previously, 
CRFK cells have a non-restrictive phenotype. Wild-type and transduced CRFK cells 
expressing Rhesus macaque and Agm TRIM5a were infected with NL4.3 HIV-1 in the 
presence or absence of 5 pM CSA (Figure 3.11). The infectivity of HIV-1 was enhanced 
by around 8-fold on CRFK cells expressing Rhesus macaque TRIM5a (Figure 3.11 B) 
and about 3-fold on CRFK cells expressing Agm TRIM5a (Figure 3.11 A). Wild type, 
unmodified, CRFK cells were insensitive to CSA treatment (Figure 3.11 C). These 
results confirmed that expression of Rhesus macaque and Agm TRIM5a molecules 
renders CRFK cells able to restrict HIV-1 in a cyclosporine A-sensitive way. The fact 
that the restoration of HIV-1 infectivity by CSA is less effective in the feline cells over­
expressing TRIM5a (Figure 3.11) than in cells expressing endogenous levels of TRIM5a 
(Figure 3.8) might be explained by higher protein levels in the feline cells. To further test 
whether higher CSA concentrations are needed to rescue HIV-1 infectivity on these cells 
further, we measured infectivity of a fixed dose of HIV-1 in the presence of 0, 2, 4, 6, 8, 
10 pM CSA (Figure 3.11 D). These data showed that 8 pM CSA is optimal in feline 
cells over-expressing Rhesus macaque TRIM5a, while the titre of HIV-1 gradually 
increases in CRFK cells expressing Agm TRIM5a in the presence of CSA at a 
concentration as high as 10 pM. As a further control we showed that Agm TRIM5a- 
sensitive SIVmac infectivity was not rescued in CRFK cells expressing Agm TRIM5a by 
CSA treatment (Figure 3.11 D). HIV-1 infection on untreated CRFK cells, and SIVmac 
infection on Rhesus cells, are shown as a control (Figure 3.11 D).
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Figure 3.11. Expression of simian TRIM5a enables permissive feline CRFK cells to restrict 
HIV-1 in a cyclosporine-sensitive way. Serial dilutions of NL4.3 HIV-1 encoding GFP were 
titrated onto feline CRFK cells expressing Agm TRIM5a (A), Rhesus TRIM5a (B), or unmodified 
CRFK cells as a control (C) in the presence of 5 pM CSA (•) or left untreated as a control (•). 
Viral dose was measured by reverse transcriptase ELISA assay. (D) A fixed dose of HIV-1 (red) 
and SIVmac (yellow), chosen to infect around 1% of the target cells, was used to infect unmodified 
CRFK cells (square), CRFK cells expressing Agm TRIM5a (triangles), or Rhesus TRIM5a 
(circles) in the presence of a serial dilution of CSA from 0 to 10 pM. The fold increase in 
infectivity after CSA treatment was measured and is plotted. Results are representative of two 
independent experiments performed with two independent virus preparations.
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3.2.5 Cyclophilin A is not required for restriction of MLV or SIVmac by 
TRIM5a
The next stage was to examine if cyclophilin A activity is required for TRIM5a-mediated 
restriction of retroviruses other than HIV-1. Therefore, wild type Agm CV1 cells, or 
CV1 cells where cyclophilin A activity was abrogated either by CSA treatment or by 
stable dowregulation of CypA, were infected with titrations of TRIM5a-sensitive N- 
MLV and SIVmac viral vectors (Figure 3.12 A, C). Unrestricted B-MLV was included as 
a control (Figure 3.12 B). The results indicate that the titre of these viruses was not 
significantly influenced by the absence of cyclophilin A activity. There are small 
increases in N-MLV titre in the absence of CypA activity, but this virus is still strongly 
restricted (Figure 3.12 A). The data demonstrated that cyclophilin A is not important for 
TRIM5a-mediated restriction of N-MLV and SIVmac. The fact that CypA is important 
only in the context of HIV-1 suggests that CypA has a direct effect on HIV-1, rather than 
on TRIM5a.
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Figure 3.12. Cyclophilin A is not required fo r restriction of MLV or SIVmac by TRIM5a.
Threefold serial dilutions of N-MLV (A), B-MLV (B) and SIVmac (C) encoding GFP were titrated 
onto Agm CV1 cells (•), Agm CV1 cells in the presence of 5 pM CSA (•), or Agm CV1 cells 
expressing shRNA to CypA (CypAKD, A).  MLV input doses are shown as CRFK infectious units 
per millilitre and SIVmac input doses are shown as nanograms of reverse transcriptase as 
measured by ELISA. Results are representative of two independent experiments performed with 
two independent preparations of virus.
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3.2.6 TRIM5a restricts HIV-1 independently of CypA binding to HIV-1 CA
The cyclophilin A domain of TRIMCyp serves to recruit this potent restriction factor to 
the HIV-1 capsid. In the presence of cyclosporine A, or when the cyclophilin A binding 
loop of the HIV-1 capsid is mutated, TRIMCyp is unable to recognise the HIV-1 capsid, 
and thus loses its ability to restrict infection of this virus. The ability of TRIMCyp to 
restrict HIV-1 completely depends on the ability of the virus to bind cyclophilin A 
(Nisole et a l , 2004; Sayah et a l, 2004b). In order to examine if CypA recruits TRIM5a 
to HIV-1 in Agm and Rhesus macaque cells, we examined the infectivity of HIV-1 
mutants (CA G89V), which are unable to bind cyclophilin A in these cells.
NL4.3 G89V, 92BR G89V and MVP G89V mutant viruses were titrated onto 
unmodified Agm CV1 and Rhesus macaque FRhK cells, and on cells where endogenous 
level of TRIM5a was stably downregulated by TRIM5-directed shRNA (Figure 3.13). 
The results showed that despite being unable to interact with CypA, all G89V HIV-1 
mutants are still sensitive to TRIM5a (between 3- to 10-fold titre reduction) on Agm and 
Rhesus macaque cells (Figure 3.13). To confirm that the G89V mutants are insensitive to 
cyclophilin A, we compared their titre on unmodified CV1 and FRhK cells, and on cells 
where cyclophilin A activity was abrogated by CypA down-regulation, or by CSA 
treatment. As shown in Figure 3.13, none of these mutants was sensitive to CSA 
treatment or to reduction of CypA expression on either Agm (Figure 3.13 A-C) or 
Rhesus macaque (Figure 3.13 D-F) cells. To further test the sensitivity of G89V mutants 
to restriction by TRIM5a, we titrated NL4.3, 92BR, MVP, and their G89V counterparts, 
on permissive CRFK cells, or CRFK cells expressing Agm TRIM5a, Rhesus TRIM5a or 
owl monkey TRIMCyp. Both wild-type and G89V mutants are strongly restricted 
(between 1 and 2 logs) by Agm and Rhesus macaque TRIM5a proteins (Figure 3.14). As 
previously reported, wild-type HIV-1 viruses, but not their G89V mutants, are restricted 
by TRIMCyp (Towers et al., 2003; Nisole et al., 2004; Sayah et a l, 2004b). This is 
demonstrated by the fact that HIV-1 G89V titres are similar in cells expressing 
TRIMCyp and in unmodified permissive CRFK cells (Figure 3.14 D-F). These data 
demonstrate a clear difference in the role of CypA in restriction by TRIM5a and 
TRIMCyp. Whilst cyclophilin A is required for maximal restriction of HIV-1 by 
TRIM5a, TRIM5a contrasts TRIMCyp by being capable of restricting HIV-1 mutants in 
the absence of cyclophilin A activity.
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Figure 3.13. TRIM5a restricts HIV-1 independently of CypA binding to HIV-1 CA. HIV-1 
NL4.3 G89V, 92BRG89V or MVP G89V were titrated onto Agm CV1 cells (A to C) and Rhesus 
FRhK4 (D to F) cells that were either untreated (•), treated with 5pM CSA (•), expressing 
reduced levels of TRIM5a protein (A),  or expressing reduced levels of CypA protein (A) .  Virus 
input doses are measured in nanograms of reverse transcriptase, as measured by ELISA. 
Results are representative of two independent experiments performed with two independent 
preparations of virus.
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Figure 3.14. TRIM5a-mediated restriction of wild-type and CA G89V HIV-1 in feline CRFK 
cells. Wild-type HIV-1 NL4.3, 92BR or MVP5180 {A to C) and their mutant CA G89V 
counterparts (D to F) were titrated onto unmodified CRFK cells (•), or CRFK cells stably 
expressing Rhesus TRIM5a (•), Agm TRIM5a (A) ,  or owl monkey TRIMCyp (A).  Virus input 
doses are measured in nanograms of reverse transcriptase, as measured by ELISA. Results are 
representative of two independent experiments performed with two independent preparations of 
virus.
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3.2.7 Cyclosporine A reduces HIV-1 infectivity in human cells 
independently of TRIM5a
Contrary to the situation in simian cells, in human cells cyclophilin A is required for 
maximal efficiency of a poorly-defined, post-entry, capsid-dependent step of HIV-1 
infection. Inhibition of CA-CypA interactions with cyclosporine A, or by capsid 
mutation, was shown to render HIV-1 replication less efficient in these cells (Franke et 
al., 1994; Thali et al., 1994; Braaten et a l , 1996a, b, c; Dorfman and Gottlinger, 1996; 
Franke and Luban, 1996; Braaten and Luban, 2001).
We therefore wanted to examine the role of TRIM5a in the negative effect of CSA on 
HIV-1 replication in human cells. We titrated HIV-1 on unmodified TE671 cells and on 
TE671 cells where expression level of TRIM5a was stably downregulated by shRNA, in 
the presence or absence of 2.5 pM CSA (Figure 3.15). The results showed that reducing 
TRIM5a expression had no effect on the decrease of HIV-1 infectivity by CSA (Figure 
3.15 D). Furthermore, TRIM5a has a little effect on HIV-1 replication in human cells 
(compare Figure 3.1 A and D), consistent with previous reports that HIV-1 is largely 
insensitive to restriction by human TRIM5a (Hatziioannou et al., 2003; Stremlau et al., 
2004). We next tested the effect of reducing endogenous TRIM5a levels on the 
infectivity of the HIV-1 G89V mutant. The titre of this mutant has been shown to be 
reduced compared to wild type virus in human cells (see chapter 1.3.4.4). Reduction of 
TRIM5a levels in human cells had no effect on the infectivity of this mutant virus 
(Figure 3.15 E). The effectiveness of TRIM5a down-regulation in human cells was 
confirmed by demonstrating equal infectivity of TRIM5a-sensitive N-MLV, and 
TRIM5a-insensitive B-MLV, on TE671 cells with reduced levels of TRIM5, as 
compared to unmodified TE671 cells (Figure 3.15 C, F). Together, these results show 
that HIV-1 is not sensitive to restriction by TRIM5a, and that the ability of CSA to 
reduce HIV-1 infectivity in human cells is independent of TRIM5a.
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Figure 3.15. Cyclosporine A or the G89V mutation reduces HIV-1 infectivity in human cells 
independently of TRIM5a. Threefold serial dilutions of wild-type HIV-1 NL4.3 (A and D) or HIV-1 
CA G89V (B and E) were titrated onto TE671 cells stably expressing TRIM5 shRNA (T5KD, D 
and E) or on to unmodified cells as a control (A and B) in the presence (A ) or absence (•) of 2.5 
pM CSA. Threefold serial dilutions of N-MLV (A ) or B-MLV (•) were titrated onto TE671 cells 
expressing TRIM5 shRNA (F) or unmodified TE671 cells (C). HIV-1 input doses are measured in 
picograms of reverse transcriptase, as determined by ELISA. MLV input doses are shown as 
CRFK infectious units per millilitre. Results are representative of two independent experiments 
performed with two independent preparations of virus.
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3.2.8 Discussion
We identified cyclophilin A as a host cell factor that is able to effect TRIM5a antiviral 
activity. We showed that the prolyl isomerase enzyme CypA has a negative effect on 
HIV-1 replication in Old World Monkey cells. Down-regulation of endogenous CypA 
levels or abrogation of CypA activity with cyclosporine A, significantly increased the 
efficiency of HIV-1 infection (Figure 3.8). Although working with cyclosporine A is 
easy, and time saving compared to the preparation of stable cyclophilin A knock-down 
cell lines, it also inhibits the enzymatic activity of immunophilins additional to 
cyclophilin A. On the other hand, the abundance of cyclophilin A within cells makes it 
difficult to achieve a complete knock-down of its expression. Therefore, we decided to 
use both approaches. We showed that the inhibitory effect of CypA on retroviral 
infection is dependent on TRIM5a. Infection of cells, where endogenous TRIM5a had 
been depleted, with HIV-1 was not affected by abrogation of CypA activity (Figure 3.9). 
Furthermore, expression of Agm or Rhesus macaque TRIM5a in permissive feline cells 
renders them able to restrict HIV-1, and this antiviral effect is partially relieved by 
treatment with CSA (Figure 3.11). The partial rescue of HIV-1 infection by CSA in 
feline cells, compared to almost complete rescue in simian cells, might be explained by 
high levels of exogenously expressed TRIM5a in feline cells. Indeed, high expression 
levels of restriction factors has been shown to broaden antiviral specificity (Bock et a l , 
2000; Ylinen et a l, 2005; Passerini et a l,  2006) and may broaden the antiviral specificity 
of simian TRIM5a to HIV-1 CA in the absence of CypA. Regardless of expression 
levels, our data clearly indicate that maximal restriction of wild-type HIV-1 by Agm or 
Rhesus macaque TRIM5a depends on CypA. Furthermore, this dependence on CypA is 
only seen for TRIM5a-mediated restriction of HIV-1. This is consistent with the 
observation that, among the viruses tested in these experiments, HIV-1 is the only 
retrovirus known to package CypA into virions during viral assembly and to have an 
exposed proline residue on its CA subject to CypA-mediated peptidyl prolyl 
isomerisation (Braaten et a l, 1996b; Bosco et a l,  2002). Inactivation of CypA activity 
had no effect on the MLV or SIVmac replication (Figure 3.12), and this not only supports 
the unique role of CypA in TRIM5a-mediated restriction of HIV-1, but also suggests that 
CypA acts on HIV-1 CA rather than on TRIM5a. Consistent with this notion is the 
inability to detect the direct interaction of CypA and TRIM5a by using either the yeast 
two-hybrid system, coimmunoprecipitation or fluorescence microscopy (Kumaran, N., 
unpublished data and Berthoux et a l,  2005b). We next investigated whether the sole
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function of CypA in TRIM5a's antiviral activity is to bridge the restriction factor and 
viral capsid. This was shown to be the case for TRIMCyp where the cyclophilin A 
moiety of this potent restriction factor recruits the remaining RBCC motif to the virus. 
This leads to absolute sensitivity of restriction to either drugs or HIV-1 CA mutations 
that prevent CypA-CA interactions. However, as shown in Figure 3.13, this is not true 
for the mechanism of action of TRIM5a. Both, Agm and Rhesus macaque TRIM5a, 
whether expressed endogenously in simian cells (Figure 3.13) or exogenously in feline 
cells (Figure 3.14), are still able to significantly restrict the infection of the HIV-1 G89V 
CA mutant, which is unable to bind cyclophilin A. We therefore propose that it is not the 
recruitment of TRIM5a to the viral capsid via cyclophilin A that is responsible for 
restriction, but rather CypA-mediated isomerisation of a proline residue in the TRIM5a 
sensitivity-determinant of the HIV-1 capsid that sensitises it to restriction by Old World 
monkey TRIM5a (Figure 3.16). We propose that an interaction between CypA and 
incoming HIV-1 core, and subsequent prolyl isomerisation, leads to an alteration in the 
conformation of the capsid target for simian TRIM5a and that this leads to altered 
sensitivity to restriction.
Figure 3.16. Two models o f involvem ent o f CypA in restriction. (A) binding of cyclophilin A 
(blue) to HIV-1 capsid (grey) recruits restriction factor TRIM5a (red). (B) cyclophilin A isomerises 
residues in HIV-1 capsid what renders HIV-1 capsid more susceptible to TRIM5a.
This model is supported by data which showed that the part of the SIVmac CA, which 
corresponds to the cyclophilin A binding loop of HIV-1, contains the TRIM5a 
sensitivity-determinant, and mutations in this part of protein render SIVmac insensitive to 
restriction by squirrel monkey and Rhesus macaque TRIM5a (Ylinen et al., 2005). These
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results suggest a role for this exposed part of the capsid in TRIM5a sensitivity, where an 
altered CA conformation might reasonably influence TRIM5a binding either directly or 
indirectly and subsequent restriction of infectivity. The possibility that CypA alters the 
HIV-1 CA’s sensitivity to TRIM5a by P90 isomerisation is also supported by the 
observation that altering residues close to the CypA binding site in NL4.3(Ba-L) renders 
TRIM5a restriction of this virus independent of CypA activity, although the NL4.3(Ba- 
L) CA has been shown to bind CypA (Kootstra et al., 2003; Chatterji et al., 2005). These 
changes could either prevent CypA from isomerising P90, or the TRIM5a binding site 
could assume a conformation in which the isomerisation status of P90 does not impact on 
TRIM5a binding and restriction. Because the CypA binding virus NL4.3(Ba-L) is 
restricted in a CypA-independent way we discount a model in which the CypA-HIV-1 
CA complex is a better target for TRIM5a restriction than HIV-1 CA alone. In the 
absence of CypA, Pro90 adopts kinetically trapped cis and trans conformations with 
nearly 8 6 % of the HIV-1 CA Gly89-Pro90 covalent bonds in the trans conformation 
(Bosco et al., 2002). Cyclophilin A catalyses the rapid isomerisation between these two 
states with the overall percentage of either isoform remaining unchanged. If TRIM5a 
recognises the cis-isomer more efficiently, then in the presence of CypA the 14% of the 
cis isoform would be renewed as it is taken out of the pool by binding to TRIM5a. It is, 
however, possible that CypA binding has some other effect on the HIV-1 capsid, but we 
believe a change in conformation due to peptidyl prolyl isomerase activity is the most 
likely explanation. In this way CypA would improve binding between TRIM5a and HIV- 
1 capsid thus enhancing the restriction of infection. Such a model is supported by studies 
considering a role for CypA in controlling protein-protein interactions in the case of the 
Itk tyrosine kinase. CypA has been shown to bind and negatively regulate protein-protein 
interactions of Itk and its signalling partners resulting in down-regulation of signalling, 
after TCR stimulation (Brazin et al., 2002; Mallis et a l, 2002; Colgan et al., 2004). 
Similarly, Pinl, a parvulin peptidyl-prolyl isomerase, was also shown to bind to and, by 
using its enzymatic activity, to alter the conformation of phosphoproteins involved in 
cell-cycle regulation. This leads to altered protein function and/or stability (reviewed in 
Yeh and Means, 2007).
Recent studies by Berthoux et al., 2005b and Stremlau et al., 2006b have also described 
an involvement of CypA in TRIM5a restriction of HIV-1. Although our data is 
consistent with the data of Stremlau et al. and also mostly support the work of Berthoux 
et al., the difference with the latter work is that Berthoux et al. have proposed that the 
HIV-1 mutant CA G89V, which is unable to recruit CypA, is unrestricted in Agm and
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Rhesus cells. Therefore, this study cannot differentiate between a model in which CypA 
recruits TRIM5a to the HIV-1 CA, as it does for TRIMCyp, and the model we propose in 
which CypA alters the conformation of the TRIM5a sensitivity-determinant and 
sensitivity to restriction. The difference in TRIM5a sensitivity of HIV-1 G89V between 
Berthoux's work on one side, and ours and Stremlau's on other side, remains 
unexplained.
In humans, the effect of cyclophilin A on HIV-1 infection is opposite to that seen in 
simian cells; abrogation of CypA activity renders HIV-1 less infectious. We, and others, 
have shown that this effect cannot be explained by alteration of TRIM5a activity and is 
thus TRIM5a-independent (Keckesova et a l , 2006; Sokolskaja et al., 2006a; Stremlau et 
a l , 2006b). CSA treatment of human cells, where TRIM5a expression levels were stably 
or transiently downregulated by siRNA, had the same inhibitory effect on HIV-1 
infection as in the wild type human cells (Figure 3.15). It was previously shown that 
CSA treatment enables wild-type HIV-1 to saturate restriction of N-MLV by TRIM5a in 
human cells (Towers et a l , 2003). This suggests that TRIM5a might be saturated by 
CSA-treated HIV-1, or it could also indicate saturation of a TRIM5a cofactor. The latter 
hypothesis is also supported by the isolation of a clone of human TE671 cells (17H1) that 
was selected for loss of N-MLV restriction. This clone was found to be permissive for 
HIV-1 in a CypA independent manner and the expression level of TRIM5a appears to be 
unchanged as compared to the wild type cells (Sayah et a l , 2004a, Luban, 2007). The 
existence of further CypA-sensitive antiviral factors might be supported by the 
observation that certain HIV-1 mutants, like HIV-1 CA A92E or G94D, appear to be 
restricted in a TRIM5a-independent way, in certain human cell lines (Sokolskaja et a l, 
2004; Hatziioannou et a l, 2005). Interestingly, abrogation of CypA function increases 
their titre, as is the case with wild-type HIV-1 in simian cells, and infectivity of these 
mutant viruses is not rescued by high doses of mutant VLP (Sokolskaja et a l, 2004).
The notion of an involvement of immunophilins and/or peptidyl prolyl isomerisation in 
the modulation of protein interaction and in innate immunity is supported by numerous 
studies. The first hint of a role for CypA in immune function is supported by the use of 
CSA as a potent immunosuppressive agent. Immunosuppression results from the 
inhibition of calcineurin caused by the interaction between calcineurin and the CypA- 
CSA binary complex. Calcineurin inhibition prevents dephosphorylation of the 
transcription factor, nuclear factor of activated T-cells (NFAT), and its translocation to 
the nucleus, resulting in the inhibition of transcription of IL-2, IFN-y, and other genes 
involved in T-cell activation. This was shown to occur only in the presence of CSA;
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CypA on its own is not thought to regulate calcineurin. Interestingly, calcineurin is also 
inhibited by a complex between another immunophilin, FK506 binding protein 
(FKBP12), and the immunosuppressant FK506 (Liu et al., 1991). The role of the FK506- 
binding proteins in TRIM5a-mediated HIV-1 restriction was also tested. Treatment of 
cells with FK506 or rapamycin, which are inhibitors of FK506-binding proteins, or 
downregulating the expression of several members of FK506 binding protein family by 
siRNA did not modulate HIV-1 infectivity (Stremlau et a l,  2006b; Keckesova, Z. data 
not shown). Thus, it seems that neither FK506-binding proteins nor calcineurin play a 
role in HIV-1 permissivity or in the TRIM5a restriction pathway.
Retroviruses are not the only viruses influenced by cyclophilin activity. Recent work 
showed that hepatitis C virus (HCV) is dependent on CypB activity for replication in 
human cells (Watashi et al., 2005). Cyclophilin B was shown to directly interact with the 
HCV RNA-dependent RNA polymerase leading to a stimulated RNA binding and more 
efficient viral genome replication. Vaccinia virus also appears to depend on 
immunophilin activity for replication, where as much as 97% of virus yield is inhibited in 
the presence of CSA, although the mechanism of this antiviral effect remains unclear 
(Damaso and Moussatche, 1998). CypA is also found associated with vesicular stomatitis 
virus where it is thought to act as a chaperone for the extremely hydrophobic 
nucleocapsid protein (Cantin et al., 2005). Apart from animals, an innate immune role for 
cyclophilins has also been found in plants. Arabidopsis cyclophilin indirectly activates 
specific innate immune resistance factor RPS2 by isomerising prolines on an incoming 
Pseudomonas protease AvrRpt2, thus causing its activation and leading to the 
elimination of RIN4; a negative regulator of RPS2 (Coaker et al., 2005). This model is 
similar to that proposed here, in which CypA sensitis es HIV-1 to Old World monkey 
TRIM5a by isomerising proline residues on the incoming HIV-1 capsid. HIV-l's 
dependence on CypA activity in human cells might not contradict an innate immune role 
for cyclophilins. If cyclophilins contribute to innate immune function by isomerising 
prolines on incoming viral proteins, then in order to replicate in human cells HIV-1 may 
have evolved to tolerate CypA activity. This could lead to dependence on CypA if the 
prolines targeted are functionally important for viral replication. We note that a proline 
rich loop is found on the outer surface of all primate lentiviral capsids and this 
conservation supports an important role of this sequence in lentiviral replication.
The precise function of cyclophilins in cell biology remains unclear. A nonessential role, 
at least under laboratory growth conditions, is indicated by the fact that yeast knocked 
out for all eight cyclophilin genes remain viable (Dolinski et al., 1997). On the other
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hand, studies of CypA knockout mice clearly established its role in vivo. The CypA 
knock-out mice are viable but spontaneously develop an allergic disease reminiscent of 
interleukin-4 over-expression. A search for the mechanism led to the discovery that the 
PPIase active site of CypA binds and inactivates interleukin-2 tyrosine kinase thus 
suppressing the T helper 2 immune response (Colgan et al., 2004). CypA was also shown 
to regulate the subcellular distribution of zinc-finger protein Zprl in Saccharomyces 
cerevisiae (Ansari et al., 2002). Thus, it was hypothesised that CypA might also regulate 
TRIM5a localisation. However, the subcellular distribution of TRIM5a, as well as the 
formation of cytoplasmic bodies, was not altered by disruption of expression of CypA 
(Berthoux, L., unpublished data). Early studies indicated that HIV-1 and the closely 
related SIVcpz from chimpanzees are the only retroviruses whose capsid protein binds 
CypA, and are dependent upon CypA for replication (Braaten et al., 1996c). However, 
even within HIV-1, naturally occurring HIV-1 variants exist that do not depend on CypA 
for optimal infection of human cells (Braaten et al., 1996c, Wiegers and Krausslich, 
2002; Ikeda et al., 2004; Chatterji et al., 2005). Two additional lentiviruses have recently 
been shown to bind CypA and to be restricted by the TRIMCyp fusion protein, SIVAgm 
from Cercopithecus tantalus and feline immunodeficiency virus (FIV) (Diaz-Griffero et 
al., 2006b; Lin and Emerman, 2006; Zhang et al., 2006). Moreover, the spreading 
infection of FIV is decreased by CSA in feline and human cells (Mortola et al., 1998; Lin 
and Emerman, 2006). It will be interesting to test if  CypA impacts on SIVAgm or FIV 
replication in cells expressing unfused TRIM5a and if  the effects of CSA depend on the 
presence of TRIM5a or related molecules. All these examples of cyclophilin activity 
suggest an important role for peptidyl prolyl isomerisation in immunity, and the further 
study of immunophilins may reveal important details of interactions between hosts and 
their pathogens.
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3.3 Results 3
3.3.1 Introduction
Arsenic trioxide (AS2 O3 ) is commonly used to treat patients with acute promyelocytic 
leukaemia (APL). This disease is caused by an oncogenic promyelocytic leukaemia 
protein (PML)-retinoic acid receptor alpha (RARa) fusion protein resulting from 
chromosomal translocation. The fusion protein interferes with functions of both RARa 
and PML (de The et al., 1991) and functions as a strong repressor of genes involved in 
myeloid differentiation, thus giving rise to promyelocytic leukaemia. Arsenic treatment 
has been shown to cause the degradation of the PML-RARa and wild type PML proteins 
(Lallemand-Breitenbach et al., 2001) and to trigger cell death by apoptosis of APL cells. 
These events most likely contribute to the therapeutic effects of this drug (reviewed in 
Zhu et al., 2002). Promyelocytic leukaemia protein (PML) belongs to the TRIM family 
of proteins and is required for the formation of discrete nuclear subdomains, known as 
PML nuclear bodies (Dyck et al., 1994). Because of the common disruption of these 
bodies by infection with DNA viruses, one of the roles of these multiprotein complexes 
has been proposed to be antiviral (see chapter 1.3.4.1; Ahn et al., 1998; Chee et al., 2003; 
Rosa-Calatrava et al., 2003). The biochemical pathways involved in the effect of arsenic 
on PML degradation have been partly unravelled. AS2 O3 treatment induces 
phosphorylation of PML through a mitogen-activated protein (MAP) kinase pathway, 
followed by increased PML sumoylation and translocation of PML to the nuclear matrix 
where it is subsequently degraded within the nuclear PML bodies (Zhu et al., 1997; 
Lallemand-Breitenbach et al., 2001; Hayakawa and Privalsky, 2004).
Some recent studies have focused on the effect of AS2 O3 and PML on retroviral infection. 
Turelli et al., (2001) reported that AS2 O3 treatment of human cells enhanced HIV-1 
infection in a PML-dependent way. In their study, HIV-1 infection caused a 
relocalisation of PML to the cytoplasm. They suggested that the addition of AS2 O3 might 
promote infection by sequestering PML in the nucleus, thus antagonising an HIV-1- 
antiviral activity associated with PML. They also found that the drug had no effect when 
added twelve hours post infection, suggesting that arsenic increases efficiency of an early 
post-entry step in the viral life cycle. Although subsequent studies confirmed the positive 
effect of AS2 O3 on HIV-1 infection they failed to confirm the role of PML in this effect 
(Bell et al., 2001; Berthoux et al., 2003). Berthoux et al., (2003) extended these
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observations by showing that arsenic trioxide also partially rescued N-MLV infection in 
human TE671 cells, thus counteracting Refl restriction.
Because Refl was shown to be encoded by TRIM5a, and both TRIM5a and PML are 
members of the tripartite motif containing family of proteins involved in cellular antiviral 
processes, it seems likely that the reported AS2 O3 effect in human cells might be 
explained by the effect of AS2 O3 on endogenous human TRIM5a. It is possible that the 
effects of AS2 O3 on these two proteins might also share some biochemical similarities. 
We therefore set up a series of experiments that would enable us to evaluate the role of 
TRIM5a in the arsenic-mediated effects on retroviral replication. Firstly, we needed to 
know if the stimulatory effect of arsenic trioxide is specific for N-MLV or if arsenic also 
affects the replication of another TRIM5a-restricted virus, equine infectious anaemia 
virus (EIAV). By stable downregulation of TRIM5a-expression in human TE671 cells 
we wanted to find out if AS2 O3 acts through the TRIM5a protein or if its enhancing effect 
on retroviral replication is due to interference with other TRIM5a-independent arsenic 
trioxide-influenced pathway. To access the role of degradation, translocation and/or 
sumoylation of TRIM5a in the arsenic trioxide-mediated effect on retroviral infection we 
used biochemistry, microscopy and mutagenesis studies.
3.3.2 Arsenic trioxide counteracts restriction in human but not Agm cells
If the reported stimulatory effect of AS2 O3 on N-MLV infection is due to its effect on 
TRIM5a we would expect the titre of other viruses inhibited by this restriction factor to 
be relieved by treatment with AS2 O3 . In that case we would expect arsenic trioxide to 
rescue restriction of EIAV.
We therefore exposed human TE671 cells to VSV-G pseudotyped N-MLV, B-MLV and 
EIAV in the presence or absence of 4 pM AS2 O3 . This dose of drug was shown to be 
optimal for the human TE671 cell line (Berthoux et al., 2003). AS2 O3 was able to 
specifically rescue infectivity of EIAV GFP and N-MLV GFP by around 10-fold in 
human cells (Figure 3.17). The titre of unrestricted B-MLV remained unchanged (Figure 
3.17). In contrast, treatment of the African green monkey CV1 cell line (Cercopithecus 
aethiops tantalus) with doses of AS2 O3 as high as lOpM did not increase N-MLV titre; it 
even had a slight inhibitory effect (Figure 3.18 A). B-MLV was included as a control 
(Figure 3.18 A). To exclude the possibility that the drug concentration was not high 
enough we infected CV1 cells with a fixed dose (multiplicity of infection of 0.01) of N- 
MLV and B-MLV in the presence of increasing doses of AS2 O3 . The result showed, that
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3.3.3 TRIM5a is required for the stimulatory effect of As2 0 3 on retroviral 
infection
Next we sought to test whether TRIM5a is required for the effect of arsenic trioxide on 
retroviral infectivity.
We therefore generated a TE671 cell line with stably reduced TRIM5 expression. 
Expression levels of TRIM5 were downregulated by stable introduction of a short hairpin 
RNA directed against TRJM5 into TE671 cells as described in Materials and Methods 
and we called these cells TEdT5. We then titrated N-MLV, B-MLV and EIAV vectors 
encoding GFP on TE671 and TEdT5 cells in the presence or absence of 4pM arsenic 
trioxide (Figure 3.19). The titre of N-MLV in TEdT5 cells was enhanced to the level of 
B-MLV, indicating efficient TRJM5 knockdown (compare Figure 3.19 B and D). While 
treatment of wild type TE671 cells with arsenic resulted in a 10-fold increase in N-MLV 
and EIAV infectivity (Figure 3.19 A, C) it had no effect on the titre of these viruses in 
the TRIM5- knockdown TEdT5 cells (Figure 3.19 D, F), thus demonstrating that AS2 O3 
acts on TRIM5a and counteracts its antiviral activity. Unrestricted B-MLV was included 
as a control (Figure 3.19 B, E).
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Figure 3.19. TRIM5a is required fo r the stim ulatory effect of As20 3 on retroviral infection in 
human cells. Human TE671 cells and TE671 cells where TRIM5 expression was downregulated 
(TEdT5) were infected with titrations of N-MLV (A, D), B-MLV (B, E) and EIAV (C, F) virus 
vectors in the presence (A ) or absence (A ) of 4 pM arsenic trioxide. Virus input doses were 
measured in CRFK infectious units. Results are representative of two independent experiments 
performed with two independent preparations of virus.
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3.3.4 Effect of AS2 O3 on retroviral restriction in cat cells expressing human 
and African green monkey TRIM5a proteins
The fact, that AS2 O3 was able to rescue infection in human TE671 cells, but not in Agm 
CV1 cells implied that the drug might suppress the restriction activity of some TRIM5a 
orthologues but not others. In order to find out if this differential effect of AS2 O3 is due to 
differences between the human and Agm TRIM5a alleles, or to differences between the 
human and Agm cells, we compared the effect of arsenic trioxide on the titre of N-MLV 
GFP in cat CRFK cells stably expressing human or Agm TRIM5a genes. Both, human 
and Agm TRIM5a cDNA, were fused to a haemagglutinin (HA) epitope tag at their C- 
terminus. We used infection with unrestricted B-MLV GFP and untransduced cells as 
controls.
Unmodified CRFK cells, and CRFK cells stably expressing human (CRFKhuT5a) or 
Agm (CRFKAgmT5a) TRIM5a genes were infected with N-MLV and B-MLV at a fixed 
multiplicity of infection (MOI of 0.01) in the presence of varying drug concentrations 
(Figure 3.20). In order to achieve similar multiplicity of infection we used more 
restricted N-MLV than unrestricted B-MLV in infectivity assays on restrictive cells. In 
the case of CRFKhuT5a we added 100 times more N-MLV than B-MLV and in the case 
of CRFKAgmT5a we added 20 times more N-MLV than B-MLV. Whilst the titre of N- 
MLV was unaffected by arsenic treatment in TRIM5a negative CRFK cells (Figure 3.20
A), it was enhanced in both, CRFKhuT5a (Figure 3.20 B) and CRFKAgmT5a (Figure 
3.20 C) cell lines in the presence of arsenic. N-MLV titre was increased about 25-fold on 
CRFKhuT5a with the maximal effect at a concentration of 10 pM arsenic (Figure 3.20
B). The decline in titre at the highest concentrations of AS2 O3 is probably due to the 
drug's toxicity as evidenced by extensive cell death.
AS2 O3 also increased the titre of N-MLV on CRFKAgmT5a cells (around 5-fold) but 
only when the higher concentrations of arsenic were applied (20 pM, Figure 3.20 C). 
One of the possible explanations for the requirement of higher doses of arsenic in 
CRFKAgmT5a cells might be the higher level of exogenously expressed Agm TRIM5a 
than human TRIM5a in CRFK cells. To test this we performed a western blot on 
CRFKhuT5a and CRFKAgmT5a cell lines detecting the HA-epitope tag (Figure 3.20 D). 
Unmodified CRFK cells were included as a control for the specificity of the antibody 
against the haemagglutinin tag. Samples were equalized for protein levels using a 
Bradford assay. Even though both TRIM5a proteins are expressed from the same 
expression vector, the expression level of Agm TRIM5a was much higher than that of
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human TRIM5a in 3 independent clones of CRFK cells. This would provide an 
explanation for the difference in arsenic sensitivity between these two cell lines. 
Interestingly, the toxic effects of arsenic trioxide were much less evident in 
CRFKAgmT5a cells than in CRFK cells expressing human TRIM5a. The reason for this 
is unclear but may suggest a protective effect of TRIM5a on the cells.
These results not only support the role of TRIM5a in the arsenic-mediated effect on 
retroviral infection, but also showed that the differential effect of AS2 O3 between TE671 
and CV1 cells and between CV1 and CRFKAgmT5a cells is probably due to the 
intracellular environment and not due to intrinsic differences between the two TRIM5a 
alleles.
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Figure 3.20. Retroviral infection o f feline cells, expressing human and Agm TRIM5a 
proteins, is enhanced by As20 3 trea tm en t Unmodified CRFK (A) cells and CRFK cells stably 
expressing human (8) or Agm (C) TRIM5a protein were infected with N-MLV (•) and B-MLV (•) 
virus vectors at a multiplicity of infection of 0.01 in the presence or absence of increasing 
concentrations of arsehic trioxide (5, 10, 15, 20 pM). The fold increase in MLV infectivity was 
plotted. Results are representative of three independent experiments performed with three 
independent preparations of virus. (D) Western blot of extracts of unmodified CRFK (control) 
cells and CRFK cells stably expressing HA-tagged human (CRFKhu) and Agm (CRFKAgm). 
Samples were equalized by Bradford essay and probed with anti-HA antibody. a-Actin blots are 
shown as a control for equal loading. Three independent clones of CRFKhu and three 
independent clones of CRFKAgm were tested. The results shown in B, C were performed using 
CRFKhu clone 1 and CRFKAgm clone 1.
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3.3.5 Degradation of human and African green monkey TRIM5a after 
arsenic trioxide treatment
The effect of arsenic on TRIM5a activity might be mediated through its deactivation 
either via translocation and/or degradation. Both of these are true for the PML (TRIM 19) 
protein which, upon arsenic treatment, is translocated from the nucleoplasm to the 
nuclear matrix-associated PML bodies and subsequently degraded. To address the role of 
degradation of TRIM5a after arsenic treatment we treated CRFKhuT5a (Figure 3.21 A) 
and CRFKAgmT5a (Figure 3.21 B) cells, where the TRIM5a protein was appended with 
a C-terminal HA epitope, with increasing concentrations of AS2 O3 for 2, 6 , 12, and 24 
hours (Figure 3.21). Cell extracts were equalised for total protein by Bradford essay and 
subjected to western blot for the haemagglutinin tag. As a control for equal loading we 
also detected p-actin. As an additional control, in the case of CRFKhuT5a, we detected 
histone deacetylase-1 (HDAC-1). This protein has expression levels that are more 
comparable to human TRIM5a than those of actin which is a very stable and abundant 
cellular protein.
The results showed that expression levels of both proteins declined in the presence of 8  
and 12 pM arsenic at later time points with the first noticeable difference after 12 hours 
of arsenic exposure. The expression levels of actin and HDAC-1 remained unchanged. 
Because of the low expression levels of human TRIM5a this protein was more sensitive 
to arsenic treatment than Agm TRIM5a, with undetectable levels of expression after 24 
hours of 8  or 12 pM arsenic (Figure 3.21).
In order to further confirm that TRJM5a is degraded after arsenic treatment we pre­
treated CRFK, CRFKhuT5a and CRFKAgmT5a cells with 8  pM AS2 O3 for 0.5, 1, 2, 6 , 
12 and 24 hours and then infected them with N-MLV, B-MLV and HIV-1 viral vectors at 
a multiplicity of infection of 0.01 (Figure 3.22). Unmodified CRFK cells and B-MLV 
vector were included as a control. N-MLV infectivity was enhanced by around 20-fold 
when the CRFKhuT5a cell line was exposed to AS2 O3 for 12 hours (Figure 3.22 B) and 
around 9-fold when the CRFKAgmT5a cell line was subjected to the same conditions 
(Figure 3.22 C). HIV-1 titre increased by around 5-fold on both TRIM5a-expressing cell 
lines after 12 hours of arsenic pre-treatment (Figure 3.22 B, C). B-MLV titre remained 
unchanged in all cell lines and under all conditions tested. Similarly, titres of N-MLV, B- 
MLV or HIV-1 vectors on wild type CRFK cells were unchanged (Figure 3.22 A).
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Figure 3.21. Degradation o f human and African green monkey TRIM5a proteins by arsenic 
trioxide. CRFK cells expressing HA-tagged TRIM5a proteins from human (A) or Agm (B) were 
subjected to 2, 4, 8, or 12 pM As20 3 for 2, 6, 12 and 24 hours. Cell extracts were equalized for 
total protein by Bradford assay and 100ng of protein was loaded. Western blots (WB) were 
probed for HA-tag {A, B), a-actin (A, B) or histone deacetylase-1 (A). Results are representative 
of two independent experiments performed with two independent cell clones.
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Figure 3.22. Pre-treatment of CRFKhuT5a and CRFKAgmT5a cells with arsenic trioxide.
Unmodified CRFK (A) cells or CRFK cells stably expressing human (B) or Agm (C) TRIM5a 
protein were subjected to 8 pM arsenic treatment for 0.5, 1, 2, 6, 12 and 24 hours and then 
infected with N-MLV (•), B-MLV (•) and HIV-1 ( A)  viral vectors at a MOI of 0.01. The fold 
increase in retroviral infectivity was plotted on the y  axis. Results are representative of two 
independent experiments performed with two independent preparations of virus.
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3.3.6 Examination of TRIM5a localisation in the presence of arsenic trioxide
Most of the experiments that showed the stimulatory effect of arsenic trioxide on 
retroviral infection, were performed with the drug added simultaneously with the virus 
(Bethoux et al., 2003; Keckesova et al., 2004; Sebastian et al., 2006) and arsenic was 
shown to exert its effect on viral replication early in the viral life cycle, before reverse 
transcription (Berthoux et al., 2003). Therefore, it seems improbable that the degradation 
of TRIM5a by arsenic would be responsible for arsenic's fast effect on retroviral 
replication. In the case of the PML protein, arsenic was shown to cause its translocation 
prior to degradation (Zhu et al., 1997; Lallemand-Breitenbach et al., 2001). In order to 
determine if arsenic treatment influences the localisation of TRIM5a we investigated the 
subcellular distribution of human and African green monkey TRIM5a proteins stably 
expressed in feline CRFK cells in the presence or absence of arsenic trioxide.
CRFK cells expressing human (CRFKhuT5a) or Agm (CRFKAgmT5a) TRIM5a were 
treated with 8 pM AS2 O3 for 0.5, 1, 2, 6 , 12 and 24 hours (Figure 3.23). Untreated cells 
were used as a control for the normal subcellular distribution of the TRIM5a protein 
(Figure 3.23 A, H) and unmodified CRFK cells were added as a control for the 
specificity of the primary anti-HA and secondary anti-mouse AlexaFluor antibodies used 
in this experiment (Figure 3.23 O). As previously reported, both TRIM5a proteins 
exhibited punctuate "cytoplasmic bodies" as well as a diffuse cytoplasmic distribution 
(Figure 3.23; Reymond et al., 2001). The high expression levels of Agm TRIM5a 
markedly enhanced its diffuse distribution but not the size or number of cytoplasmic 
bodies (Figure 3.23 H). These bodies were more evident in the case of human TRIM5a, 
but this might reflect a dimmer diffuse staining (Figure 3.23 A). A thirty minute 
treatment with arsenic did not have an effect on this distribution (Figure 3.23 B, I). Cells 
treated for 1 or 2  hours with arsenic however, showed an increase in brightness and 
number of cytoplasmic bodies (Figure 3.23 C, D, J, K), especially in the case of Agm 
TRIM5a where less diffuse staining was also observed (Figure 3.23 J, K). A 6  hour 
treatment had the most pronounced effect on TRIM5a localisation with human TRIM5a 
being localised within large, bright structures (Figure 3.23 E). Most cells contained only 
one or two of these bodies. The brightness and size of the Agm TRIM5a bodies also 
increased but not to such an extent as in the case of the human TRIM5a (Figure 3.23 L). 
At 12 and 24 hours of treatment with arsenic trioxide the cytoplasmic aggregates of 
human TRIM5a protein were lost and less diffuse staining was seen (Figure 3.23 F, G). 
After 12 hours of AS2 O3 treatment Agm TRIM5a was still localised in a few cytoplasmic
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bodies but the strong diffuse staining was lost (Figure 3.23 M). At 24 hours the 
cytoplasmic bodies were also lost (Figure 3.23 N) and cell death was evident for both, 
CRFKhuT5a and CRFKAgmT5a, cell lines (Figure 3.23 G, N).
In summary, within the first 2 hours of treatment, AS2 O3 had only subtle effects on the 
subcellular localisation of TRIM5a proteins expressed in cat cells. The most noticeable 
effects in the cytoplasmic distribution were seen at, and after 6  hours of arsenic treatment 
when both human and Agm TRIM5a proteins were localised within large, bright bodies 
which later disappeared. These structures are likely to represent the sites where TRIM5a 
proteins are degraded.
Control 30 minutes 1 hour
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Figure 3.23. TRIM5a localisation in the presence of arsenic 
trioxide. Untransduced CRFK cells (O) and CRFK cells 
expressing HA-tagged human (CRFKhuT5a, A-G) and Agm 
(CRFKAgmT5a, H-N, next page) TRIM5a protein were 
subjected to 8 pM arsenic treatment for 0.5, 1, 2, 6, 12 and 24 
hours, immunolabeled with primary anti-HA and secondary 
Alexa Fluor 488 anti-mouse antibody and analysed by confocal 
microscopy. Results are representative of three independent 
experiments.
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3.3.7 Mutagenesis of putative TRIM5a sumoylation sites
In the case of PML, its degradation by arsenic treatment is preceded by its 
phosphorylation and sumoylation (Lallemand-Breitenbach et al., 2001; Hayakawa and 
Privalsky, 2004). Sumoylation is a post-translational modification. The SUMO (small 
ubiquitin-like modifier) protein is covalently attached to other proteins on lysine 
residues. Sumoylation does not usually trigger degradation but rather modulates protein- 
protein interactions. Sumoylation at single site of the PML protein at K160 is responsible 
for As2 0 3 -induced proteasome recruitment and degradation (Lallemand-Breitenbach et 
a l,  2001). Is it therefore possible that degradation of TRIM5a, and thus its arsenic­
responsiveness, is also mediated via sumoylation?
Sumoylation occurs on a VF-K-X-D/E consensus where ¥  is a hydrophobic residue, K is 
the lysine conjugated to SUMO, X is any amino-acid and D and E are acidic residues. A 
SUMOplot prediction (www.abgent.com/doc/sumoplot) revealed two motifs within 
human and Agm TRIM5a proteins with a high probability of sumoylation. They are the 
lysine at position 10 and two adjacent lysines in positions 263 and 264.
In order to test if these two putative sumoylation sites are involved in the AS2 O3 - 
mediated effect on retroviral replication we mutated lysines within these motifs to 
arginines. HuKlOR and huKK263,264RR TRIM5a proteins were then stably expressed 
in feline CRFK cells and analysed for their ability to restrict N-MLV and for their 
sensitivity to AS2 O3 (Figure 3.24 A, C). B-MLV was included as a control (Figure 3.24 
B, D). Both of the mutant TRIM5a proteins restricted N-MLV with a similar magnitude 
to wild type human TRIM5a, by around two orders of magnitude; compare Figure 3.2 
and Figure 3.24 A, C. In both cases N-MLV infectivity was enhanced by more than 10- 
fold by treatment with 8 pM AS2 O3 (Figure 3.24 A, C). B-MLV infectivity remained 
unchanged in all cases (Figure 3.24 B, D). These results showed that mutating the lysines 
within these putative sumoylation sites had no effect on TRIM5a function or on its 
sensitivity to arsenic trioxide, at least not when these motifs were mutated individually.
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Figure 3.24. Mutagenesis o f putative TRIM5a sum oylation sites does not impact on 
TRIM5a-mediated restriction or sensitiv ity to  As20 3. Unmodified CRFK cells (triangles) and 
CRFK cells stably expressing human TRIM5a (circles) mutated either in K10 (huKIOR, A, B) or in 
KK263.264 (huKK263,264RR, C, D) were infected with titrations of N-MLV (A, C) and B-MLV (B, 
D) virus vectors in the presence (•) or absence (•) of 8 pM arsenic trioxide. Virus input doses 
were measured in CRFK infectious units per milliliter. Results are representative of two 
independent experiments performed with two independent preparations of virus.
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3.3.8 Discussion
In this study, we have examined the effect of arsenic trioxide on TRIM5a-mediated 
retroviral restriction. Arsenicals have accompanied the human population for more than 
two thousand years and have been used either as a medicine for treatment of various 
diseases, or as a poison. Nowadays, many of the arsenic-induced biochemical pathways 
have been partly elucidated. Arsenic was shown to affect numerous cellular signalling 
molecules and transduction pathways and to cause many alterations in cellular 
biochemistry. The action of arsenic may result in activation of differentiation, 
senescence, cell growth arrest and apoptosis (Kaltreider et al., 2001; Halicka et a l , 2002; 
Chelbi-alix et al., 2003). Apoptosis is triggered by arsenic through inhibiting anti- 
apoptotic molecules (NFkB, Bcl-2), stimulating apoptotic ones (caspases, p53) and 
affecting oxidative stress pathways and mitochondrial pore permissivity (reviewed in 
Miller, 2002a; Miller et al., 2002b). AS2 O3 has 87% efficacy in the treatment of acute 
promyelocytic leukaemia (APL), where it induces partial differentiation and promotes 
apoptosis of malignant promyelocytes, through the inactivation and degradation of the 
oncogenic PML-RARa fusion protein (Chen et al., 1996; Shao et al., 1998).
Recently, another effect of arsenic was described by Turelli et al., (2001), where AS2 O3 
was reported to enhance HIV-1 replication through its effect on promyelocytic leukaemia 
(PML) protein. Although, the role of PML in HIV-1 replication was not confirmed by 
subsequent studies, the stimulatory effect of arsenic on HIV-1 and other retroviruses was 
later confirmed (Berthoux et al., 2003, 2004; Keckesova et al., 2004; Sebastian et al., 
2006). Berthoux et al., (2003) showed, that apart from HIV-1 infection in HeLa cells, N- 
MLV infection in human TE671 cells was also enhanced by arsenic treatment, thus 
demonstrating the ability of arsenic trioxide to counteract Refl mediated restriction.
These observations raised the possibility, that although arsenic effects many diverse 
cellular functions, it might influence the retroviral replication through deregulation of the 
Refl/ TRIM5a restriction factor. If this is the case, we would expect the titre of other 
Refl restricted viruses to be enhanced by arsenic treatment, while the titre of unrestricted 
viruses would remain unchanged. As Figure 3.17 shows this was indeed the case. The 
infection of human TE671 cells by equine infectious anaemia virus (EIAV), another Refl 
restricted virus, was enhanced in the presence of arsenic while the titre of unrestricted B- 
MLV was not affected. To further test if the effects of arsenic trioxide are dependent on 
the presence of TRIM5a, a factor that encodes Refl activity, we knocked-down the 
endogenous human TRIM5a protein in TE671 cells. Figure 3.19 shows, that retroviral
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infection of cells, in which TRIM5a-expression levels had been downregulated, were 
unresponsive to arsenic treatment. This confirms that the effect of arsenic trioxide on 
retroviral infection is dependent on the presence of human TRIM5a.
In contrary to human cells, N-MLV infection of CV1 cells from African green monkey 
(Agm) was unaffected by arsenic treatment, even at high arsenic concentration (Figure 
3.18; Berthoux et al., 2003; Sebastian et al., 2006), although they express a TRIM5a 
protein capable of restricting various viruses (Hatziioannou et a l , 2004b; Keckesova et 
a l , 2004; Yap et a l, 2004). This implied, that the drug might be active against some 
TRIM5a orthologues but not others. In order to resolve this, we stably expressed both, 
human and Agm TRIM5a proteins in feline CRFK cells and tested their responsiveness 
to arsenic. As Figure 3.20 shows, AS2 O3 increased the titre of N-MLV on both of the 
transduced CRFK cell lines, while it did not have an effect on unmodified CRFK cells. 
We reported previously (Keckesova et a l,  2004) that CRFK cells expressing Agm 
TRIM5a, as well as CV1 cells, did not respond to arsenic, but the concentrations of 
arsenic used were lower than IOjxM. While the effect of arsenic on N-MLV replication in 
CRFKhuT5a cell line was very strong even at lower arsenic concentration (around 20- 
fold at 5pM arsenic concentration), N-MLV was enhanced by 5-fold at most on 
CRFKAgmT5a cells, even when the arsenic concentration was as high as 20pM. 
Subjecting these cells to western analysis revealed, that the differences in arsenic 
sensitivity on these cell lines can be attributed to much higher expression levels of Agm 
TRIM5a than those of human TRIM5a in all the clones tested. The difference in 
expression levels between CRFK cells expressing human and Agm TRIM5a proteins 
was also reported by Sebastian et a l, (2006), although in this study the TRIM5a was 
expressed using a different expression vector. Perhaps, high expression levels of human 
TRIM5a are toxic for the cell and only clones with low levels of human TRIM5a 
survive. In concordance, analysis of TE671 cells showed that endogenous TRIM5a 
protein is expressed at very low levels (Berthoux et a l,  2005a). It is possible that Agm 
TRIM5a is more stable with a slower turn over rate than that of human TRIM5a, the 
half-life of which was shown to be around 60 minutes (Diaz-Griffero et a l, 2006a). 
These results not only supported the role of TRIM5a in the arsenic-mediated effect on 
retroviral infection but also showed that the differential effect of AS2 O3 between TE671 
and CV1 cells and between CV1 and CRFK cells expressing Agm TRIM5a might be due 
to the cell environment as was suggested by Sebastian et a l , 2006. On the other hand, it 
is possible that the unresponsiveness of CV 1 cells to arsenic treatment might simply be 
explained by their high TRIM5a-expression levels or inefficient cellular drug uptake.
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This is supported by the fact that no toxic effects of the drug were evident on CV 1 cells, 
even at concentration as high as 20pM. Because of the unavailability of a specific anti- 
TRIM5a antibody the endogenous levels of TRIM5a protein in CV1 could not be 
accessed. CRFK cells expressing human TRIM5a protein exhibited extensive cell death 
at 20pM AS2 O3 while toxicity on CRFKAgmT5a cells was less evident with only a small 
percentage of cells being killed. Thus, the ability of AS2 O3 to enhance retroviral 
replication correlated well with the increase of toxic effects of the drug. Furthermore, the 
more TRIM5a protein was present in the cell the less toxic effects AS2 O3 exerted on these 
cell and the less it was able to enhance retroviral replication. The ability of arsenic to 
optimally stimulate retroviral replication at toxic concentrations was also observed by 
Berthoux et al., 2003. They also showed, that it is not the general effect of apoptosis that 
caused the enhancement of viral infection. Titre of sensitive viruses remained unchanged 
on cells treated with apoptosis-inducing agents like camptothecin, cisplatin, and anti-Fas 
antibody. Attempts to lower the expression levels of Agm TRIM5a protein in CRFK 
cells were either unsuccessful or clones that were expressing amount of Agm TRIM5a 
comparable to human TRIM5a were impaired in their ability to restrict. Therefore, we 
still cannot rule out the possibility that Agm TRIM5a, because of some intrinsic 
differences between Agm and human TRIM5a orthologues, does not respond to arsenic 
as well as the human protein.
All the results presented so far showed, that AS2 O3 positively influences retroviral 
infection through its effect on the TRIM5a protein. This might happen through 
deregulation, inactivation, translocation or degradation of the TRIM5a protein. AS2 O3 
was shown to cause the translocation and degradation of the TRIM5-related protein PML 
(Lallemand-Breitenbach et al., 2001). Whether other members of the TRIM family are 
affected by arsenic trioxide remains untested. We have shown that both of the TRIM5a 
proteins were degraded in the presence of arsenic with the first noticeable decrease at 1 2  
hours of arsenic treatment (Figure 3.21). This observation was also confirmed by 
enhancement of N-MLV infection in CRFKhuT5a and CRFKAgmT5a cells pre-treated 
with arsenic for 12 hours (Figure 3.22). Similarly, PML was shown to be degraded 8  to 
24 hours after arsenic preexposure (Lallemand-Breitenbach et al., 2001). It is possible 
therefore, that arsenic exerts this effect on more than just these two TRIM proteins. This 
might have therapeutic implications in the treatment of diseases caused by this large 
family of proteins.
Because arsenic was shown to act early in the viral infection cycle, we next examined the 
subcellular localisation of human and Agm TRIM5a proteins at various time points
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(Figure 3.23). Arsenic had no strong effect on TRIM5a subcellular distribution at the 
earlier time points. Later, the number, size and brightness of cytoplasmic bodies slowly 
increased with the longer exposures of cells to arsenic. By 6  hours human TRIM5a 
expressed in CRFK cells was localised within a few bright cytoplasmic structures. A 
similar, although less obvious effect was observed in CRFKAgmT5a cells. The delay on 
the effects of arsenic on the Agm TRIM5a protein might be explained by the higher level 
of this protein within the cell. Diffuse cytoplasmic staining of both proteins, mainly Agm 
TRIM5a, is slowly decreasing in time with longer AS2 O3 exposure. By 12 and 24 hours 
the cytoplasmic bodies are lost and cell death becomes prevalent. These events most 
probably represent TRIM5a degradation. Previous studies implied, that cytoplasmic 
bodies are not important for TRIM5a activity (Perez-Caballero et al., 2005a; Song et al., 
2005a). It was suggested that, they might simply represent sites where over-expressed 
TRIM5a protein is localised and later degraded (Diaz-Griffero et al., 2006a; see chapter 
1.3.4.5). This theory is consistent with the data presented here.
Although we showed, that the localisation of TRIM5a changes after 6  hours of arsenic 
treatment it is probably not responsible for the observed enhancement of retroviral 
replication. As shown in Figure 3.22, CRFKhuT5a cells pre-treated with arsenic for 6  
hours were not more susceptible to N-MLV infection. The observed translocation and 
degradation of TRIM5a within cytoplasmic bodies upon arsenic treatment might be 
preceded by one or more postranslational modifications (phosphorylation, ubiquitination, 
sumoylation, acetylation) which could cause deregulation of TRIM5a and enhancement 
of retroviral infection. These mechanisms of modulating protein activity are much faster 
than degradation and might explain the ability of AS2 O3 to enhance retroviral infection 
when added together with the virus. The PML protein must be sumoylated prior to its 
degradation and a single lysine (K160) is responsible for this posttranslational 
modification (Lallemand-Breitenbach et al., 2001). In order to find out, if TRIM5a 
shares the same fate as that of PML protein, we decided to mutate two sites (three 
lysines) within human TRIM5a that were predicted with high probability of becoming 
sumoylated in vivo (lysine at position 10 and two adjacent lysines at positions 263 and 
264 of human TRIM5a). As Figure 3.24 shows, these mutants lost neither their 
restricting capabilities, nor their ability to respond to arsenic treatment. This, of course, 
does not exclude the possibility that these sites are redundant for arsenic sensitivity or 
that their combination with other lysines within human TRIM5a might have an effect on 
arsenic responsiveness. We will further continue these studies by applying the 
biochemistry techniques and analysing the sumoylation and phosphorylation status of
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TRIM5a protein. Ultimately, studies with arsenic trioxide may help to elucidate the 
mechanism of TRIM5a-mediated restriction.
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Chapter 4 
Summary and directions for future research
In my thesis, I have described several aspects of TRIM5a-mediated restriction 
investigated throughout my PhD studies. Restriction factors called Refl in humans and 
Lvl in simians, responsible for poor species-specific infectivity of certain retroviruses, 
were shown to be encoded by a common factor called TRIM5a. The most notable 
difference between the various TRIM5a orthologs was seen in their C-terminal B30.2 
domain suggesting that this region of TRIM5a mostly contributes to its species- 
specificity and is important for virus recognition. This was supported by the examination 
of a short splice isoform of TRIM5a, lacking a B30.2 domain, showing its loss of 
restriction activity and ability to exert dominant negative effect on wild-type TRIM5a. 
Attempts to untangle the role of cyclophilin A in retroviral replication led to the 
discovery of cooperation between TRIM5a and cyclophilin A which results in a potent 
restriction of HIV-1 replication in simian cells. This might be explained by the prolyl- 
isomerisation of the HIV-1 capsid by cyclophilin A, thus making it a better target for 
TRIM5a. Nuclear magnetic resonance studies comparing the cis/trans isomerisation 
status of wild-type and mutant retroviral capsids could be performed to confirm this 
hypothesis. Investigation of the intriguing ability of arsenic trioxide to enhance retroviral 
replication led to the discovery of an important role for TRIM5a in this effect. The 
stimulation of retroviral infection by arsenic treatment seems to be due to its effects on 
TRIM5a deregulation and degradation. More detailed analysis of post-translational 
modifications of TRIM5a upon arsenic exposure will be required to fully understand its 
effect on this protein. Identifying the underlying biochemical pathways could lead not 
only to the ability to properly modulate TRIM5a activity but also to the discovery of 
other factors involved in TRIM5a-mediated retroviral restriction.
Despite the hard work of many laboratories, a number of interesting questions 
considering TRIM5a still remain unanswered. Are there any TRIM5a-binding proteins 
or cofactors able to influence TRIM5a activity? In such a complex and carefully 
controlled environment as the eukaryotic cell is it would seem improbable that TRIM5a 
does not have any interacting partner. Using yeast 2-hybrid, immunoprecipitation, 
affinity chromatography, or siRNA library studies will ultimately lead to the answer. 
Does TRIM5a block viruses other than retroviruses and does it have a role in cellular 
processes other than retroviral restriction? All viruses must appear inside the cell
137
cytoplasm, where TRIM5a resides. It is therefore possible that TRIM5a might directly or 
indirectly, through an adaptor protein, affect replication of other viral families apart from 
retroviruses. The capacity of diverse TRIMs to form higher-order structures, possibly 
recruiting multiple cellular proteins, as is the case of the PML protein, would potentially 
allow them to counteract cellular infection by a wide array of viruses. Of the almost 70 
members of TRIM family less than 20 have been studied. Does the TRIM family 
represent a new class of antiviral proteins involved in innate immunity or are those few 
members that were shown to possess antiviral activity fortunate exceptions? A careful 
and comprehensive study of other TRIM members will be needed to fully elucidate the 
functions of this family of proteins. The large variety of proteins regulated by 
ubiquitination demands a high specificity for E3 ligases. This results in the growing 
number of E3 ubiquitin ligases and this might explain the rapid evolution of the TRIM 
family in metazoans. This would be a good start for their subsequent evolution into 
restriction factors if a virus bears recognisable capsid. An important goal for the future is 
thus to more precisely determine the mechanism by which TRIM5a acts and to clarify 
the role of ubiquitin and TRIM5's E3 ubiquitin ligase activity in this mechanism. When 
the mechanism of action of TRIM5a is uncovered, the next step will be to recreate its 
effect in a therapeutic setting.
Understanding the determinants of species-specific retroviral replication and host-virus 
interactions will not only enable the design of better retroviral vectors for gene therapy 
but also the improvement of animal models for AIDS. Because of the described TRIM5a 
and APOBEC3G activity HIV-1 does not replicate in most nonhuman primates. Research 
has therefore had to rely on animal models comprising Rhesus macaques infected with 
simian immunodeficiency virus (SIVmac) and its derivatives. Although these models have 
been successful in understanding immunology and pathogenesis of AIDS disease they 
have limitations for testing anti-HIV therapeutics and vaccines. Recently, two studies 
have constructed an HIV-1 mutant viruses containing both, the entire SIVmac Vif gene, 
and either the whole SIVmac capsid or just a segment of SIVmac capsid which corresponds 
to the cyclophilin A-binding site (Hatziioannou et al., 2006; Kamada et al., 2006). 
Introducing these changes into HIV-1 resulted in a mutant virus that is around 90% HIV- 
1 and is capable of spreading infection in Rhesus monkey and other simian cell lines. 
While the replication properties of these HIV-1 derivatives within simian cells have 
greatly improved in vitro, this success was not recapitulated in vivo (Hatziioannou et al., 
personal communication) implying that additional changes will be required to resolve 
this issue.
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There are still examples of poor permissivity to retroviral infection evident in various cell 
lines for which TRIM5a and other known restriction factors are not responsible. Certain 
HIV-1 capsid mutants (A92E, G94D) were shown to be restricted in human HeLa cells in 
a TRIM5a-independent and cyclophilin A-dependent way (Sokolskaja et al., 2004; 
Hatziioannou et al., 2005). The identity of the factor(s) responsible for the Lv2 
phenotype, which was shown to restrict certain strains of HIV-1/2 in human cells 
(Schmitz et a l , 2004), is not known yet but is shown to be independent of TRIM5a 
(Kaumanns et al., 2006). Apart from primates, some cell lines from rabbit (Hofmann et 
al., 1999; Besnier et al., 2002), bat or pig (Towers et al., 2000; Besnier et al., 2003) 
origin are also less permissive for certain retroviruses with TRIM5a possibly accounting 
for this phenotype, although this has not yet been confirmed. The importance and 
potency of some cellular restriction factors is supported by the fact that retroviruses, with 
their limited coding activity, have had to evolve special genes to counteract them. The 
viral infectivity factor (Vif) of HIV-1 inactivates cytoplasmic APOBEC3G, which was 
found to restrict HIV-1 infection in human T-lymphocytes at the stage of retroviral DNA 
synthesis. Another example is the viral protein U (Vpu) encoded by HIV-1 which is 
thought to overcome a cellular restriction responsible for the impairment of HIV-1 
particle release in human cells (Varthakavi et al., 2003; Neil et al., 2006). The 
identification and characterisation of these host factors influencing viral replication is 
likely to impact on drug discovery and the development of animal models for viral 
infection and eventually, I hope, will help to combat the current HIV-1 pandemic.
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